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Abstract 
Staphylococcus aureus is a common commensal organism and a clinically important pathogen. 
S. aureus is able to establish infection in a range of tissues owing to its production of a wide 
variety of proteins which aid its invasion, attachment and immune evasion. Characterisation of 
S. aureus proteins is required to deepen understanding of infection and immunity and for 
continued development of antibacterial therapy. Extracellular fibrinogen binding protein, Efb, 
binds both fibrinogen and complement components. The C-terminal complement modulating 
domain of Efb, Efb-C, is well characterised. NMR data analysis suggests that the N-terminal 
fibrinogen binding region of Efb is natively unstructured. Previously characterised fibrinogen 
binding domains of S. aureus proteins are typically structured and so Efb may show a novel 
mechanism of fibrinogen binding. Staphylococcal binder of immunoglobulin, Sbi, confers host 
immune evasion through binding to both immunoglobulins and complement components. The 
solution structure of the complement binding domain of Sbi, Sbi IV, has been determined and 
reveals a conformation seen in other complement modulating proteins of S. aureus. The effect 
of Sbi IV and Efb on the complement activation pathways has been investigated and reveals key 
differences in the action of each of these proteins. The crystal structure of Sbi IV in complex 
with C3d has been determined and reveals that the interaction of Sbi IV with C3d is similar to 
that of other complement modulating proteins with C3d. NMR and X-ray diffraction data also 
reveal a potential second physiologically relevant mode of Sbi IV – C3d binding. 
Immunodominant staphylococcal antigen B, IsaB, is an uncharacterised protein whose 
expression may be correlated with immune evasion. NMR data indicate that IsaB adopts a 
folded conformation in solution but results of preliminary functional analyses of IsaB are 
currently unclear. 
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1. Introduction 
1.1. Staphylococcus aureus 
Staphylococcus aureus (S. aureus) is a Gram positive member of the genus Staphylococcus. 
The genus is comprised of over 30 species of which S. aureus and Staphylococcus epidermidis 
are clinically the most important. Both are commensals but also well known human pathogens. 
S. aureus colonises the skin and anterior nares of a large proportion of the human population; 
20% are persistent carriers and 60% are intermittent carriers (Kluytmans et al., 1997). The 
bacterium is able to persist in these locations without causing disease. It is however able to 
invade and colonise a range of tissues. Diseases caused by S. aureus range from superficial skin 
infection through to serious invasive disease such as endocarditis and septic arthritis. S. aureus 
is a major cause of disease in both the hospital environment and the community. 
1.2. Diseases caused by S. aureus 
Minor skin infections are the most common Staphylococcal infections. Such infections are often 
self-limiting or can be easily treated with topical applications. Impetigo is a minor skin infection 
characterised by boils and scabs with most cases being attributed to S. aureus. Colonised nasal 
epithelium provides a reservoir of bacteria from which subsequent skin colonisation can occur 
(Darmstadt and Lane, 1994). 
The most important Staphylococcal infections are those that cause significant morbidity and 
mortality. S. aureus bacteraemia, for example, can itself be life threatening and can lead to 
further infection. Endocarditis is a serious complication of bacteraemia. Endocarditis is an 
infection of the cardiac valve, whereby bacteria can adhere to and establish thrombi on healthy 
or damaged valves. Complications of endocarditis include stroke and cardiac arrest and the 
mortality rate is relatively high (Murdoch et al., 2009). S. aureus is the most common cause of 
endocarditis (Fowler et al., 2005). 
S. aureus and group A Streptococci produce toxins which cause toxic shock syndrome (TSS). 
TSS is an acute onset illness characterised by rash, fever and hypotension which can lead to 
multiple organ failure and lethal shock. Toxic Shock Syndrome Toxin 1 (TSST-1) is an 
exotoxin which causes menstrual toxic shock syndrome and is associated with some non-
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menstrual TSSs (McCormick et al., 2001). The Staphylococcal enterotoxins B and C cause non-
menstrual TSSs (Bohach et al., 1990). 
S. aureus is a major cause of food poisoning. The causative agent of Staphylococcal food 
poisoning is enterotoxin A. Enterotoxin A is heat resistant and therefore able to persist in 
cooked foods. S. aureus is present in raw meats and recontamination of cooked meats can occur 
from handling by commensally colonised individuals (Genigeorgis, 1989). 
1.3. Methicillin resistant Staphylococcus aureus 
S. aureus was first discovered in the 1880s and the mortality rate was 80% until the 1940s, 
when penicillin became available. By 1942, S. aureus was becoming resistant to penicillin due 
to acquisition of a plasmid encoding penicillinase. As a result, 80% of S. aureus strains have 
been resistant to penicillin since the 1960s (Deurenberg et al., 2007). 
Methicillin was first used in 1959 to treat penicillin resistant S. aureus. By 1961 there were 
reports of resistance (Enright et al., 2002). This resistance was brought about by acquisition of 
the MecA gene which encodes penicillin binding protein 2a (Deurenberg et al., 2007). The 
methicillin resistance gene is carried on a staphylococcal cassette chromosome mec element (Ito 
et al., 2003). Methicillin resistant S. aureus – MRSA – is a term used to describe bacteria that 
are resistant to a broad spectrum of antibiotics. Since these initial reports of methicillin 
resistance, MRSA has become more prevalent and the impact of this on hospitals has lead to the 
description of MRSA as a superbug. The prevalence of MRSA has continued to rise. The 
percentage of bacteraemia cases in England and Wales caused by MRSA rose from 2% in 1990 
to 43% in 2002 (Johnson et al., 2005). The percentage of S. aureus infections in US intensive 
care units caused by MRSA increased from 2% in 1974 to 64% in 2004 (Klevens et al., 2006). 
Although the emergence of MRSA was initially seen predominantly in hospitals, community 
acquired MRSA (CA-MRSA) is becoming more widespread. Hospital acquired MRSA (HA-
MRSA) strains usually carry large SCCmec elements whereas CA-MRSA strains carry smaller 
SCCmec variants. Many CA-MRSA strains also carry Panton-Valentine Leukocidin (PVL) 
genes (Boyle-Vavra and Daum, 2007). Most CA-MRSA infections are minor skin infections but 
life threatening infections such as sepsis and necrotising pneumonia have been reported 
(Moreno et al., 1995, Maltezou and Giamarellou, 2006). 
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Severe MRSA infection is most commonly treated with vancomycin. Vancomycin disrupts cell 
wall peptidoglycan synthesis in susceptible bacteria. Resistance is conferred through the 
acquisition of genes encoding enzymes which modify or remove the molecular target of 
vancomycin (Courvalin, 2006). Vancomycin resistance has now been reported (Sievert et al., 
2008). The emergence of bacteria that are resistant to this ‘last resort’ antibiotic makes the case 
for the requirement of development of novel antibacterial therapy. 
1.4.	 S. aureus proteins for invasion, attachment and immune 
evasion 
S. aureus is able to colonize and establish infection in a variety of tissues and as a result causes 
a broad spectrum of disease. To enable itself to do this, S. aureus produces a plethora of factors 
which aid its invasion, attachment and host immune evasion. 
There are various ways to classify the array of proteins produced by S. aureus. A key group of 
these proteins are those that interact with host fibrinogen and platelets, as these interactions are 
crucial for persistence of the bacterium both in the commensal setting and in invasive disease 
processes. Immune evasion is also central to establishment of infection and survival of the 
bacterium. The fibrinogen binding and immune evasion proteins of S. aureus will be considered 
in the following sections. It should be noted, however, that these groups are not mutually 
exclusive, with some of the fibrinogen binding proteins playing a key role in immune evasion. 
1.4.1. S. aureus fibrinogen binding proteins 
Individuals who are colonized with S. aureus are more likely to become infected. This 
colonization requires attachment of the bacterium to host cells, which can be mediated through 
its binding to fibrinogen and related proteins such as fibronectin. For example, nasal 
colonization by S. aureus requires attachment of the bacterium to mucin on nasal epithelial cells 
(Shuter et al., 1996). Binding to fibrinogen and related proteins is also a crucial part of the 
establishment of serious invasive infection. For the establishment of infective endocarditis a 
bacterial thrombus is made. Production of thrombi requires the interaction of bacteria with 
resting platelets and then platelet stimulation and aggregation must occur. Key to this process is 
the interaction of the bacterium with fibrinogen, fibronectin, and platelets. S. aureus fibrinogen 
binding proteins are shown in table 1.1. 
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Cell - bound 
fibrinogen 
binding proteins 
Target within host Effect within host 
Clumping factor A Fibrinogen γ-chain Platelet activation leading to bacterial 
thrombus formation 
Clumping factor B Fibrinogen Aα-chain 
Cytokeratin 10 
Squamous cell adherence required for 
nasal colonisation 
Fibronectin 
binding proteins A 
and B 
Fibronectin 
Fibrinogen γ-chain 
Platelet activation leading to bacterial 
thrombus formation 
Secreted 
fibrinogen 
binding proteins 
Extracellular 
adherence protein 
Fibrinogen Aα-chain 
Fibronectin 
Vitronectin 
Laminin 
Intercellular adhesion 
molecule-1 
Internalisation into fibroblasts and 
epithelial cells 
Anti-inflammatory activity 
Coagulase Fibrinogen 
Prothrombin 
Platelet activation and fibrinogen 
cleavage leading to thrombus formation 
Extracellular 
fibrinogen binding 
protein 
Fibrinogen 
Complement component 
C3 
Platelet activation hindered leading to 
delayed wound healing 
Complement evasion 
Table 1.1 S. aureus fibrinogen binding proteins 
The host target and effect of the known cell-bound and secreted fibrinogen binding proteins of S. aureus 
are shown. 
1.4.1.1. Fibrinogen and platelets in haemostasis 
Human fibrinogen is a 340 kDa glycoprotein synthesised primarily by hepatocytes. Fibrinogen 
circulates in the blood where it is a major regulator of haemostasis. The molecule is comprised 
of three pairs of polypeptide chains termed Aα, Bβ and γ which are arranged into two D 
domains and a central E domain as shown in figure 1.1 (Herrick et al., 1999). 
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B!-chain! 
"-chain! 
Disulphide 
knot! 
D domain! E domain! D domain! 
A#-chain! 
Carbohydrate 
cluster! 
Figure 1.1 Fibrinogen (adapted from Herrick et al., 1999)

The arrangement of fibrinogen is shown. The Aα- Bβ- and γ-chains are labelled as are the two distal D

domains, the central E domain and the location of the disulphide knot. The carbohydrate cluster

associated with the Bβ-chain is indicated.

Fibronectin is a 440 kDa glycoprotein produced by hepatocytes which has a role in various 
processes including cell adhesion and wound healing. It can bind to various receptors including 
integrins on platelets through which platelet activation is mediated. It exists in a soluble form 
which is found in the blood, and in an insoluble form which is found in the extra-cellular matrix 
(ECM) of cells. 
Fibrinogen and fibronectin play crucial roles in mediation of platelet aggregation and blood 
coagulation which lead to the production of a thrombus. At a site of damaged endothelium, 
ECM proteins such as collagen, immobilised fibrinogen and von Willebrand factor (vWF) are 
exposed. Platelets bind to these proteins via integrin receptors such as αIIbβ3. This binding 
contributes to platelet activation but a further signal is required. The Fc region of IgG binds the 
FcγRIIa integrin on platelets. This causes dimerisation of FcγRIIa which, along with fibrinogen 
binding, leads to platelet activation. The platelet integrin receptor αIIbβ3 changes conformation 
such that it can bind soluble fibrinogen. Soluble fibrinogen can cross-link platelets by binding to 
two αIIbβ3 receptors simultaneously. Activated platelets release factors which stimulate other 
platelets. 
At sites of tissue injury, proteolytic cleavage of prothrombin occurs to produce α-thrombin. α-
thrombin cleaves fibrinogen such that fibrinopeptides A and B are released from the amino-
termini, within the central E domain (figure 1.1) of the Aα- and Bβ-chains respectively. These 
fibrinopeptides are fibrin monomers which, in the presence of factor XIIIa, polymerise and 
cross-link to form a stable fibrin clot. 
5

1.4.1.2. Cell-bound fibrinogen binding proteins 
Key to the ability of S. aureus to colonise tissues and establish infection is the production of 
factors which have been termed microbial surface components recognising adhesive matrix 
molecules, or MSCRAMMs (Patti et al., 1994). These proteins are cell surface-associated and 
are predominantly expressed during the exponential growth phase (Lowy, 1998). MSCRAMMs 
are included in the class of Staphylococcus aureus surface proteins (Sas proteins) (Mazmanian 
et al., 2001). Sas proteins are a group of S. aureus proteins which contain a C-terminal sorting 
signal with an LPXTG cell wall anchoring motif, except for two which contain an LPXAG 
motif although are still associated with the cell wall (Roche et al., 2003). 
Clumping factor B (ClfB) is an MSCRAMM which is key to S. aureus nasal colonisation 
(Wertheim et al., 2008). ClfB binds the Aα-chain of fibrinogen, namely a short region near the 
C-terminus (Walsh et al., 2008). ClfB also binds cytokeratin 10 and this binding is required for 
Staphylococcal colonisation of the anterior nares through adherence to squamous cells (O'Brien 
et al., 2002b, Walsh et al., 2004). 
Clumping factor A (ClfA) is an MSCRAMM that mediates platelet activation through its 
binding to fibrinogen. The binding site in fibrinogen for ClfA has been located to the C-
terminus of the γ-chain (McDevitt et al., 1997) The crystal structure of ClfA binding to a 
synthetic fibrinogen peptide which mimics the ClfA binding site has been solved (Ganesh et al., 
2008). ClfA binding fibrinogen alone is not sufficient for platelet activation: binding of anti-
ClfA antibody to the platelet FcγRIIa receptor is also required (Loughman et al., 2005). The 
importance of ClfA in virulence has been shown in a mouse model of Staphylococcal arthritis. 
Severity of infection was reduced when the mice were challenged with a mutant negative for 
ClfA in comparison with challenge with wild type, and vaccination with ClfA has been shown 
to protect mice against septic arthritis (Josefsson et al., 2001). 
The fibronectin binding proteins A and B (FnbpA and FnbpB) are MSCRAMMs which bind 
fibronectin at their C-termini and fibrinogen at their N-termini (Wann et al., 2000). FnbpA and 
FnbpB activate platelets through binding the αIIbβ3 receptor via fibronectin or fibrinogen. The 
site in fibrinogen to which FnbpA and FnbpB bind is the C-terminal of the γ-chain. Activation 
of platelets by FnbpA and FnbpB also requires engagement of the FcγRIIa receptor on platelets 
through binding with an anti-FnBP antibody (Fitzgerald et al., 2006b). The interaction between 
FnbpA and fibronectin also mediates the invasion of endothelial cells and subsequently a pro-
inflammatory response occurs (Bingham et al., 2008). 
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1.4.1.3. Secreted fibrinogen binding proteins 
Extracellular adherence protein (Eap) is a 60kDa protein which binds various host adhesive 
proteins including fibrinogen and fibronectin. Eap binds the Aα-chain of fibrinogen (Harraghy 
et al., 2003). Eap is secreted by S. aureus but is able to adhere to the bacterium subsequent to 
secretion (Flock and Flock, 2001). Eap is key to the binding of S. aureus to eukaryotic cells 
(Palma et al., 1999) and it is important for internalisation (Haggar et al., 2003). Eap has an anti-
inflammatory action whereby it inhibits neutrophil recruitment to the site of infection (Haggar 
et al., 2004, Chavakis et al., 2002). Eap was found in 135 of 140 S. aureus strains tested but not 
in S. epidermis (Hussain et al., 2001). 
Coagulase is an 87 kDa protein whose C-terminal region contains a variable number of tandem 
repeats. These C-terminal tandem repeats are thought to be responsible for fibrinogen mediated 
binding of coagulase to platelets (Heilmann et al., 2002). Coagulase also binds to prothrombin. 
This binding causes production of fibrin from fibrinogen without proteolytic cleavage of 
prothrombin which is normally required (Hendrix et al., 1983). Most strains of S. aureus carry 
the gene for coagulase but expression varies. 
Extracellular fibrinogen binding protein, Efb, is a secreted 19 kDa S. aureus protein which 
binds both fibrinogen (Boden and Flock, 1994) and the central complement component C3 (Lee 
et al., 2004a). The complement-modulating properties of Efb will be considered in the Immune 
Evasion section. The Efb gene was present in all S. aureus clinical isolates tested but in none of 
the other Staphylococcal species tested (Boden Wastfelt and Flock, 1995). 
The N-terminal region of Efb shares homology with the fibrinogen binding protein coagulase 
(Kaida et al., 1987). Palma et al identified that Efb contained two binding sites for fibrinogen, 
one in the N-terminal half of the protein within the repeat region, and one in the C-terminal half 
of Efb (Palma et al., 1998). Lee et al, however, have since shown that a C-terminal Efb 
construct did not bind fibrinogen and that binding was seen only in an N-terminal Efb construct 
(Lee et al., 2004b). 
The binding site in fibrinogen for Efb has been identified as the Aα-chain of the D fragment 
(Palma et al., 2001). Binding of Efb to this region on fibrinogen inhibits platelet aggregation 
(Shannon and Flock, 2004) and as a result of this, wound-healing in vivo is inhibited (Shannon 
et al., 2005). The Aα-chain of the D fragment of fibrinogen is situated close to the αIIbβ3 
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recognition site within fibrinogen (Hawiger et al., 1989) and so Shannon and Flock propose that 
Efb binds platelets via fibrinogen such that fibrinogen can no longer bridge two αIIbβ3 receptors, 
hindering platelet activation. Efb is also able to inhibit platelet activation in a fibrinogen-
independent manner and so an Efb receptor on platelets has been proposed. 
1.4.2. S. aureus immune evasion proteins 
Evasion of both innate and adaptive host immunity is central to establishment of infection and 
survival of S. aureus. Host innate immunity is comprised of various factors. External barriers to 
infection include the skin and mucous membranes. Other constituents of innate immunity 
encountered by the bacterium include phagocytic cells, antimicrobial peptides and the 
complement system. The adaptive immune response is a more specific antibody-mediated 
response. S. aureus is able to overcome these host defenses. 
1.4.2.1.	 S. aureus fibrinogen binding proteins in immune 
evasion 
Some of the fibrinogen binding proteins described contribute to the immune evasion activity of 
S. aureus. Generation of bacterial thrombi during infective endocarditis requires platelet 
activation which is mediated by ClfA, FnbpA and FnbpB. The bacterial thrombus is devoid of 
neutrophils and so bacteria contained therein are effectively ‘hidden’ from the immune system 
(Fitzgerald et al., 2006a). Eap is not only important for attachment but also is required for 
internalisation and inhibits neutrophil recruitment to the site of an infection (Haggar et al., 2004, 
Chavakis et al., 2002) thereby conferring host immune evasion. 
1.4.2.2. S. aureus defence against antimicrobial peptides 
S. aureus has cell wall constituent modifications which enable it to resist antimicrobial peptides 
both extracellularly and within the neutrophil phagosome, should it become phagocytosed. The 
composition and net charge of S. aureus lipoteichoic acid and wall teichoic acid can be changed 
such that the affinity of antimicrobial peptides for the bacterium is reduced (Peschel, 2002). 
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Staphylokinase is a secreted S. aureus protein which is able to bind to and neutralize the effect 
of α-defensins, a group of antimicrobial peptides (Jin et al., 2004). Staphylokinase has a further 
role in immune evasion through its degradation of IgG and C3b (Rooijakkers et al., 2005b). 
1.4.2.3. S. aureus toxin production 
S. aureus produces a range of toxins (table 1.2). S. aureus is able to secrete toxins which 
damage host cell membranes. Cytolytic toxins are able to form pores in the membranes of target 
cells, such as erythrocytes and leukocytes, which leads to cell lysis (Menestrina et al., 2003). 
Cytolytic toxins contribute to immune evasion through lysing of cells of the immune system 
such as leukocytes. Superantigens are potent exotoxins which cause over-stimulation of the 
immune system through binding to class II major histocompatibility complex and T-cell 
receptors (Fraser et al., 2000). These superantigens are responsible for disease associated with 
shock for example TSS. Related to the superantigens are the staphylococcal superantigen-like 
proteins (SSLs). SSL7 exerts effects on both antibody-mediated immunity and complement 
through its binding to both IgA and complement component C5 (Langley et al., 2005). SSL7, 
therefore, contributes to evasion of both adaptive and innate immunity. 
Toxin Target within host Effect within host 
Superantigens such 
as toxic shock 
syndrome toxin 1 
Class II major 
histocompatibility complex 
and T-cell receptors 
Shock-associated disease 
Cytolytic pore-
forming toxins 
such as Panton-
Valentine 
leukocidin 
Erythrocytes and 
leukocytes 
Forms a β-barrel pore in host target 
cells leading to cell lysis which 
contributes to immune evasion 
Enterotoxins such 
as enterotoxin A 
Intestinal endothelial cells Change of ion-permeability in host 
target cells leading to abhorrent water 
and salt movement 
Exfoliative toxins Desmosomal glycoprotein Scalded skin syndrome 
Table 1.2 S. aureus toxins

The host target and the effect on the host of S. aureus toxins are shown.
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1.4.2.4. The complement system 
The complement system is a major part of innate immunity and plays a role in the adaptive 
immune response. It is comprised of over 30 cell bound and soluble factors and can be activated 
in three different ways (figure 1.2). 
Classical pathway of complement activation 
The classical complement pathway is initiated through the binding of C1 to immunoglobulins 
which are bound to a bacterial cell surface. This results in the cleavage of C4 and C2 and 
subsequent production of C4b and C2a which together form the C3 convertase C4bC2a. 
Lectin pathway of complement activation 
The lectin pathway is initiated upon binding of mannose-binding lectin (MBL) or ficolin to 
carbohydrate groups on a bacterial cell surface. The MBL or ficolin are associated with serine 
proteases which subsequently act to cleave C4 and C2, resulting in the production of C4bC2a. 
Alternative pathway of complement activation 
The alternative pathway is initiated through spontaneous hydrolysis of C3. C3b is released and 
binds to activated factor Bb to form the C3 convertase C3bBb. This is stabilised by properdin. 
The alternative pathway acts as an amplification loop for the classical and lectin pathways. 
All three complement activation pathways result in the production of C3 convertases (Walport, 
2001). C3 convertases are proteases that cleave the central complement component, C3. C3 is a 
187 kDa multi-domain protein which is a member of the α2-macroglobulin family of proteins. 
Proteins of this family typically contain a reactive thioester group which confers their 
attachment to cell membranes (Gros et al., 2008). The crystal structure of native human C3 has 
been solved to 3.3 Å and the structure of C3c, the main proteolytic fragment of C3, has been 
solved to 2.4 Å (Janssen et al., 2005). The structure of C3 is shown in figure 1.3. 
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Figure 1.2 The complement activation pathways and the late stage of complement activation (from 
(Walport, 2001) 
Components of the classical, lectin and alternative pathways of complement activation are their ligands 
are shown. Membrane attack complex formation is also shown. 
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Figure 1.3 The central complement component C3 (adapted from Janssen et al., 2005)

Ribbon representation of C3 showing the 13 domains, an anchor region and the position of the thioester

group.

The thioester group of C3 is formed by the side chains of C1010 and Q1013 (Thomas et al., 
1982). In the intact C3 protein, this thioester group is shielded by a hydrophobic pocket which 
prevents it from reacting (Janssen et al., 2005). Upon cleavage of C3 by C3 convertase, the 9 
kDa component C3a is released (denoted as ANA in figure 1.2). C3a is an anaphylatoxin which 
confers neutrophil recruitment. Within the remaining 177 kDa piece of C3, which is termed 
C3b, nucleophilic attack occurs on Q1013 by H1126 (Gadjeva et al., 1998). This produces a 
highly reactive acyl-imidazole intermediate which reacts readily with hydroxyl groups on 
molecules on a bacterial cell surface. This confers the attachment of C3b to a bacterial cell (Law 
and Dodds, 1997). C3b acts as an opsonin, targeting the bacterial cell for destruction. C3b on a 
bacterium is further broken down by complement regulators into iC3b, C3dg and C3d (C3dg 
and C3d comprise the TED domain in figure 1.3). 
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A C3b-C2a-C4b complex is also formed and is a C5 convertase. The C5 convertase is a 
protease which cleaves C5. C5, like C3, is a large multi-domain protein member of the α2-
macroglobulin family of proteins. Cleavage of C5 results in the release of the small component 
C5a which, like C3a, is a potent anaphylatoxin which confers neutrophil recruitment. The 
remainder of C5, termed C5b, assembles with various other complement components into a 
membrane attack complex which facilitates lysis of the bacterial cell (figure 1.2). 
C3b and its degradation products iC3b and C3d are recognised by complement receptors 
expressed by leukocytes (Nielsen and Leslie, 2002). Recognition of C3b and C4b by 
complement receptor 1 (CR1) on phagocytes confers bacterial clearance (Gasque, 2004). 
Binding of the complement components iC3b, C3dg and C3d to complement receptor 2 (CR2) 
on B cells acts to enhance the B cell response (Carroll, 2004). Non-specific B cells can act as 
antigen-presenting cells (APCs) and present to specific T cells due to the interaction of C3 
fragments with CR1 and CR2 (Thornton et al., 1996). In this way complement provides a 
crucial link between the innate and adaptive immune responses. 
A range of cell surface and secreted regulatory proteins act to prevent aberrant complement 
activity and to stop binding of C3b to self cells. Factor H, also known as decay accelerating 
factor, binds to C3b to dissociate the convertases. Factor I proteolytically degrades C3b to iC3b, 
C3c and C3dg, which cannot form convertase complexes. CR1 and membrane cofactor protein 
assist with this (Gros et al., 2008). 
Insufficient regulation of the complement system leads to a range of disorders. Aberrant 
complement activation can lead to inflammation-induced damage in situations such as 
myocardial infarction and stroke. Complement also plays a role in various autoimmune diseases 
including rheumatoid arthritis and asthma (Ricklin and Lambris, 2007). 
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1.4.2.5. Complement modulating proteins of S. aureus 
S. aureus produces a number of complement modulating proteins which act at different stages 
of the complement cascade (table 1.3). 
Target within host Contribution to immune evasion 
Staphylococcal 
superantigen-like 
protein 7 
IgA 
Complement component C5 
Immunoglobulin sequestering and 
complement cascade inhibition 
Chemotaxis 
inhibitory protein 
of staphylococci 
C5a receptor Inhibition of neutrophil activation 
Staphylococcal 
complement 
inhibitor 
C3 convertases Inhibition of C3 cleavage and 
therefore the complement cascade 
Efb-homologous 
protein 
Complement component C3 Complement cascade inhibition 
Staphylococcal 
binder of 
immunoglobulin 
Immunoglobulins 
Complement component C3 
Immunoglobulin sequestering and 
complement cascade inhibition 
Protein A Immunoglobulins Immunoglobulin sequestering 
Classical pathway inhibition 
Table 1.3 S. aureus immune evasion proteins

The host target and the effect on the immune system of each protein is shown.

The chemotaxis inhibitory protein of staphylococci, CHIPS, is a 14.1 kDa protein which binds 
to the C5a receptor and the formyl peptide receptor on neutrophils (Postma et al., 2004). This 
inhibits neutrophil activation. Staphylococcal complement inhibitor, SCIN, is a 9.8 kDa 
secreted protein which binds to and subsequently stabilises the C3 convertases C4bC2a and 
C3bBb, inhibiting C3 cleavage and any further production of C3b. As such, all three 
complement pathways are inhibited (Rooijakkers et al., 2005a). 
Efb binds fibrinogen through its N-terminal region resulting in inhibition of platelet activation 
(Palma et al., 2001, Shannon and Flock, 2004). Efb confers host immune evasion through 
binding via its C-terminal region, Efb-C, to complement components. Efb inhibits both the 
classical and alternative complement pathways through binding with C3d in native C3. 
Subsequently, both C3 deposition onto bacterial cell surfaces and downstream complement 
activity is blocked (Lee et al., 2004a). Efb does this by altering the conformation of C3 such that 
it can no longer be converted to C3b. Formation of the C3b-containing alternative pathway 
convertase C3bBb is prevented. Efb-C also has affinity for C3b, and Hammel et al have 
suggested that Efb-C3b binding could have the effect of preventing C3bBb formation (Hammel 
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et al., 2007c). It has been shown that recombinant Efb can bind both C3b and fibrinogen 
simultaneously (Lee et al., 2004b). 
Efb-homologous protein, Ehp, is a secreted S. aureus protein which is 88 residues long and, like 
Efb, binds C3 via C3d (Hammel et al., 2007b). Ehp shares 44% homology with Efb-C and its 
crystal structure reveals that Ehp adopts the same fold as Efb-C and binds C3d at the same 
position (Hammel et al., 2007c, Hammel et al., 2007b). 
Staphylococcal binder of immunoglobulin, Sbi, was first described as a 436 amino acid protein 
which binds IgG (Zhang et al., 1998). Small-angle X-ray scattering (SAXS) data has shown that 
the N-terminal region of Sbi is elongated and comprised of four globular domains (Burman et 
al., 2008). Domains I and II bind immunoglobulins and domains III and IV modulate 
complement activity (Burman et al., 2008). 
Sbi was the second S. aureus IgG-binding protein to be identified. The first was protein A 
(SpA). SpA is a 47 kDa Sas protein which contains 4 or 5 highly homologous immunoglobulin 
binding domains (Moks et al., 1986). SpA forms soluble immune complexes through its binding 
to the Fc region of IgG. SpA also forms insoluble immune complexes through binding the Fc and 
Fab portion of IgGs (Atkins et al., 2008). This sequestering of IgG has a specific effect whereby 
when SpA is bound to the Fc region of IgG, cells with Fc receptors are prevented from 
interacting with the immunoglobulin: phagocytosis and the Fc mediated triggering of the 
classical complement pathway are thereby hindered. 
1.4.3. Therapeutic potential of S. aureus proteins 
The immunoglobulin sequestering and complement inhibiting properties of S. aureus immune 
evasion proteins give them potential for development of therapy for immune-mediated diseases. 
For example, C5a binding to neutrophils is associated with the disease process of rheumatoid 
arthritis (Jose et al., 1990). The selective and potent inhibition of this neutrophil activation by 
CHIPS makes CHIPS an attractive target for therapeutics of this and related diseases (Postma et 
al., 2004). 
Diseases such as rheumatoid arthritis which are associated with uncontrolled regulation of C3b 
may benefit from therapy with molecules which mimic proteins such as Efb and Ehp which 
specifically inhibit C3 activation (Lambris et al., 2008). 
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The IgG sequestering activity of SpA means that it can be used for immunoadsorption therapy. 
A side effect of SpA immunoadsorption therapy is the availability of Fc to bind FcγR and fixate 
complement (Kozlowski et al., 1998). Atkins et al have suggested that Sbi may provide more 
effective immunoadsorption therapy due to its specific binding to IgG Fc (Atkins et al., 2008). 
Features of these proteins such as immunogenicity and susceptibility to breakdown, however, 
mean that considerable work is required to produce suitable mimics. Characterisation of the 
structures and functions of such proteins will aid in the development of therapeutics. 
1.5. Prevention and treatment of S. aureus infection 
With an increase of MRSA prevalence and associated mortality, development of novel 
therapeutics is required. Immune evasion proteins are an attractive target due to their 
importance in pathogenesis, but redundancy amongst them may be a problem. Characterisation 
of the structures and functions of these proteins is therefore important. 
Vaccination with antibodies can protect against S. aureus infection in animal models. 
Vaccination of mice with ClfA leads to protection against septic arthritis (Josefsson et al., 2001) 
and vaccination of mice with Efb reduced severity of wound infection (Shannon et al., 2006). 
1.5.1. Immunodominant Staphylococcal antigen B 
IsaB is a 19.5 kDa secreted S. aureus protein which was first identified in a study which sought 
to find potential MRSA vaccination targets. The immune response to IsaB was considerably 
higher for individuals with MRSA sepsis compared to that of colonised and healthy individuals 
(Lorenz et al., 2000). Little is known about IsaB. A study that compared the genomics of S. 
aureus musculoskeletal isolates identified that the gene was not found in the most virulent 
strains studied which led the authors to suggest it could be correlated with immune evasion 
(Cassat et al., 2005). IsaB expression has been shown to be down-regulated subsequent to 
neutrophil phagocytosis (Voyich et al., 2005). The role of IsaB in immune evasion is unclear. 
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1.6. Aims 
The complement modulating properties of the C-terminal region of Efb, Efb-C, have been 
partially characterised previously. The effect of Efb on each of the three complement activation 
pathways will be investigated. Less is known about the fibrinogen binding N-terminal region of 
Efb. NMR and crystallography will be used to carry out structural analysis of the N-terminal 
region of Efb. Binding of Efb to fibrinogen has been localised to the Aα-chain of the D 
fragment of fibrinogen and this binding results in inhibition of platelet activation (Palma et al., 
2001). As well as residing close to the αIIbβ3 recognition site of fibrinogen (Hawiger et al., 
1989), which may account for the inhibition of platelet aggregation by Efb, the Aα-chain of the 
D fragment of fibrinogen contains other sites which are important for platelet activation. NMR 
analysis will be carried out to analyse the Efb – fibrinogen interaction. Attempts will also be 
made to carry out crystallographic analysis of Efb bound to fibrinogen. 
The complement modulating proteins Efb-C and Ehp bind C3 via the C3d domain and crystal 
structures of both Efb-C and Ehp bound to C3d have been solved (Hammel et al., 2007c, 
Hammel et al., 2007b). Domains III and IV of Sbi also bind to the C3d domain of C3 (Burman 
et al., 2008). Further characterisation of the structure and function of the complement 
modulating domains of Sbi will be carried out. The effect of Sbi IV on each of the three 
complement activation pathways will be investigated. NMR analysis of Sbi IV will be carried 
out. The interaction of Sbi with complement component C3d will be investigated using both 
NMR and x-ray crystallographic analysis. 
IsaB is an as yet uncharacterised protein which may have a role in immune evasion and so 
further elucidation of its structure and function will be carried out. 
The results are expected to deepen our understanding of infection and immunity and provide 
insight into some of the mechanisms deployed by S. aureus to enable host immune evasion. An 
understanding of immune evasion is required not just for the development of antibacterial 
therapies; understanding of complement modulation by bacterial proteins may also aid in the 
development of therapies for complement-mediated disease. 
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2. Materials and methods 
2.1. Chemicals and Reagents 
All chemicals and reagents were purchased from BDH unless otherwise stated. 
2.2. Bacterial strains and plasmids 
2.2.1. E. coli strains 
The E. coli strains XL1-Blue subcloning-grade competent cells (Stratagene) and DH5α cloning 
efficiency cells (Invitrogen) were used for cloning. 
The E. coli expression strains BL21(DE3), BL21(DE3) Arctic ExpressTM and BL21(DE3) Star 
cells (Stratagene) were used for protein expression. 
2.2.2. Expression plasmids 
pET15b (Novagen) contains an N-terminal 6His tag coding sequence and a thrombin cleavage 
site. The plasmid contains an ampicillin resistance gene and expression is via the T7 promoter 
region. pET15b containing the C3d gene was a kind gift from Professor David Isenman, 
University of Toronto, Ontario, Canada. 
pQE30 was a kind gift from Professor Timothy Foster, Trinity College, Dublin. The plasmid 
contains an N-terminal 6His tag coding sequence and expression is via the T5 promoter region. 
Contains an ampicillin resistance gene. 
pET28a was a kind gift from Dr Paul Whitley of the University of Bath, UK. The plasmid 
contains a kanamycin resistance gene and expression is via the T7 promoter region 
pHIS-Parallel is based on the pET22b vector and contains an N-terminal 6His tag coding 
sequence and a TEV protease cleavage site. The plasmid contains an ampicillin resistance gene 
and expression is via the T7 promoter region (Sheffield et al., 1999). 
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pGST-Parallel is based on the pGEX4T1 vector and contains an N-terminal GST-tag coding 
sequence and a TEV protease cleavage site. The plasmid contains an ampicillin resistance gene 
and expression is via the T7 promoter region (Sheffield et al., 1999). 
pSV281 (Vanderbilt University Centre for Structural Biology, Nashville, Tennessee, US) 
contains an N-terminal 6His tag coding sequence followed by a TEV protease cleavage site. The 
plasmid contains a kanamycin resistance gene and expression is via the T7 promoter region. 
pBG101 (Vanderbilt University Centre for Structural Biology, Nashville, Tennessee, US) 
contains an N-terminal 6His tag coding sequence and a GST tag coding sequence followed by a 
3C protease site. The plasmid contains a kanamycin resistance gene and expression is via the T7 
promoter region. 
2.3. Media and supplements 
Expression strains and subcloning efficiency cells were grown in Luria Bertani (LB) medium 
which contained 10 g Bacto Typtone, 5 g Yeast Extract and 10 g sodium chloride per 1 L 
distilled water. Medium was sterilised by autoclaving prior to use. 
For LB agar plates, LB was prepared as described above with the addition of 12 g agar 
(Melford) per 1 L medium. Subsequent to autoclaving the medium was allowed to cool before 
the appropriate antibiotic was added. ~25 ml medium was poured into 90 mm petri plates which 
were left to set. Plates were then stored at 4 °C until use. 
To enable selection of bacterial plasmids, cultures were supplemented with the appropriate 
antibiotic. Stock solutions of 100 mg ml -1 ampicillin (Melford) and 50 mg ml -1 kanamycin 
(Melford) were prepared and were used to supplement culture medium as appropriate. 
2.4. Molecular biology 
2.4.1. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to visualise DNA fragments. 1 % agarose gels of either 50 
ml or 160 ml were prepared by dissolving 0.5 g or 1.6 g agarose (Sigma) in Tris acetate EDTA 
(TAE) (40 mM Tris acetate, 1 mM EDTA [ethylenediamine tetraacetic acid]). 6 x DNA sample 
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buffer (0.25% (w/v) bromo phenol blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol, 2 mM 
EDTA and 70% (v/v) water) was added to samples which were then electrophoresed in TAE in 
a Novex gel system. DNA bands were visualised under UV light on a gel documentation system 
(BioRad). 
2.4.1.1. DNA markers 
New England Biolabs (NEB) 1 kb, 100 bp and PCR ladders and the Fermentas 1kb DNA ladder 
were used as markers and are shown in figure 2.1. 
Figure 2.1 DNA markers 
(A) NEB 1 kb ladder; (B) NEB 100 bp ladder (C) NEB PCR marker and (D) Fermentas 1 kb ladder. The 
size, in base pairs, of each band is indicated. 
2.4.2. Cloning 
2.4.2.1. Polymerase Chain Reaction 
Polymerase chain reaction (PCR) was used to amplify DNA fragments for the purpose of 
insertion into vectors and to screen colonies for positive clones. Primers for PCR were designed 
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to produce DNA fragments which included restriction sites at their termini to facilitate 
subsequent restriction. All primers were purchased from MWG Biotech. 
Re-cloning of Sbi IV and Sbi III-IV 
The Sbi IV and Sbi III-IV constructs were amplified using the pHIS-Parallel vector containing 
the Sbi III-IV gene as template which was previously constructed in this lab (Burman et al., 
2008). The oligonucleotide primers used are shown in figure 2.2. 
Sbi IV forward primer (Bam HI) CGG GAT CC GTT TCA ATT GAA AAA GCA ATC 
Sbi III-IV forward primer (Bam HI) CGG GAT CC GAA CGT CAA AAT ATT GAA AAT G 
Sbi IV forward primer (Nco I) CAT GCC ATG GTT TCA ATT GAA AAA GCA ATC 
Sbi III-IV forward primer (Nco I) CAT GCC ATG GAA CGT CAA AAT ATT GAA AAT G 
Reverse for both CCC AAG CTT TCA TTA CGC CAC TTT CTT TTC AGC 
Figure 2.2 Oligonucleotide primers for amplification of Sbi IV and Sbi III-IV 
The forward primers incorporated a Bam HI restriction site (for cloning into pQE30) or an Nco I 
restriction site (for cloning into pET28a) at their 5’ ends. The reverse primer incorporated a Hind III 
restriction site at its 3’ end. The reverse primer incorporated a stop codon at its 3’ end which in the case 
of pET28a cloning facilitated expression of protein without the optional C-terminal His tag. 
Efb-N cloning 
The pET15b vector containing the full length Efb gene was previously constructed in this lab 
and was used as template for amplification of the Efb-N gene. The oligonucleotide primers used 
are shown in figure 2.3. 
Forward primer CGG GAT CCG CGA GCG AAG GAT ACG GTC C 
Reverse primer CCC AAG CTT TCA CTA TGC ATC AGT TTT CGC TGC 
Figure 2.3 Oligonucleotide primers for amplification of Efb-N.

The forward primer incorporated a Bam HI restriction site at its 5’ end and the reverse primer

incorporated a Hind III restriction site at its 3’ end for cloning into pQE30, pSV281 and pBG101.

A DNA annealing temperature screen was carried out to determine the optimal annealing 
temperature for PCR of Sbi IV and Sbi III-IV constructs. PCRs for annealing temperature 
screens were carried out in a total volume of 15 µl and contained 9.7 µl water, 1.5 µl 10 x 
DreamTaq reaction buffer (Fermentas), 1.5 µl forward primer, 1.5 µl reverse primer, 0.3 µl 50 x 
dNTPs, 0.3 µl template DNA and 0.2 µl DreamTaq (Fermentas). A  PCR was carried out for 
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each fragment with annealing temperatures of 45.5 °C, 50.5 °C, 59.6 °C and 64.6 °C in an MJ 
Research PTC-200 Thermocycler. The following temperature cycle was used: 
94 °C for 2.5 minutes 
34 cycles of 94 °C for 30 seconds followed by 45.5 – 64.6 °C for 30 seconds followed by 72 °C 
for 1 minute 
72 °C for 5 minutes 
PCRs for production of the Sbi IV and Sbi III-IV constructs for subsequent restriction were 
carried out in a reaction volume of 25 µl. Each reaction contained 17.3 µl water, 5 µl 5 x HF 
Phusion buffer, 0.5 µl forward primer, 0.5 µl reverse primer, 0.5 µl 50 x dNTPs, 1 µl template 
DNA and 0.2 µl Phusion (NEB). 
PCRs for production of the Efb-N construct for subsequent restriction were carried out in a 
reaction volume of 25 µl. Each reaction contained 17.3 µl water, 5 µl 5 x HF Phusion buffer, 
0.5 µl forward primer, 0.5 µl reverse primer, 0.5 µl 50 x dNTPs, 1 µl template DNA and 0.2 µl 
Phusion. The reactions were carried out on an MJ Research PTC-200 Thermocycler using the 
temperature cycle described above. Each reaction used a different annealing temperature. The 
annealing temperatures used ranged from 50 °C to 70 °C. 
PCRs for screening for positive clones were set up as described for fragment amplification with 
template DNA replaced with 1 µl bacterial culture. The temperature cycle used contained an 
additional 5 minute 100 °C step at the beginning of the PCR cycle to facilitate lysing of 
bacterial cells and availability of DNA. 
Fragments were isolated from the PCR mixture using a Qiagen PCR purification kit (Qiagen, 
Alameda, California, US) following the manufacturer’s instructions. Briefly, five volumes of 
binding buffer was added to one volume PCR mixture and DNA was bound to a QIAquick 
column by centrifugation at 3000 g for 30 s. The column-bound DNA was then washed with 
wash buffer and DNA was eluted from the column using an appropriate volume of water. DNA 
fragments were visualised on an agarose gel. 
2.4.2.2. Restriction digestion 
Restriction endonucleases were used to restrict DNA fragments and plasmids. All restriction 
endonucleases were purchased from NEB and were used with the supplied appropriate buffers. 
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Where the enzymes used for restriction worked optimally with the same buffer, a double digest 
was carried out. Where the enzymes used for restriction required different buffers for optimal 
digestion, a sequential digestion was carried out. All restriction digests were carried out at 37 °C 
for two hours. 
The Sbi IV and Sbi III-IV PCR products were digested (1) simultaneously with Nco I and Hind 
III in preparation for insertion into the pSV281 vector or (2) sequentially with Bam HI and then 
Hind III in preparation for insertion into the pQE30 vector. A double digest was carried out for 
restriction with Nco I and Hind III. Each digestion reaction contained 30 µl DNA, 3 µl of each 
restriction enzyme, 15 µl of buffer and 99 µl water. Sequential digests were carried out for 
restriction with Bam HI and Hind III. DNA was firstly digested with Bam HI – each reaction 
contained 30 µl DNA, 3 µl Bam HI, 15 µl buffer, 1.5 µl 100 x BSA and 100.5 µl water. Bam HI 
- digested products were purified using the PCR purification kit and DNA was eluted in 30 µl. 
This was then digested with Hind III in a reaction which contained 30 µl DNA, 15 µl buffer, 3 
µl Hind III and 102 µl water. 
The Efb-N PCR product was subject to sequential digestion by the restriction endonucleases 
Bam HI and Hind III as described for Sbi IV and Sbi III-IV. 
The vectors pSV281, pBG101 and pQE30 were subject to sequential digestion with Bam HI and 
Hind III as described for the PCR products. pET28a was subject to simultaneous digestion by 
Nco I and Hind III as described for the PRC products. 
2.4.2.3. Ligation 
Restricted DNA fragments were ligated using T4 DNA ligase (NEB) as per the manufacturers 
instructions. Each ligation reaction was carried out in a total volume of 20 µl and contained 1 µl 
enzyme, 2 µl 10 x buffer, 6 µl amplified PCR product, 2 µl restricted vector and 9 µl water. The 
reaction was allowed to proceed for 2 hours at 18 °C before ligation mixture was used to 
transform cloning efficiency cells. 
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2.4.2.4. Plasmid isolation 
5 ml cultures were inoculated from colonies which grew on LB agar plates supplemented with 
the appropriate antibiotic. The cultures were incubated over night at 37 °C with shaking at 200 
rpm. Plasmids were isolated from cultures using a Qiagen mini prep kit (Qiagen) following the 
manufacturer’s instructions. Briefly, cells were harvested from over night cultures and 
resuspended in 250 µl resuspension buffer. Cells were lysed through the addition of lysing 
buffer and then a neutralisation buffer was added. The mixture was then spun at 3000 g for 10 
minutes and the supernatant applied to a QIAprep spin column. DNA was bound to the column 
through centrifugation at 3000 g for 30 s. DNA was then washed with wash buffers before 
being eluted with an appropriate volume of water. 
2.4.3. Transformation of cells 
2.4.3.1. Transformation of XL1-Blue and DH5α cells 
Ligated DNA was used to transform XL1-Blue cells (Stratagene) or DH5α cells (Invitrogen) 
according to the manufacturer’s instructions. For transformation of XL1-Blue cells, 10 µl cells 
were thawed on ice. 10 µl ligation mixture was added to the cells and the mixture was left on ice 
for 20 minutes. The cells were then heat-shocked by placing in a 42 °C water bath for 45 
seconds before being put back on ice for a further two minutes. 800 µl pre-warmed LB medium 
was added to the mixture which was then shaken at 200 rpm at 37 °C for one hour. 50 – 200 µl 
of the mixture was spread on LB agar supplemented with the appropriate antibiotic. Plates were 
then incubated at 37 °C over night. Transformation of DH5α cells proceeded as for XL1-Blue 
cells except cells were heat-shocked by placing in a 37 °C water bath for 30 seconds before 
being placed back on ice. 
2.4.3.2. Transformation of BL21 DE3 cells 
Plasmids were used to transform BL21(DE3) cells, BL21(DE3) Arctic ExpressTM and 
BL21(DE3) Star cells and cells according to the manufacturers instructions. 10 µl cells were 
thawed on ice. 1 µl DNA was added to the cells and the mixture was left on ice for 30 minutes. 
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The cells were then heat-shocked by placing in a 42 °C water bath for 20 seconds (45 seconds 
for BL21(DE3) Arctic ExpressTM cells) before being put back on ice for a further two minutes. 
800 µl pre-warmed LB medium was added to the mixture which was then shaken at 200 rpm at 
37 °C for one hour. 50 – 200 µl of the mixture was used to inoculate an LB agar plate 
supplemented with the appropriate antibiotic. The plate was then incubated at 37 °C over night. 
2.4.4. Screening for positive clones 
After ligation and subsequent transformation of ligated plasmids into subcloning efficiency 
cells, resultant colonies were tested for the presence of the desired inserts. Resultant colonies 
were used to inoculate 100 µl cultures of LB supplemented with the appropriate antibiotic. 
These colonies were incubated at 37 °C for four hours with shaking at 200 rpm. Each culture 
was then tested for the presence of the desired insert through a PCR screen. PCRs were set up as 
described in section 2.4.2.1 and clones containing the correct insert were identified by agarose 
gel electrophoresis. Plasmids containing the correct inserts were obtained by inoculating 5 ml 
LB broth, supplemented with the appropriate antibiotic, with 20 µl of the corresponding 100 µl 
culture. This was left over night at 37 °C with shaking at 200 rpm and a mini prep was 
preformed the next day using a mini prep kit (Qiagen). Samples of plasmids prepared by mini 
prep were sent for sequencing (GATC Biotech, Constance, Germany). 
2.5. Protein methods 
2.5.1. Gel electrophoresis and staining 
2.5.1.1. SDS-PAGE 
For each batch of protein purification, uninduced, induced, soluble, insoluble and purified 
protein samples were analysed on  a 15% bis-acrylamide gel using a Novex gel system. 
Uninduced, induced and insoluble protein samples were resuspended in 100 µl of 2 x protein 
sample buffer (200 mM Tris, 0.3% SDS, 30% glycerol, 15% β-mercaptoethanol and 0.075% 
bromo-phenol blue) and 100 µl water. 10 µl samples of soluble and purified protein were added 
to 10 µl protein sample buffer. Samples were then denatured by boiling at 95 °C for 5 minutes 
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and 10 µl of each sample was electrophoresed in a Tris buffer (20 mM Tris, 200 mM glycine 
and 3.5 mM sodium dodecyl sulphate [SDS] pH 8.3). 
2.5.1.1.1. Coomassie staining 
Gels were placed in staining solution (50% water, 40% methanol, 10% acetic acid and 0.1% 
(w/v) Coomassie Brilliant Blue) and were left at room temperature (~21 °C) with agitation for 1 
hour. Gels were then washed with water and left in destaining solution (50% water, 40% 
methanol, 10% acetic acid) until adequately stained. Gels were the placed in drying solution 
(50% water, 30% methanol, 10% acetic acid, 10% glycerol) for 20 minutes before being sealed 
between two pieces of mini cellophane and mounted into a gel drying frame (Sigma). 
2.5.1.1.2. Silver staining 
Gels were silver stained using reagents in a Fermentas PageSilverTM Silver Staining Kit 
according to the manufacturer’s instructions. Gels were fixed, sensitized, stained, developed and 
development was terminated using the supplied standard reagents. 
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2.5.1.1.3. Markers 
Molecular mass markers were run alongside protein samples. Figure 2.4 shows the markers 
used. 
Figure 2.4 Protein molecular mass markers 
Protein molecular mass markers used are shown. (A) Fermentas unstained protein molecular weight 
marker; (B) Fermentas PageRulerTM Plus Prestained Protein Ladder. 
2.5.2. Glycerol stock preparation 
Plasmids for protein expression were transformed into the appropriate expression strains and LB 
agar plates supplemented the appropriate antibiotic were inoculated and left over night at 37 °C. 
The following morning, a colony was picked and used to inoculate 5 ml LB broth supplemented 
with the appropriate antibiotic. When the optical density at 600 nm (OD600) reached between 0.6 
and 0.9, two aliquots each of 750 µl were added to sterile cryovials. The optical density was 
measured on a spectrophotometer using 1 ml aliquots of the culture in 1 ml plastic cuvettes. 750 
µl of 50% glycerol was added to each cryovial and these were frozen at -80 °C. Subsequent 
primary cultures were inoculated from these glycerol stocks. 
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2.5.3. Protein expression 
Typically, 20 ml primary cultures of LB supplemented with the appropriate antibiotic were 
inoculated from glycerol stocks and grown over night at 37 °C. The following morning the 
bacterial cells were harvested by centrifugation at 5000 g for 5 minutes and resuspended in 1 ml 
fresh medium which was used to inoculate 1 L secondary cultures of LB supplemented with the 
appropriate antibiotic. This culture was then incubated at 37 °C with shaking at 200 rpm until 
the OD600 reached between 0.6 and 0.9. Protein expression was induced by addition of 
isopropyl-1-thio-B-galactopyranoside (IPTG) to a final concentration of 1 mM and the culture 
was incubated at either 37 °C, 18 °C or 12 °C for a further 3 hours, or over night. 
Expression trials were carried out as described except that 3 ml primary cultures were grown 
and used to inoculate 50 ml secondary cultures. 
2.5.4. Protein purification 
2.5.4.1. Nickel ion chelating chromatography 
The cells were harvested by centrifugation (6000 g for 10 minutes at 4 °C) and resuspended in 
His buffer A (50 mM Tris, 300 mM sodium chloride, 20 mM imidazole, pH 8.0) to give a total 
volume of 10 ml. The cells were then kept on ice and sonicated (80% amplitude in 0.5 second 
pulses with 3 seconds between pulses for a total sonication time of 1 minute) on a Branson 450 
Digital Sonifier. A further ~20 ml His buffer A was added and cleared supernatant containing 
soluble protein was produced by centrifuging at 60 000 g for 30 minutes at 4 °C. To maximise 
protein yield, in some cases the pellet was resuspended in His buffer A to give a total volume of 
5 ml and kept on ice whilst being subjected to a further 1 minute of sonication as before. Further 
cleared lysate was produced through centrifugation as before and the two fractions were pooled 
and His buffer A added to give a total volume of 50 ml. Cleared lysate was loaded into a 50 ml 
superloop and connected to an AktaPurifier 10 chromatography unit (GE Healthcare). The 6His 
tagged proteins were purified on either a 1 ml or 5 ml His trap HP or His Trap FF column (GE 
Healthcare) using a gradient of imidazole from 0 – 500 mM using His buffer B (50 mM Tris, 
300 mM sodium chloride, 500 mM imidazole, pH 8.0). In some cases the flow through fraction 
from this purification was reloaded onto the AktaPurifier to ensure maximum extraction of 
protein. The resultant peak(s) were visualised on an SDS-PAGE gel and similar fractions 
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containing protein were pooled and concentrated to an appropriate concentration in an 
appropriate buffer. 
2.5.4.2. Ion-exchange chromatography 
Ion-exchange chromatography was carried out as described for nickel ion chelating 
chromatography except that His buffers A and B were replaced with HEPES buffer A (50 mM 
HEPES pH 5.5) and HEPES buffer B (50 mM HEPES, 500 mM sodium chloride, pH 5.5) 
respectively. Protein was purified on a 5 ml HiTrap column (GE Healthcare) using a 0 – 500 
mM gradient of sodium chloride using HEPES buffer B. 
2.5.4.3. GST-tag purification 
GST-tagged proteins were purified as described for nickel ion chelating chromatography except 
that His buffers A and B were replaced with GST buffers A (phosphate buffered saline [PBS] 
(137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM phosphate buffer pH 7.4)) and 
GST buffer B (50 mM Tris-hydrochloride, 10 mM reduced glutathione, pH 8.0). Protein was 
purified on a 1ml GSTrap column (GE Healthcare) using GST buffer B. 
2.5.5. His tag removal 
2.5.5.1. TEV protease cleavage 
Purified His tagged protein was buffer exchanged into cleavage buffer (50 mM Tris, 0.5 mM 
EDTA pH 8.0) in preparation for cleavage with the Tobacco Etch Virus (TEV) recombinant 
protease (Invitrogen). 
After buffer exchange into cleavage buffer, dithiothreitol (DTT) was added to a final 
concentration of 1 mM. One unit of TEV protease per 100 µg of protein was added to the 
protein solution. The reaction proceeded over night with gentle mixing at 4 °C. The following 
morning, the reaction mixture was loaded in a 10 ml loop on the AktaPurifier and passed over a 
1 ml His trap HP column to facilitate removal of the cleaved His tag. Protein without His tag 
was obtained in the flow-throw fractions of the purification run as it failed to bind to the resin. 
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The pure protein without the His tag was visualised on an SDS-PAGE gel. In some cases, traces 
of uncut His tagged protein were found in this fraction. This could result in instability in the 
resultant sample. In order to further purify the protein, ion-exchange chromatography was used. 
The contaminated sample was buffer exchanged into 20 mM Tris pH 7.5 and was then loaded 
on to a MonoS HR 5/5 column (GE Healthcare). Cleaved protein bound to the column and was 
eluted using a gradient of sodium chloride from 0 - 500 mM in 20 mM Tris pH 7.5. The 
fractions were collected and visualised on a gel. Any remaining His tagged protein was found in 
the flow through fractions. Peak fractions were collected, pooled, concentrated and buffer 
exchanged into an appropriate buffer. 
2.5.6. Protein concentration and buffer exchange 
Purified protein was concentrated in either 15 ml or 5 ml centrifugal concentrators (Millipore) 
using an appropriate molecular mass cut off, typically 5 or 10 kDa. Protein solution was added 
to the top of the concentrator which was then spun at 5000 g until the desired volume of 
concentrate was reached. To facilitate buffer exchange, the desired buffer was added to the 
concentrated protein and the process was repeated until the desired buffer conditions were 
obtained. 
Buffer exchange was also facilitated though the use of a PD-10 desalting column (GE 
Healthcare) according to the manufacturers instructions. The column was equilibrated with 25 
ml of the appropriate elution buffer and the flow through discarded. 2.5 ml of the protein sample 
was then passed through the column and the flow through discarded. 3.5 ml of the elution buffer 
was then passed through the column and the resultant flow through containing the protein was 
collected. 
2.5.7. Protein concentration determination 
Protein concentrations were estimated on a UV spectrophotometer which measures the optical 
density of a sample at 280 nm (OD280). 995 µl 6 M guanidium hydrochloride in a glass cuvette 
was used to zero the machine. 5 µl protein solution was added to the cuvette and mixing was 
facilitated through inversion of the cuvette with the top end sealed with parafilm. The OD280 
was then measured on the UV spectrophotometer. The protein concentration (mg ml-1) was 
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estimated with the equation protein concentration = (OD280/ε) x 1 x 200 where ε = protein 
extinction coefficient, 1 = path length of the spectrophotometer and 200 is the dilution factor. 
2.5.8. Protein refolding 
Protein refolding was carried out on a sample of unfolded His-Efb-N. 0.3 g guanidium 
hydrochloride was added to 0.5 ml purified His-Efb-N to give a final guanidium chloride 
concentration of 6 M. This was added to 20 ml native buffer (20 mM Tris pH 8.0, 500 mM 
sodium chloride) which was rapidly stirring at room temperature (~21 °C). This was run over a 
1 ml His trap HP column and protein was purified using an imidazole gradient of 0 – 500 mM 
in native buffer. 
2.5.9. Protein complex formation 
The Sbi IV-C3d and Sbi III-IV – C3d protein complexes were each prepared on a 1 ml His trap 
HP column (GE Healthcare) using the AktaPurifier. Purified Sbi IV or Sbi III-IV was 
concentrated to ~1 mg ml-1 and buffer exchanged into 20 mM MES pH 5.5 and was coupled to a 
1 ml His trap HP column. Purified C3d was concentrated to ~1 mg ml-1 in 20 mM MES pH 5.5 
and was run over the column. Purified protein was eluted using an imidazole gradient of 0 – 500 
mM using His buffer B. Purified protein complexes were then buffer exchanged into 50 mM 
Tris pH 7.0 prior to crystal trials. 
2.5.10. Protein binding experiments 
2.5.10.1. NHS column 
HiTrap NHS-activated columns (GE Healthcare) consist of a medium of NHS-activated 
SepharoseTM to which ligands containing primary amino groups can be coupled. A 1 ml HiTrap 
NHS-activated column was used to couple His-IsaB. The column was then used in pull-down 
experiments which identified binding partners for IsaB in serum. 
31

2.5.10.1.1. Column preparation 
His-IsaB was coupled to a HiTrap NHS-activated HP 1 ml column according to the 
manufacturer’s instructions. Purified His-IsaB was buffer exchanged into coupling buffer (200 
mM sodium carbonate, 500 mM sodium chloride pH 8.3) using a PD-10 desalting column as 
described in section 2.5.6 and the solution was concentrated to a volume of 1 ml. 1 mM ice cold 
hydrochloric acid was added to the top of the column to avoid formation of air bubbles and a 
HiTrap luer adaptor (GE Healthcare) was attached to the top of the column. A 5 ml syringe was 
attached to the luer adaptor and the storage isopropanol was washed off by passing 1 mM ice 
cold hydrochloric acid through the column. 1 ml His-IsaB in coupling buffer was immediately 
applied to the column which was then sealed and left to stand for 30 minutes at room 
temperature (~21 °C). Excess active groups were deactivated and unbound ligand washed out 
with a series of washes using two buffers in alternation. Buffer A contained 500 mM 
ethanolamine, 500 mM sodium chloride pH 8.3. Buffer B contained 100 mM acetate, 500 mM 
sodium chloride pH 4.0. 2 ml PBS was then applied to the column and the column was stored at 
4 °C until use. 
2.5.10.1.2. Pull-down experiment 
The His-IsaB column was washed with 5 ml PBS. 2.5 ml human (Cambrex) or calf or horse 
(Sigma) serum was thawed on ice and 2.5 ml PBS added to it. This serum was then passed 
through the column and the column was washed with 10 ml PBS. Bound proteins were eluted 
with 5 ml 1 M sodium chloride. The column was then washed with 10 ml PBS and remaining 
bound protein was eluted with 1 M glycine pH 2.0. The column was then washed with 10 ml 
PBS. Eluted protein was concentrated to 500 µl on a 5 ml 5 kDa cut off protein concentrator and 
eluted protein was visualised on an SDS gel. 
2.5.10.2. Sepharose beads binding experiment 
Glutathione Sepharose 4B is a medium in which glutathione ligand is coupled to 4% agarose. A 
binding experiment was carried out according to the manufacturer’s instructions to determine if 
IsaB binds IgG Fc or Fab fragments. 
1 ml Glutathione Sepharose beads were pipetted into a 15 ml Falcon tube and centrifuged at 500 
g for 5 minutes and the supernatant, consisting of 20% ethanol storage solution, was removed. 
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All subsequent centrifugations were carried out at 500 g for 5 minutes. The beads were then 
washed by the addition of binding buffer (PBST [PBS with 20% (v/v) tween]) and inversion of 
the tube followed by centrifugation and removal of supernatant. The wash step was then 
repeated to ensure removal of any residual ethanol. To facilitate binding of GST-IsaB to the 
beads, 1 ml GST-IsaB at ~1 mg ml-1 was added to the tube which was then incubated at room 
temperature (~21 °C) for 30 minutes with gentle agitation. The beads were then centrifuged and 
the supernatant removed. The beads were then washed as before. To facilitate binding of either 
IgG Fc or Fab to IsaB, Fc or Fab at 1 mg ml -1 was added to the tube which was then incubated at 
room temperature (~21 °C) for 30 minutes with gentle agitation. The beads were then washed 
four times. Bound proteins were then eluted by adding 500 µl elution buffer (50 mM Tris-
hydrochloride, 10 mM reduced glutathione, pH 8.0) to the tube and inverting. The tube was then 
centrifuged and the supernatant removed. Eluter protein was visualised on an SDS gel. 
2.5.11. MALDI-TOF analysis of proteins 
Protein bands were excised from SDS gels and were sent for MALDI-TOF analysis at the 
University of the West of England. Proteins were analysed using standard procedures. Briefly, 
in-gel trypsin digestion was carried out and the resulting peptides were extracted and analysed. 
Each digested protein produced a unique peptide mass fingerprint (PMF) which was compared 
with PMFs held in the SwissProt database. 
2.5.12. Trypsin digestion of human fibrinogen 
Three time-course trials were carried out to identify optimal conditions for fragment D 
production. 1 mg human fibrinogen (Sigma) was dissolved in 20 µl trypsin buffer (50 mM tris-
hydrochloride, 20 mM calcium chloride, pH 8.0). DTT was added to a final concentration of 5 
mM and trypsin (Sigma) was added to a final concentration of 0.5 mg ml -1. The digestion 
proceeded for ~18 hours at either 4 °C, room temperature (~21 °C) or 37 °C. 2 µl samples were 
taken at various time points throughout the digestion. 
To prepare fragment D for crystal trials with Efb, the trypsin digest was repeated with either 20 
mg fibrinogen dissolved in 400 µl trypsin buffer or 2 mg fibrinogen dissolved in 40 µl trypsin 
buffer. DTT was added to a final concentration of 5 mM and trypsin was added to a final 
concentration of 0.5 mg ml -1. The digestions proceeded for 6 hours at room temperature (~21 
°C). After 6 hours the reaction mixtures were frozen at -20 °C. 
33

2.6. NMR methods 
NMR spectroscopy exploits the magnetic properties of atoms to provide structural and 
functional information on a range of molecules. Protein NMR requires the production of pure, 
stable protein samples to enable collection of sufficient data. To enable a protein to be ‘seen’ by 
NMR spectroscopy, the protein needs to contain particular isotopes. Protons are the most 
naturally abundant hydrogen isotope and can be ‘seen’ by NMR spectroscopy. Information that 
can be obtained by 1H spectroscopy is limited and for more information proteins need to be 
labelled with specific isotopes which are not naturally abundant. The most common isotopes 
used to label proteins for NMR spectroscopy are 15N and 13C. The naturally abundant 14N and 
12C isotopes are unsuitable for NMR spectroscopy. When a protein is labelled with the 15N and 
13C isotopes, their behaviour under the controlled specific conditions of an NMR experiment 
can be ‘observed’ and gives information on their chemical environment. This, in turn, can be 
interpreted to give a picture of the three-dimensional arrangement of residues within a protein. 
2.6.1. 15N and 15N/13C isotope labelling 
To facilitate uniform isotope labelling, over night primary cultures were set up as for unlabelled 
protein. The bacterial cells were then harvested by centrifugation as before and resuspended in 1 
ml minimal medium with vitamins and trace elements. 
For the production of a 15N-labelled sample, each litre of medium contained 900 ml sterile 
water, 100 ml 10 x minimal medium (500 mM sodium phosphate, 220 mM potassium 
phosphate, 86 mM sodium chloride, pH 7.0), 650 µl metal stock solution, 1 ml 1M magnesium 
sulphate, 50 µl 1M calcium chloride, 1 ml multivitamins, 1 g 15N-labelled ammonium chloride 
(Cambridge Isotype Laboratories, Cambridge, Mass, USA) and 4 g glucose. For the production 
of a 13C/15N -labelled sample, 4 g glucose was replaced with 2 g 13C-labelled glucose 
(Cambridge Isotype Laboratories). Subsequent protein expression and purification was achieved 
as described and purified protein fractions were pooled, concentrated and buffer exchanged into 
an appropriate buffer. Final NMR samples were in Shigemi NMR tubes. 
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2.6.2. NMR spectroscopy 
NMR experiments were performed on a Varian Unity INOVA spectrometer operating at a 
nominal proton frequency of 600 MHz, using a room temperature triple resonance 5 mm probe 
equipped with pulse field gradients (PFG) along the z axis. 
2.6.2.1. Data processing and analysis 
All NMR data processing was performed using the NMRPipe/NMRDraw software suite 
(Delaglio et al., 1995). NMR data were analysed with Analysis (Vranken et al., 2005). 
Efb resonance assignments 
Sequence-specific backbone resonance assignments of Efb were made using three-dimensional 
HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, HNHA, and HBHA(CBCACO)NH data sets. 
Sbi IV resonance assignments 
Sequence-specific backbone resonance assignments of Sbi-IV were made using three-
dimensional HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, HNHA, and 
HBHA(CBCACO)NH data sets. Side chain resonance assignments of Sbi IV were made using 
CCC-TOCSY-NNH, HCC-TOCSY-NNH, HCCH TOCSY, and 15N-edited TOCSY (12.1, 12.1, 
15.6, and 50 ms mixing times). 1H chemical shifts were referenced to DSS. 15N and 13C chemical 
shifts were referenced indirectly to DSS (Wishart et al., 1995). Sbi IV NOE distance restraints 
were obtained by analysis of 15N-NOESY HSQC (50, 100, and 150 ms mixing times) and 13C-
NOESY HSQC (70 and 175 ms mixing times) spectra. All pulse sequences were from the 
Varian BioPack suite of pulse sequences. 
Sbi IV structure calculation 
NOE peak intensities were converted to distance restraints within Analysis. Distances involving 
methyl groups, aromatic ring protons, and non-stereospecifically assigned methylene protons 
were represented as a (Σr-6)-1/6 sum (Nilges, 1993). Backbone dihedral angles Φ and Ψ were 
predicted from 13Cα, 13Cβ, 13C', 1Hα, and backbone 15N chemical shifts using TALOS (Cornilescu 
et al., 1999). The Φ dihedral angles were restrained to TALOS-predicted values ±30 ° or ±40 °, 
and Ψ dihedral angles were restrained to TALOS-predicted values ±50 °. Hydrogen bond 
distance restraints were established from NOE patterns, and the proximities of donor and 
acceptor groups in structures calculated using NOE-derived distance restraints. For hydrogen 
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bond restraints, the NH-O distance was assigned lower and upper distance bounds of 1.5 and 2.5 
Å, and the N-O distance assigned lower and upper distance bounds of 2.5 and 3.5 Å. 
Structures were calculated using the Python interface of Xplor-NIH 2.18 (Schwieters et al., 
2003, Schwieters et al., 2006) using simulated annealing starting from random extended 
structures. Default values were used for all force constants and molecular parameters. 
Ensembles of NMR structures were analyzed for violated restraints using the VMD-Xplor 
visualization package (Schwieters and Clore, 2001). The structure determination was carried out 
iteratively whereby consistently violated restraints were reassigned, wherever possible, using 
existing structures or removed until a consistent set of constraints was obtained with few 
violations in the ensemble. The ensemble of structures was further refined with Xplor-NIH 
standard refinement protocols using the final set of restraints. The quality of the structures was 
assessed using PROCHECK-NMR (Laskowski et al., 1996). 
2.6.3. NMR titration experiments 
An NMR titration experiment can give residue-specific information on the effect of a protein 
upon its binding to a ligand. An HSQC spectrum shows one backbone 1H-15N peak per amino 
acid of a protein, except proline. Resonances are also seen for the side-chain NH2 groups of 
glutamine and asparagine. Changes in the chemical shifts on an HSQC spectrum can be tracked 
upon addition of a ligand to the NMR sample. Changes in chemical shift and peak intensity 
(peak intensity is represented by peak height) can be indicative of a change in the local chemical 
environment of the corresponding nuclei and more specifically can identify residues which may 
be involved in binding. 
2.6.3.1. Efb – fibrinogen titration experiment 
Peaks on an HSQC of 15N labelled His-Efb were tracked upon increasing concentration of a 
fibrinogen peptide. The concentration of fibrinogen peptide was increased through the addition 
of fibrinogen peptide to the NMR samples. Peptides were purchased from GenScript and were 
in lyophilised powder form. Five His-Efb NMR samples were prepared. The final samples 
contained 20 mM MES, 100 mM sodium chloride pH 5.5, 10% D2O. It was thought that the 
addition of fibrinogen peptides may effect the pH of the Efb NMR samples and so 20 mM MES 
was used. Each sample had a total volume of 500 µl and Efb was at a concentration of 0.244 
mM (5 mg ml -1). For each sample, an HSQC spectrum was recorded and then 3.05 x 10-5 mmol 
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fibrinogen peptide was added to the sample such that the concentration of peptide in the sample 
was 0.061 mM. The Efb : peptide molar ratio in the sample was therefore 1 : 0.25. An HSQC 
spectrum was recorded. A further 3.05 x 10-5 m mol peptide was then added to the sample and 
an HSQC spectrum recorded. Addition of 3.05 x 10-5 m mol peptide was repeated twice. An 
HSQC spectrum was recorded at each titration point. Details of the conditions of each 
experiment are contained in section 3.2.4. 
2.6.3.2. Sbi IV – C3d titration experiment 
Peaks on an HSQC of 15N-Sbi IV were tracked upon increasing concentration of C3d. Two 15N-
labelled Sbi IV samples were prepared as described previously, each with a total volume of 500 
µl. Sample 1 contained 0.6 mM Sbi IV (1:0 molar ratio of Sbi IV:C3d), 5 mM MES, 100 mM 
sodium chloride, 1 mM EDTA, 1 mM benzamidine and 10% D2O pH 5.5. Sample 2 contained 
0.6 mM Sbi IV, 1.2 mM C3d (1:0.1 molar ratio of Sbi IV: C3d), 5 mM MES, 100 mM sodium 
chloride, 1 mM EDTA,1 mM benzamidine and 10% D2O, pH 5.5. An HSQC spectrum was 
recorded on each sample. Throughout the titration the concentration of Sbi IV was maintained at 
0.6 mM. The concentration of C3d was varied by simultaneously taking equal aliquots from 
both samples and then transferring the aliquots to the other tube. This gave rise to a series of 
molar ratios as described in section 5.2.2. An HSQC spectrum was recorded at each titration 
point. 
2.7. X-ray crystallography methods 
2.7.1. The vapour diffusion method 
X-ray crystallography is a technique commonly used to solve the structure of macromolecules. 
Repeating units of the species being observed are required. To enable protein structure 
determination by crystallography, protein crystals need to be grown as they provide this 
repeating unit. The conditions in which proteins crystallise vary. Typical crystallisation 
solutions contain protein, buffer and a precipitant. Protein concentration, temperature, pH and 
precipitant concentration all have a bearing on the success of crystal growth. Figure 2.5 shows 
the crystal saturation curve. 
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Figure 2.5 Crystal saturation curve 
Crystals can grow under supersaturated conditions. In the nucleation zone nucleation can occur and 
crystals can grow. In the precipitation zone the level of saturation is too high and precipitation occurs. In 
the metastable zone nuclei are unable to form however crystals can grow from seeds. 
 
The vapour diffusion method can produce conditions of supersaturation. The vapour diffusion 
method works on this principle: Each well contains a solution in which the concentration of 
precipitant may be ideal for crystal growth. A drop of protein is added to a drop of well solution 
such that the drop contains a concentration of precipitant lower than that which is ideal for 
crystal growth. In the sitting drop method, a drop of protein sits on a shelf next to a well 
containing solution. In the hanging drop method, a drop of protein is suspended above the well. 
The drop solution equilibrates with the well solution - water goes from drop to reservoir until 
optimal concentration of precipitant in the drop is reached. Net diffusion then occurs and so this 
condition is maintained. 
2.7.2. Crystal screens; Sbi IV – C3d and Sbi III-IV – C3d 
 
All crystal screens were set up to grow crystals using the vapour diffusion method. Protein 
complexes were in 50 mM Tris pH 7.0 at ~7.5 mg ml-1. Initial crystal screens were carried out 
to identify conditions in which the protein complexes crystallised.  
 
2.7.2.1. ProPlex-96 screen 
 
The Molecular Dimensions screen ProPlex-96 was used to screen 96 conditions which have 
been formulated specifically to encourage growth of protein complexes. For details of this 
screen refer to appendix 2. The Molecular Dimensions Phoenix Crystallisation robot was used 
to screen these conditions using the sitting drop method. Each well of a 96-well crystallisation 
Protein 
concentration 
Precipitant concentration 
undersaturation 
Precipitation zone 
Nucleation zone 
Metastable zone 
supersaturation 
plate contains a reservoir containing a solution next to a shelf on which protein drops were 
placed. A plate was set for each of the Sbi IV – C3d and Sbi III-IV – C3d complexes. An 
automated program was used to place two drops of protein/reservoir solution in each well. The 
drops differed in protein complex concentration. 150 nl reservoir solution was mixed with 150 
nl protein solution to produce 300 nl drops with a final protein complex concentration of ~7.5 
mg ml-1. 150 nl reservoir solution was mixed with 300 nl protein solution to produce 450 nl 
drops with a final protein concentration of ~10 mg ml -1. Wells were sealed with plastic covers 
and incubated at 18 °C. 
2.7.2.2. Tacsimate screen 
Tacsimate is a pH titrated mixture of organic acids developed by Hampton Research which is 
available at a range of pH values. For the composition of tacsimate solution refer to appendix 3. 
24 well plates were used to screen 24 tacsimate conditions using the hanging drop method. 
Solutions of 50%, 55%, 60%, 65% and 70% tacsimate were prepared, each at pH 5, 6, 7 and 8. 
A plate was set for each of the Sbi IV – C3d and Sbi III-IV – C3d complexes. 1 ml tacsimate 
solution was added to each of 24 wells. 2 µl hanging drops containing protein complex at ~7.5 
mg ml -1 were placed on glass coverslips which were suspended over the wells and sealed with 
vacuum grease. Plates were incubated at 18 °C. 
2.7.3. Optimisation through seeding 
When crystals are grown which are deemed to be insufficient for data collection, they can be 
used as ‘seed’ to grow crystals in the metastable zone (see figure 2.5). Small needle-like crystals 
of the Sbi IV – C3d complex which grew in the ProPlex-96 screen were used as seeds. Seeding 
was carried out using the Seed Bead kit (Hampton Research) according to the manufacturers 
instructions. Briefly, 50 µl of the reservoir condition in which the seed crystals grew – the 
stabilising solution - was put into an eppendorf along with a Seed Bead. The drop containing the 
collection of small needle-like crystals which grew in the ProPlex screen was added to the tube 
which was then vortexed for 90 seconds. A further 450 µl of the stabilising solution was added 
to the tube. A serial dilution was then carried out to make a range of concentrations of seeding 
solution; 1/101, 1/102, 1/103, 1/104 and 1/105. Drops containing a range of seed concentrations 
were then set up on glass coverslips in 24-well plates. 1 µl seeding solution was added to 1 µl 
fresh protein complex solution. Each well contained 1 ml of stabilising solution and drops were 
placed on glass cover slips which were suspended above the wells and sealed with vacuum 
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grease. Plates were incubated at 18 °C. A crystal of the Sbi IV – C3d complex which grew when 
seeding solution was at a dilution of 1/103 was removed from the drop using a cryo loop. The 
crystal was then washed by being passed through 1 µl drops of well solution on a glass cover 
slip. The crystal was then used to produce seeding solution as described previously. A 1/103 
dilution of this seeding solution was prepared and was used to set an additives screen. 1 ml of 
the condition in which the crystal grew was added to each of 12 wells along with an additive. 
For details of the additives refer to appendix 4. 2 µl seeding solution was added to 2 µl fresh 
protein solution and drops were placed on glass cover slips which were suspended above the 
wells and sealed with vacuum grease. Plates were incubated at 18 °C. 
2.7.4. Data collection and processing 
Data was collected at the Diamond Light Source (Oxfordshire, UK) on an ADSC Q315 3x3 
CCD detector on station I04 (λ=0.9702 Å). A crystal of the Sbi IV – C3d complex was removed 
from the drop in which it grew using a cryoloop and was placed into a drop of cryoprotectant 
for 1 minute. Cryoprotectant consisted of reservoir solution (100 mM Tris pH 8.0, 200 mM 
sodium chloride, 20% (w/v) PEG 4000) with 20% (v/v) glycerol. The crystal was then removed 
from the drop using a micromount and held in a stream of gaseous nitrogen to facilitate freezing 
of the crystal. 360 images were collected at an oscillation angle of 1 °. Data was processed 
using the HKL2000 package (Otwinowski and Minor, 1997). 
2.7.5. Model building and refinement 
Molecular replacement was carried out using Balbes (Long et al., 2008). The structure of C3d 
was used as a search model (Protein Data Bank access code C3D1). Automated rebuilding and 
refinement was carried out by Arp/wArp (Perrakis et al., 1999). Model building was done with 
Coot (Emsley and Cowtan, 2004) and refinement was done with Refmac5, part of the ccp4i 
software (CCP4, 1994). 
2.8. Complement assay 
The WieslabTM Complement system Screen (Euro-Diagnostica) is an enzyme immunoassay 
which can determine the effect of a protein on each of the three complement activation 
pathways. Assay wells are coated with specific activators of either the classical, lectin or 
alternative pathways of complement activation and specific blocker is used to ensure that only 
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the respective pathway is activated. Residual complement activity is determined through the 
detection of an antigen produced during the production of the membrane attack complex. The 
effect of Sbi IV and Efb on each of the classical, lectin and alternative pathways was 
investigated. The assay was carried out according to the manufacturer’s instructions as 
described briefly below. 
Human serum was incubated with either His-Sbi IV or His-Efb at either 4 or 37 °C for 30 
minutes prior to addition to the assay wells. Duplicate blanks (buffer from the kit), positive 
controls (human serum from the kit) and negative controls (inactivated human serum from the 
kit) were prepared for each pathway and each sample well was set up in duplicate. Subsequent 
to incubation of human serum with the protein of interest, serum was added to the assay wells 
which were then incubated for 60 minutes at 37 °C. The wells were then washed three times 
with washing solution from kit before conjugate was added to each well. The wells were then 
incubated for 30 minutes at room temperature (~21 °C). The wells were then washed three times 
as before. Substrate solution was then added to the wells which were then incubated for 30 
minutes at room temperature (~21 °C). The absorbance of the wells at 405 nm was then 
measured on a microplate reader. The absorbance correlates with the amount of complement 
activity that has occurred. The absorbance of the blanks for each pathway was subtracted from 
each value and the percentage activity was calculated using absorbance values in the equation 
activity = [(sample – negative control)/positive control] x 100. 
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3. Structural and functional characterisation of Efb 
3.1. Introduction 
3.1.1. The complement modulating properties of Efb 
Some details of the complement modulating properties of the C-terminal domain of Efb, Efb-C, 
have been described (Hammel et al., 2007c, Lee et al., 2004b). Binding of Efb-C to C3 results 
in inhibition of complement activity. An ELISA-based assay will be used to investigate the 
effect of Efb on each of the three complement activation pathways. 
3.1.2. The fibrinogen binding properties of Efb 
Efb is one of many fibrinogen binding proteins of S. aureus. The fibrinogen and fibronectin 
binding proteins of S. aureus mediate both attachment of the bacterium to host cells and platelet 
activation. 
ClfA, FnbpA and FnbpB bind fibrinogen and fibronectin which leads to the activation of 
platelets (McDevitt et al., 1997, Fitzgerald et al., 2006b). The structural organisation of ClfA 
and FnbpA is shown in figure 3.1. The N-terminal fibrinogen binding domain of ClfA folds into 
three subdomains through which ClfA binds the C-terminus of the γ-chain of fibrinogen 
(McDevitt et al., 1997). FnbpA of S. aureus binds the γ-chain of fibrinogen through its C-
terminal A-domain (Wann et al., 2000). FnbpA also binds fibronectin through its N-terminal 
repeat regions. These regions are natively unfolded and undergo binding-induced folding 
(Bingham et al., 2008). The fibrinogen binding region of ClfB adopts the same conformation as 
ClfA (Perkins et al., 2001) and is required for nasal colonisation. ClfB binds both the C-
terminus of the Aα-chain of fibrinogen (Walsh et al., 2008) and cytokeratin 10 (Wertheim et al., 
2008). Eap binds various molecules associated with attachment (Harraghy et al., 2003) and has 
a superantigen like fold (Geisbrecht et al., 2005). 
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Figure 3.1 Domain organisation of ClfA and FnbpA 
The fibrinogen binding domain of ClfA is folded into three sub-domains; N1, N2 and N3. The R region is 
a repeat region required for functional expression of ClfA on the bacterial surface. The 11 fibronectin 
binding domains of FnbpA are indicated. Signal sequences which target the proteins for secretion are 
marked S. LPXTG/LPETG motifs for cell wall anchorage are indicated. Wall- (W) and membrane- (M) 
spanning regions are indicated. ClfA schematic is adapted from Loughman et al., 2005. FnbpA schematic 
is adapted from Bingham et al., 2008. 
Less is known about the fibrinogen binding N-terminal region of Efb. The N-terminal region of 
Efb contains two near identical 22 amino acid repeats (Boden and Flock, 1994). The repeating 
region of Efb shares homology with the 27-residue repeating sequence in coagulase (Kaida et 
al., 1987, Phonimdaeng et al., 1990). This region of Efb is known to bind to the Aα-chain of 
fragment D of fibrinogen (Palma et al., 2001) The Aα-chain of fragment D is comprised of 
residues V111 – R197 of the Aα-chain. The structure of fragment D is shown in figure 3.2. 
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Figure 3.2 Crystal structure of fragment D of fibrinogen taken from Spraggon et al., 1997 
A ribbon representation of fragment D of human fibrinogen is shown. The Aα-, Bβ- and γ-chains are 
coloured blue, green and red, respectively. Disulphide bonds are shown in yellow. ‘C’ indicates a calcium 
binding site, and CH2O is a carbohydrate cluster associated with the Bβ-chain. The two ‘hole’ areas 
indicated are involved in formation of fibrin polymers. The N- and C-termini are indicated. 
Unlike the other fibrinogen binding proteins discussed so far, Efb-fibrinogen interaction results 
in inhibition of platelet activation (Palma et al., 2001). The site within fibrinogen to which Efb 
binds is within 14 residues of the R95-D97 integrin αIIbβ3 recognition site. Binding of 
fibrinogen to this integrin on platelets is required for platelet activation (Hawiger et al., 1989). 
Binding of thrombospondin to fibrinogen is also required for platelet aggregation and the 
thrombospondin binding site in fibrinogen is found at residues 113 -116 of the Aα-chain 
(Tuszynski et al., 1985). Efb-fibrinogen binding may interfere with either or both of these 
interactions which are required for platelet activation. 
The structure of the N-terminal region of Efb and its interaction with fibrinogen will be further 
characterised using NMR analysis. Work will also be carried out towards production of an Efb – 
fragment D complex for use in crystal trials. 
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3.2. Results 
3.2.1. Purification of Efb 
Efb is comprised of 165 residues, the first 28 of which are a signal sequence and are not part of 
the functioning protein. A construct of residues 29 – 165 of Efb was previously cloned in this 
lab into a pET15b vector to enable His tag purification. For the sequence of this construct refer 
to appendix 1. The plasmid was transformed into E. coli BL21(DE3) cells (Stratagene) and 
glycerol stocks were prepared as described in the Materials and Methods. 
Unlabelled His-Efb was purified as described in the Materials and Methods. Figure 3.3 shows 
the elution profile and figure 3.4 shows a gel of fractions. His-Efb showed a relative mobility in 
SDS PAGE similar to its predicted molecular mass of 18.24 kDa. 15N and 15N/13C labelled 
samples of His-Efb were prepared as described in the Materials and Methods. The elution 
profile shown in figure 3.3 and the gel shown in figure 3.4 are representative of those obtained 
for labelled samples. 
Absorbance 
(mAU) 
Flow volume (ml) 
Figure 3.3 Elution profile of His-Efb purification 
A 1.5 L culture was induced over night at 12 °C and 50 ml cleared lysate was produced through two 
rounds of sonication as described in the Materials and Methods. His-Efb was purified by loading 25 ml 
aliquots of cleared lysate on a 5 ml His trap FF column and eluting with an imidazole gradient of 0 – 500 
mM (green line) using His buffer B. UV absorbance (blue line) is correlated with protein concentration. 
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Figure 3.4 SDS PAGE analysis of His-Efb purification 
His-Efb was purified as described in the Materials and Methods. Lane 1 – uninduced; lane 2 – induced; 
lane 3 – complete lysate; lane 4 – insoluble fraction, lane 5 - soluble fraction 1; lane 6 – soluble fraction 
2; lane 7 – purified protein fraction A2; lane 8 – purified protein fraction A3; lane 9 – purified protein 
fraction A4; lane 10 – purified protein fraction A5; lanes 11 and 12 – purified protein fractions from 2nd 
25 ml cleared lysate aliquot; lane 13 – flow through fraction X1. Efb migrating at ~18.4 kDa is indicated 
by an arrow. 
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3.2.2. Efb complement assay 
 
A complement assay was carried out to determine the effect that Efb has on each of the three 
complement activation pathways. The assay was carried out using the ELISA-based Wielisa kit, 
as described in the Materials and Methods. The result, shown in figure 3.5, shows that Efb 
inhibits the classical pathway moreso after incubation at 4 °C than at 37 °C whereas the lectin 
pathway is inhibited moreso after incubation at 37 °C. Efb completely inhibits the alternative 
pathway after incubation at either 4 °C or 37 °C.  
 
 
 
 
Figure 3.5 Efb complement assay result 
His-Efb at a final concentration of 0.96 mg ml-1 (52.62 µM) was incubated with human serum at either  
4 °C (blue bars) or 37 °C (red bars) prior to addition to the assay wells. Percentage activity was calculated 
using absorbance values in the equation activity  =  [(sample – negative control)/positive control] x 100. 
Each assay well was set up in duplicate and error bars represent the upper and lower result.  
 
3.2.3. NMR analysis of Efb 
 
NMR spectroscopy was carried out as described in the Materials and Methods. Initially an 
HSQC spectrum was recorded on 15N-labelled His-Efb. Sequence-specific backbone resonance 
assignments were made using data sets obtained as described in the Materials and Methods 
(figure 3.6).  
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Figure 3.6 Assigned His-Efb HSQC spectrum 
1H-15N HSQC spectrum of uniformly 15N-enriched Efb recorded at 25 ºC and 600 MHz (blue peaks). The 
sample contained 5 mM MES, 100 mM sodium chloride, and 10% D2O at pH 5.5. The concentration of 
His-Efb in the samples as determined by UV spectroscopy was ~0.244 mM (5 mg ml-1). Backbone peaks 
are labelled with the residue number for the construct. Residues 1 to 21 are derived from the vector and 
residues labelled A22 to R158 correspond to residues A29 to R165 of the full length Efb protein. 
Overlaid onto the spectrum is an NH2-edited HSQC (red peaks). These peaks result from side chain NH2 
resonances of glutamine and asparagine residues. Unassigned peaks are marked with asterisks. For the 
table of assignments refer to appendix 5. 
 
The peaks in the HSQC are generally well dispersed suggesting that the protein has tertiary 
structure. Resonance assignment was hindered by the presence of a) a small consensus repeat in 
the N-terminal region of Efb and b) considerable peak overlap in the central part of the HSQC 
spectrum. The His-Efb construct contains 152 non-proline residues. 104 residues have been 
assigned – 3 of these are tag-derived and 101 are from Efb. Assigned residues are 
predominantly in the C-terminal part of the protein (figure 3.7). N-terminal residues which have 
been assigned fall within a narrow (~7.9 - ~8.5 ppm) 1H resonance range which suggests that 
the N-terminal region of Efb is unstructured. 
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Figure 3.7 Efb resonance assignments

The Efb sequence (residues A29 to R165) is shown with assigned residues highlighted.

3.2.4. NMR analysis of the Efb – fibrinogen interaction 
It is reported that Efb binds fibrinogen via the Aα-chain of the D fragment of fibrinogen (Palma 
et al., 2001). The Aα-chain contribution to the D fragment is comprised of residues V111 – 
R197. The N-terminal region of Efb is reported to be responsible for this binding (Lee et al., 
2004b). The NMR data presented above suggest that the N-terminal region of Efb is 
unstructured. 
An NMR titration experiment was carried out to track changes in the Efb 15N-1H HSQC 
spectrum upon addition of unlabelled fibrinogen peptides to the NMR sample. Tracking these 
changes could (a) identify binding-induced structural changes in Efb and (b) identify which part 
of the fibrinogen Aα-chain fragment D molecule may be particularly important in binding. Each 
peptide is 30 residues long and the peptides span E92 – H201 of the Aα-chain of fibrinogen. 
Details of the peptides are shown in table 3.1. The conditions for each HSQC experiment are 
shown in table 3.2. 
Fibrinogen peptide Section of Aα-chain of 
fibrinogen spanned 
Amino acid sequence 
I E92 – V121 EILRGDFSSANNRDNTYNRVSEDLRSRIEV 
II S112 – R141 SEDLRSRIEVLKRKVIEKVQHIQLLQKNVR 
III H132 – C161 HIQLLQKNVRAQLVDMKRLEVDIDIKIRSC 
IV V152 – Q181 VDIDIKIRSCRGSCSRALAREVDLKDYEDQ 
V E172 – H201 EVDLKDYEDQQKQLEQVIAKDLLPSRDRQH 
Table 3.1 Fibrinogen peptides used in the NMR titration

The region of the Aα-chain spanned and the sequence of each peptide is shown.
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Spectrum number Conc. of peptide (mM) Molar Ratio (Efb : peptide) 
1 0 1 : 0 
2 0.061 1 : 0.25 
3 0.122 1 : 0.50 
4 0.183 1 : 0.75 
5 0.244 1 : 1.0 
 
Table 3.2 Efb - fibrinogen NMR titration experiment 
The concentration of Efb was 0.244 mM in each case. The concentration of peptide and the molar ratio of 
the two proteins at each stage are shown. 
 
Reassignment of Efb in different buffer conditions 
Figure 3.8 shows spectrum 1 of peptide I. This spectrum is representative of the starting point of 
each NMR titration experiment. 
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Figure 3.8 Efb – fibrinogen NMR titration peptide I, spectrum 1 
1H-15N HSQC spectrum of uniformly 15N-enriched His-Efb recorded at 25 ºC and 600 MHz. The sample 
contained 20 mM MES, 100 mM sodium chloride, 1 mM EDTA,1 mM benzamidine and 10% D2O, pH 
5.5. The concentration of His-Efb was 0.244 mM. 
 
The labelled HSQC of full length Efb (figure 3.6) was used to assign the starting spectrum for 
each titration experiment. This assignment was hindered by the considerable overlap in the 
central part of the HSQC spectra. For example, D76, R84, F79 and Q51 are residues whose 
resonances could be assigned in the original HSQC spectrum (figure 3.6) but it was not possible 
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 to clearly identify which peaks in the new HSQC spectra (figure 3.8) were representative of 
these residues.  
 
Binding-induced folding of Efb 
Figure 3.9 shows spectrums 1 and 5 for peptide I and is representative of the end point of each 
titration. The peaks of spectrum 5 are no more spread out than those of spectrum 1 which 
suggests that binding-induced folding of the N-terminal region of Efb has not occurred. 
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Figure 3.9 Efb – fibrinogen titration peptide I, spectrum 1 and spectrum 5 overlay 
1H-15N HSQC spectrum of Efb at 0.244 mM is shown in the absence of any peptide (red peaks) and in the 
presence of 0.244 mM fibrinogen peptide I (blue peaks) (molar ratio Efb: peptide of 1 : 1).  
 
Chemical shift perturbation 
Table 3.3 shows the number of peaks which could be assigned in the starting spectra and 
tracked throughout the titration.  
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Peptide number N-terminal assigned (29-104) C-terminal assigned (105-165) 
I 28 40 
II 29 40 
III 30 40 
IV 27 40 
V 29 40 
 
Table 3.3 Efb – fibrinogen peptide titration, tracked residues 
In the original HSQC spectrum of Efb (figure 3.6), 44 of the 76 N-terminal non-proline residues and 57 
of the 61 C-terminal residues could be assigned. Of these, the numbers that could be tracked in the 
titration experiment are shown. 
 
During the course of the NMR titration experiments, no peaks split or broadened beyond 
detection. 
 
Simple observation of the NMR spectra showed that most chemical shift perturbations were 
small. In order to clearly see the extent of chemical shift perturbation, chemical shift 
perturbations were plotted in a bar chart. Figure 3.10 shows the combined NH proton and 15N 
chemical shift change in ppm -  Δδ(NH/15N) - which is calculated as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 
"# NH /15N( ) =
"# NH[ ]( )
2
+
"# 15N[ ]( )
2
25
2
!
PAGE 53

53 
3.2.5. Crystal trials 
It was not possible to observe binding-induced folding of N-terminal Efb in the presence of 
fibrinogen peptides. To enable structure determination of Efb in complex with fibrinogen, work 
was carried out to prepare a complex of Efb and fibrinogen fragment D for crystal trials. 
3.2.5.1. Preparation of fragment D by trypsin digest 
The ProtParam tool of the online server Expasy provided by the Swiss Institute of 
Bioinformatics (www.expasy.ch/tools/protparam.html; accessed 07 August 2009) was used to 
determine the predicted molecular masses of the constituent chains of fragment D of fibrinogen. 
The predicted molecular masses of the Aα-chain (V111 – R197), Bβ-chain (D134 – Q461) and 
γ-chains (M89 – E411) of fragment D of fibrinogen are 10.2 kDa, 37.7 kDa and 36.7 kDa 
respectively. A personal communication with Professor Russell Doolittle, however, identified 
that these fragments ran at 12, 42 and 38 kDa when prepared in a similar manner by Everse et al 
(Everse et al., 1995). One would also expect to see the non-fragment D parts of each of these 
chains subsequent to trypsin digest. The ProtParam tool was therefore used to obtain the 
predicted molecular masses of these species. The non-fragment D parts of the Bβ- and γ-chains 
have predicted molecular masses of 18.4 kDa and 11.3 kDa respectively. The remaining pieces 
of the Aα-chain have predicted molecular masses of 12.6 and 43.4 kDa. 
Initially a time-course of trypsin digestion of human fibrinogen was carried out. The results are 
shown in figures 3.11, 3.12 and 3.13. 
Figure 3.11 Fibrinogen trypsin digest time-course 4°C 
1 mg human fibrinogen was digested as described in the Materials and Methods. 2 µl samples were taken 
prior to addition of trypsin (lane 1) and at 10 min (lane 2), 20 mins (lane 3), 40 mins (lane 4), 1 hour (lane 
5), 2 hr (lane 6), 4 hr (lane 7), 6 hr (lane 8) and after over night incubation (lane 9). 
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Figure 3.12 Fibrinogen trypsin digest time-course 21°C 
1 mg human fibrinogen was digested as described in the Materials and Methods. 2 µl samples were taken 
prior to addition of trypsin (lane 1) and at 10 min (lane 2), 20 mins (lane 3), 40 mins (lane 4), 1 hour (lane 
5), 2 hr (lane 6), 4 hr (lane 7), 6 hr (lane 8) and after over night incubation (lane 9). Candidate bands 
which may be Bβ- and γ-chains of fragment D migrating close to 42 and 38 kDa respectively are 
indicated by arrows in lane 8. 
Figure 3.13 Fibrinogen trypsin digest time-course 37°C 
1 mg human fibrinogen was digested as described in the Materials and Methods. 2 µl samples were taken 
prior to addition of trypsin (lane 1) and at 1 min (lanes 2 and 3), 5 mins (lane 4), 10 mins (lane 5), 30 
mins (lane 6), 1 hour (lane 7), 2hr (lane 8), 4hr (lane 9), 6hr (lane 10) and after over night incubation 
(lane 11). Candidate bands which may be Bβ- and γ-chains of fragment D migrating close to 42 and 38 
kDa respectively are indicated by arrows in lane 6. 
Bands which may be the Bβ- and γ-chains of fragment D migrating at 42 and 38 kDa 
respectively are observed after digestion at 37 °C for 30 minutes (figure 3.13 lane 6) and after 
digestion at 21 °C for 6 hours (figure 3.12 lane 8). Figure 3.11 shows that these fragments are 
not produced before the end point of the time-course when carried out at 4 °C. It is possible that 
the 43.3 kDa non-fragment D species is migrating at or near this size too. Any of the bands 
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which migrate below the 14.4 kDa marker may be the 10.22 kDa Aα-chain fragment D or either 
of the 12.63 kD or 11.34 kDa non-fragment D species. 
To prepare fragment D for crystal trials with Efb, the trypsin digest was repeated with 20 mg 
fibrinogen. 20 mg of fibrinogen was trypsinised as described in the Material and Methods and 
after 6 hours the reaction mixture was frozen at -20 °C. 
Purified His-Efb was bound to a 1 ml His-trap column (GE Healthcare). To remove fragment D 
from the digestion mix and to bind fragment D to Efb, the trypsin digestion mixture prepared 
previously was thawed and then passed over the column. The result is shown in figures 3.14 and 
3.15. 
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Figure 3.14 Elution profile of Efb – fragment D complex preparation 
(A) Purified His-Efb was bound to a 1 ml His-trap column. (B) The trypsin digest mixture was run over 
the column and the complex was eluted with an imidazole gradient of 0 – 500 mM (green line) using His 
buffer B. UV absorbance (blue line) is correlated with protein concentration. 
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Figure 3.15 SDS PAGE analysis the Efb – fragment D complex preparation 
Lane 1 – trypsin mixture with Bβ- and γ-chains identified with arrows; lane 2 – His-Efb; lane 3 – His-Efb 
flow through fractions A3 and A4; lane 4 – fragment D flow through peak A9; lane 5 – peak fractions 
A14 and A15. Arrows indicate fragments of 42 kDa (Bβ-chain) and 38 kDa (γ-chain) in lane 1. 
Figure 3.15 shows that His-Efb was impure. Contaminating species can be seen beneath the Efb 
band in lane 2. These impurities remain in the eluted peak (lane 5). The 42 kDa band indicated 
by an arrow in lane 1 is a doublet. Faint bands can be seen in lane 5 at the positions indicated by 
arrows in lane 1. This suggests that fragment D may have been pulled down with His-Efb. In 
order to verify this, a sample of the peak was re-run and the gel was silver stained as described 
in the Materials and Methods. 
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Figure 3.16 Preparation of the Efb – fragment D complex – silver stain 
Lane 1 shows the eluted proteins (equivalent of figure 3.15 lane 5). Candidate Bβ- and γ-chains are 
labelled. 
This gel shows that two fragment D chains were pulled down with Efb. Efb can be seen 
migrating at ~18.4 kDa and Efb impurities can be seen underneath as in figure 3.16. This gel 
shows that non-fragment D contaminating species are also pulled down with Efb. 
A further digest of fibrinogen was carried out and a different method of separating fragment D 
from the digestion mixture was attempted. 2 mg of human fibrinogen was digested as described 
in the Materials and Methods. Ion-exchange was used to try to remove fragment D from the 
digestion mixture. Fragment D has an estimated pI of 6.27. Attempts were made to purify 
fragment D on both a cation and an anion exchange column. The result is shown in figure 3.17. 
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Figure 3.17 Elution profile of ion-exchange purification of fragment D 
2 mg fibrinogen in a total volume of 40 µl was trypsinised as described in the Materials and Methods. 
After the digestion reaction, 20 µl of the digestion mixture was buffer exchanged into HEPES buffer A 
and was run over a Resource S column (A). Protein was eluted using a sodium chloride gradient of 0 – 
500 mM (green line) using HEPES buffer B. 20 µl of the digestion mix was buffer exchanged into 50 
mM Tris pH 7.5 and was run over a Resource Q column (B). Protein was eluted using a gradient of 
sodium chloride from 0 - 500 mM (green line) in 20 mM Tris pH 7.5. UV absorbance (blue line) is 
correlated with protein concentration. The flow rate within the Akta system is represented by the orange 
line in (A). 
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A gel of the fractions of the elution profiles revealed that no protein was present. 
3.2.1. Efb-N cloning 
After the difficulty of assigning the N-terminal of Efb, and being unable to observe binding-
induced folding of N-terminal Efb N, or to set crystal trials, it was decided to clone N-terminal 
Efb (residues 29 -104), here on in named Efb-N, to facilitate expression and subsequent 
structural and functional analysis of this part of Efb on its own. 
Cloning of Efb-N into the vectors pQE30, pSV281 and pBG101 would allow expression of the 
protein with (a) a small non-cleavable 6His tag (pQE30), (b) a TEV protease cleavable 6His tag 
(pSV281) and (c) a 3C protease cleavable 6His-GST tag (pBG101). 
The Efb-N construct was amplified by PCR and the reaction cleaned up as described in the 
Materials and Methods and the result is shown in figure 3.18. 
Figure 3.18 Agarose gel analysis of the Efb-N DNA fragment and vectors 
PCR of the Efb-N construct was carried out as described in the Materials and Methods and the PCR 
cleaned up. Lane 1 shows a sample of the cleaned up Efb-N PCR product. Samples of the vectors 
pSV281 (lane 2), pBG101 (lane 3) and pQE30 (lane 4) are also shown. 
The Efb-N fragment was then subject to sequential digestion by the restriction endonucleases 
Bam HI and Hind III as described in the Materials and Methods. The vectors pSV281, pBG101 
and pQE30 were also subjected to digestion with the enzymes as described. The digested 
vectors and fragments were ligated and then 10 µl ligation mixture was used to transform the 
sub-cloning efficiency cells E. coli DH5α as per the manufacturer’s instructions. 
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Ten of the resultant colonies from each agar plate were screened for the desired insert as 
described in section 2.4.2.1. The results are shown in figures 3.19, 3.20 and 3.21. 
Figure 3.19 PCR screen for positive pBG101_Efb-N clones 
Ten colonies were tested for the presence of the desired plasmid. 2 µl 6 x DNA sample buffer was added 
to 10 µl of each PCR for loading onto the agarose gel. Lanes 1 to 10 show the ten clones tested. The Efb-
N construct consists of ~240 base pairs. In lanes 2 and 3 bands can be seen migrating between 200 and 
300 base pairs. This indicates that this clone is positive. Lane 11 shows a sample of the PCR positive 
control. 
Figure 3.20 PCR screen for positive pSV281_Efb-N clones 
Ten colonies were tested for the presence of the desired plasmid. 2 µl 6 x DNA sample buffer was added 
to 10 µl of each PCR for loading onto the agarose gel. Lanes 1 to 10 show the ten clones tested. The Efb-
N construct consists of ~240 base pairs. In lane 3 a band can be seen migrating between 200 and 300 base 
pairs. This indicates that this clones are positive. Lane 11 shows a sample of the PCR positive control. 
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Figure 3.21 PCR screen for positive pQE30_Efb-N clones 
Ten colonies were tested for the presence of the desired plasmid. 2 µl 6 x DNA sample buffer was added 
to 10 µl of each PCR for loading onto the agarose gel. Lanes 1 to 10 show the ten clones tested. The 
absence of any bands in these lanes indicates that no positive clones have been identified. Lane 11 shows 
a sample of the PCR positive control. 
Plasmids containing the correct inserts were obtained as described in the Materials and Methods 
and samples of plasmids were sent for sequencing (GATC Biotech, Constance, Germany). The 
sequencing result showed that the Efb-N gene was inserted correctly into the vectors. Plasmids 
were then used to transform the expression strain BL21(DE3) and glycerol stocks were prepared 
as described in the Materials and Methods. 
3.2.2. Expression and purification of Efb-N 
Expression and purification of Efb-N from pBG101 and pSV281 was tested. The elution 
profiles are shown in figures 3.22 and 3.23. 
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A 
Flow volume (ml) 
Absorbance 
(mAU) 
B 
Flow volume (ml) 
Absorbance 
(mAU) 
Figure 3.22 Expression and purification of Efb-N from pBG101 – elution profiles 
A 50 ml secondary culture was split into two subsequent to addition of IPTG. 25 ml was left at 37 °C for 
three hours before harvesting. The remaining 25 ml was left at 12 °C over night before harvesting. 5 ml 
cleared lysate was produced from each culture and Efb-N was purified from the cleared lysate on a 1 ml 
HisTrap FF column using an imidazole gradient of 0 – 500 mM (green line) using His buffer B. UV 
absorbance (blue line) is correlated with protein concentration. Elution profiles of the 37 °C induction (A) 
and the 12 °C induction (B) are shown. 
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A 
Absorbance 
(mAU) 
Flow volume (ml) 
B 
Absorbance 
(mAU) 
Flow volume (ml) 
Figure 3.23 Expression and purification of Efb-N from pSV281 – elution profiles 
A 50 ml secondary culture was split into two subsequent to addition of IPTG. 25 ml was left at 37 °C for 
three hours before harvesting. The remaining 25 ml was left at 12 °C over night before harvesting. 5 ml 
cleared lysate was produced from each culture and Efb-N was purified from the cleared lysate on a 1 ml 
HisTrap FF column using an imidazole gradient of 0 – 500 mM (green line) using His buffer B. UV 
absorbance (blue line) is correlated with protein concentration. Elution profiles of the 37 °C induction (A) 
and the 12 °C induction (B) are shown. 
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Protein fractions were visualised on an SDS-PAGE gel (figure 3.24). His-Efb-N expressed from 
pSV281 showed a relative mobility in SDS PAGE similar to its predicted molecular mass of 
10.79 kDa. GST-Efb-N showed a relative mobility in SDS PAGE similar to its predicted 
molecular mass of 36 kDa. 
Figure 3.24 SDS PAGE analysis of Efb-N expression and purification

Expression and purification of Efb-N from pSV281 and pBG101 was tested. pSV281: Lane 1 –

uninduced; lane 2 – induced (37 °C); lane 3 – soluble (37 °C); lane 4 – insoluble (37 °C); lane 5 – pure

protein fraction C13 (37 °C); lane 6 – soluble (12 °C); lane 7 – insoluble (12 °C); lane 13 – pure protein

fraction E1 (12 °C). pBG101: lane 9 – uninduced; lane 10 – induced (37 °C); lane 11 – soluble (37 °C);

lane 12 – insoluble (37 °C); lane 8 – pure protein fraction D7 (37 °C); lane 14 – soluble (12 °C); lane 15 –

insoluble (12 °C); lane 16 – pure protein fraction E11 (12 °C). His-Efb and GST-Efb migrating at ~11

and ~ 36 kDa respectively are identified with arrows.

Protein expression and purification trials showed that the purest Efb fraction was obtained from 
pSV281 through induction at 37 °C for one hour and so subsequent purification of Efb-N was 
carried out using this construct and this induction temperature. Purified protein elution profiles 
and SDS visualisation of fractions were as seen in figures 3.23 and 3.24. 
3.2.3. NMR analysis of Efb-N 
A 15N-Efb-N NMR sample was prepared as described in the Materials and Methods from the 
construct of Efb-N in pSV281. Final samples of Efb-N for NMR analysis contained 5 mM 
MES, 100 mM sodium chloride, 1 mM EDTA,1 mM benzamidine and 10% D2O, pH 5.5. An 
HSQC spectrum of Efb-N is shown in figure 3.25. The Efb-N HSQC was superimposed on the 
Efb HSQC (figure 3.6) to facilitate labelling of the Efb-N HSQC. 
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Figure 3.25 HSQC spectrum of Efb-N 
1H-15N HSQC spectrum of uniformly 15N-enriched Efb-N recorded at 25 ºC and 600 MHz. The sample 
contained 5 mM MES, 100 mM sodium chloride and 10% D2O, pH 5.5. Backbone peaks are labelled 
with the residue number facilitated by superimposition of the Efb-N HSQC spectrum onto the Efb HSQC. 
Peaks exclusive to this spectrum are marked with an ‘x’. Peaks which appear on both HSQC spectra and 
are unassigned are marked with asterisks. 
10 peaks are exclusive to the Efb-N HSQC spectrum. A further 7 peaks are present and 
unassigned on the Efb spectrum. 29 assigned backbone NH Efb-N peaks are present. These 
peaks fall within a narrow 1H chemical shift range (7.8 -8.6 ppm) which suggests that Efb-N has 
no significant tertiary structure. 
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3.2.4. Refolding of Efb-N 
The NMR data presented above suggested that in this sample of Efb-N the protein has no 
significant tertiary structure. To enable production of folded protein which should yield better 
quality NMR spectra, a refolding experiment was carried out and the result is shown in figures 
3.26 and 3.27. 
Absorbance 
(mAU) 
Flow volume (ml) 
Figure 3.26 Efb-N refolding experiment – elution profile 
A refolding experiment was carried out as described in the Materials and Methods. Refolded protein was 
purified from 20 ml native buffer on a 1 ml HisTrap HP column. Protein was eluted using a gradient of 
imidazole from 0 - 500 mM (green line) in native buffer. UV absorbance (blue line) is correlated with 
protein concentration. 
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Figure 3.27 Efb-N refolding experiment – gel of purified refolded protein 
Samples of fractions A10, A11 and A12 (figure 3.26) were taken and are shown in lanes 1, 2 and 3 
respectively. 
Figure 3.37 shows that Efb-N was repurifed from the refolding buffer. Fractions A10 and A11, 
represented by lanes 1 and 2 on the gel shown in figure 3.27, were pooled and buffer exchanged 
into NMR buffer. The sample did not contain sufficient protein to produce an NMR spectrum. 
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3.3. Discussion 
3.3.1. The effect of Efb on the complement activation pathways 
Efb at 52.62 µM shows complete inhibition of the alternative pathway after incubation at both 4 
°C and 37 ºC. A relatively strong inhibition of the classical pathway after incubation at 4 ºC but 
not at 37 °C was observed. The binding of Efb-C to C3 is mediated by electrostatic interactions 
(Haspel et al., 2008). This may account for enhanced classical pathway inhibition after 
incubation of Efb with serum at 4 °C in comparison with incubation at 37 °C. 
Inhibition of the classical and alternative pathways of complement activation by Efb has been 
shown previously (Lee et al., 2004a, Hammel et al., 2007c). The effect of Efb on the lectin 
pathway has not previously been investigated. The results presented here show that Efb inhibits 
the lectin pathway, moreso after incubation at 37 °C than 4 °C. 
3.3.2. Structural analysis of Efb 
NMR analysis was carried out on Efb. 57 of the 61 C-terminal (residues 105 – 165) backbone 
resonances of the Efb HSQC were assigned (figure 3.6). Difficulties arose in completing the 
assignment of the rest of Efb. This was due partly to the considerable overlap in the middle of 
the Efb HSQC spectrum which made identification of individual peaks difficult. The presence 
of a repeat in the N-terminal region of Efb also made assignments in this area particularly 
difficult. An alignment between the two Efb repeats is shown. 
N I V E Y N D G T F K Y Q S R P K F N

N I L E F N D G T F E Y G A R P Q F N

Figure 3.28 Short consensus repeats of Efb 
Alignment between two stretches of the Efb sequence. Residues 46 to 64 are aligned with residues 77 to 
95. 
44 of the 76 N-terminal backbone resonances have been assigned (figure 3.26). These N-
terminal backbone NH peaks fall within a narrow 1H chemical shift range (7.8 - 8.4 ppm) 
suggesting that the N-terminal region of Efb has no significant tertiary structure. 
70

3.3.1. Efb – Fg titrations 
NMR analysis of Efb revealed that the N-terminal region of Efb has no significant tertiary 
structure. It was thought that folding of the N-terminal region of Efb may occur upon binding to 
fibrinogen. An NMR titration experiment was carried out whereby five 30-residue peptides 
which span the Aα-chain of fragment D of fibrinogen in an overlapping fashion were titrated 
into NMR samples of Efb. If binding-induced folding of N-terminal Efb were to occur, one 
would expect N-terminal-derived peaks to become more widely dispersed in the HSQC 
spectrum. Even if such induced folding did not occur, it is possible that chemical shift 
perturbations could indicate which Efb residues are involved in binding to fibrinogen. This 
experiment could also identify which part of the Aα-chain of fibrinogen is important in the 
binding. 
No binding-induced folding is seen for Efb in the presence of each peptide. Only 46 backbone 
peaks are present and all are within the narrow 1H ppm range occupied in previous HSQC 
spectra. 
It was not possible to clearly identify assigned Efb-N peaks in the starting spectra for each 
peptide titration and so the chemical shift perturbation of only a small number of Efb N-
terminal resonances was tracked. The results show that no significant perturbation of any of 
these Efb residues occurred upon addition of fibrinogen peptides I - IV to the NMR sample. The 
largest perturbations were observed for I78, Q134 and L159. These perturbations were 
considerably larger than those observed across the remainder of the Efb residues. Peptide V 
binding may occur at or near these residues. The sensitivity of chemical shifts, however, is such 
that perturbations may occur for residues remote from the binding site. 
These results suggest that the fibrinogen peptides do not bind strongly to Efb. A possible reason 
for this is that the whole of the Aα-chain is required for binding. The structure of fragment D in 
figure 3.2 shows that the N-terminal of the Aα-chain of the D fragment ‘doubles back’ on itself 
such that the two halves of the sequence lie next to one another. The binding site for Efb on the 
Aα-chain may incorporate residues from both halves of the chain. 
Carrying out the NMR titration using the complete Aα-chain of fragment D from which the 
peptides are derived may be more successful and allow the residues involved in Efb binding to 
fibrinogen to be identified. It is reported that Efb can bind the Aα-chain of fragment D when it 
is isolated (Palma et al., 2001), suggesting that the Bβ- and γ-chain segments are not required 
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for formation of the Efb binding site. Analysis of the binding of the entire fragment D to Efb 
would, however, be more informative, and so this was attempted. 
An NMR titration experiment of this sort could not be carried out with fragment D due to the 
size of fragment D. Fragment D is an ~ 86 kDa protein. A complex of Efb – fragment D would 
tumble so slowly in solution that line-broadening would substantially reduce the number of 
observable Efb peaks. Complicated and expensive isotope labelling schemes would be required 
to overcome this problem, including deuteration of the proteins whilst retaining protonation of 
the methyl groups of leucine, isoleucine and valine residues. To analyse binding of Efb to 
fragment D, X-ray crystallographic methods would therefore have to be employed. 
3.3.2. Preparing fragment D for crystal trials with Efb 
A review of the literature revealed that fragment D of fibrinogen could be prepared by trypsin 
digest (Everse et al., 1995). Using a method based on that of Everse et al., 0.01 mg trypsin was 
used per mg of fibrinogen. Trypsin digestion time-course experiments were carried out initially 
at 4 °C, room temperature (~21 °C) and 37 °C to determine a suitable time and temperature. 
Samples taken during the time-course experiments were split into two. Reduced samples were 
prepared in the normal way and non-reduced samples were prepared by adding SDS buffer 
which did not contain the reducing agent β-mercaptoethanol, and the samples were not boiled. 
Fragment D is 86 kDa and so is expected to run at about this on a non-reducing SDS gel. Under 
reducing conditions, the sulphide bonds which anchor together the Aα-, Bβ- and γ-chains of 
fragment D are reduced and so these fragments run separately. The samples run on the gels 
shown in figures 3.11, 3.12 and 3.13 were also run under non-reducing conditions but these gels 
were identical to their reducing-gel counterparts. This may be due to the volatile nature of β-
mercaptoethanol – non-reduced samples may have become contaminated with β-
mercaptoethanol during the process of sample preparation. 
In the absence of non-reduced samples, reduced samples were used to track digestion of 
fibrinogen. The three chains of non-digested human fibrinogen, Aα, Bβ and γ, have molecular 
masses of 70 kDa, 56 kDa and 48 kDa respectively (Herrick et al., 1999). These are seen in lane 
1 of figure 3.13. When Everse et al. trypsinised human fibrinogen using a method similar to the 
one used here, they identified that trypsin cut the Aα-chain N-terminally at V111 producing 
V111 – R197, Bβ-chain at D134 producing D134 – Q461 and γ-chain at M89 producing M89 – 
E411 (Everse et al., 1995). An online proteomics server was used to obtain the predicted 
molecular masses of each of these chains in fragment D, but a personal communication with 
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Professor Russell Doolittle established that these Aα-, Bβ- and γ-chains ran on an SDS gel at 
12, 42 and 38 kDa respectively. After 30 minutes at 37 °C (figure 3.13) and 6 hours at 21 °C 
(figure 3.12) bands of these sizes are seen but could not be positively identified due to the 
presence of other species in the digestion mixture. It was hoped that fragment D could be fished 
from the mixture on an Efb column. 
A larger-scale digest was carried out at 21 °C and figure 3.15 shows that the proteins migrating 
at 42 and 38 kDa are present in the digestion mixture. The gel was over-run to the extent that 
species smaller than 14 kDa could not be observed. Silver staining, figure 3.16, revealed that 5 
further proteins were contained in the digestion mixture. 
An attempt was made to purify fragment D from the digestion mixture using His-Efb bound to a 
His column. Figure 3.15 shows that contaminating species in the digestion mixture which do not 
correspond to fragment D chains, were pulled down with Efb. Silver staining, figure 3.16, 
revealed that the 42 kDa (Bβ-chain) and 38 kDa (γ-chain) constituents of fragment D are pulled 
down by Efb. Again, it was not possible to visualise the 12 kDa band as the gel was run for too 
long. Attempts to purify fragment D using ion-exchange were unsuccessful. 
A review of the literature revealed proven success in isolation of fragment D from a trypsin 
digest of fibrinogen mixture. Pietrocola et al purified fragment D using ion-exchange 
chromatography; their trypsin digest was run over a mono Q HR 5/5 column and fragment D 
was eluted with a sodium chloride gradient (Pietrocola et al., 2006). 
Gel filtration may facilitate separation of fragment D from the digestion mixture. This method 
separates species according to their size. Intact fragment D would be expected to be the largest 
protein present in the digestion mixture and so would be contained in the leading peak. 
Spraggon et al digested a fibrin clot with trypsin in order to obtain ‘double – D’ – a fragment 
composed of two fragment D molecules. Gel filtration was used to purify the double-D 
fragment from the digest mixture (Spraggon et al., 1997). Everse et al used a Gly-Pro-Arg 
affinity column to purify fragment D from a fibrinogen trypsin digest mixture (Everse et al., 
1995). Palma et al used gel filtration followed by affinity chromatography on an Efb-sepharose 
column to remove fragment D from a plasmin digestion mixture (Palma et al., 2001). Further 
work to optimise the conditions under which fragment D is fished from the digestion mixture is 
required. 
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3.3.3. NMR analysis of Efb-N 
NMR analysis of Efb revealed that the N-terminal part of the protein had no significant tertiary 
structure and binding-induced folding in the presence of fibrinogen-derived 30 mer peptides 
was not observed. Attempts to crystallise Efb in complex with fragment D were also 
unsuccessful and so it was decided to clone the N-terminal part of Efb to enable analysis of this 
domain on its own. It was also hoped that Efb-N could be used to study Efb-Fg interaction. 
Figure 3.35 shows that the peaks on the HSQC fall within a narrow 1H ppm range (7.9 to 8.6). 
This suggests that the protein has no significant tertiary structure. 
Superimposition of the Efb-N HSQC (figure 3.35) onto the Efb HSQC (figure 3.6) facilitated 
labelling of the Efb-N HSQC. Of the 40 resonances present on the Efb HSQC which were 
assigned to residues derived from Efb-N, 27 are present on the Efb-N HSQC and the resonances 
are very similar between the two spectra. 
There are 17 unlabelled peaks on the Efb-N HSQC. Of these, 7 are present and unassigned on 
the Efb HSQC and ten of these peaks appear exclusively on the Efb-N HSQC. Peaks which 
appear exclusively on the Efb-N HSQC may be derived from the His tag - this protein was 
expressed from pSV281 with a 16 residue His tag. Alternatively, these peaks which are not 
present in the Efb HSQC may be derived from the Efb-N itself but just not appear on the Efb 
HSQC. Coupled with the fact that 15 peaks assigned to Efb-N on the Efb HSQC are not present 
on the Efb-N sample, this suggests that the N-terminal part of Efb may have taken on a different 
conformation in each sample. This may be the result of slight changes in the buffer conditions 
between the two samples. Or it may be because of the presence or absence of the C-terminal 
part of the molecule. Interactions between the two parts of the molecule may produce the effect 
that is seen. 
The presence of 46 poorly dispersed backbone peaks on the Efb-N HSQC when one would 
expect 76 protein-derived peaks plus 17 His tag derived peaks suggests that this sample is of 
poor quality and so no further NMR spectra were obtained for this sample. 
An attempt was made to refold the protein. The chromatogram shown in figure 3.26 shows that 
protein was purified from native buffer and the gel in figure 3.27 shows that the protein 
migrates as it did before the refolding experiment was carried out. Preparation of an NMR 
sample from this protein, however, yielded a sample of low protein concentration that was 
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insufficient for NMR data acquisition. The protein may have degraded during the course of the 
refolding experiment. No further attempts to fold Efb-N were carried out as the NMR data 
suggest that the N-terminal of Efb is natively unstructured. 
Efb-N as a natively unfolded protein 
The N-terminal region of Efb contains two near identical 22 amino acid repeats (Boden and 
Flock, 1994). Tandemly repeated short segments is a feature associated with natively unfolded 
proteins moreso than other proteins (Tompa, 2003). 
Natively unfolded domains are a feature of S. aureus fibronectin binding proteins. The 
fibronectin binding region of FnbpA is comprised of repeating units which are unstructured but 
become structured upon binding (Bingham et al., 2008). This beta-zipper mechanism of binding 
has also been identified in a Streptococcal fibronectin binding protein, B3, which binds 
fibronectin through a tandem repeat region (Schwarz-Linek et al., 2003). The fibronectin 
binding protein of Streptococcus FbsA (fibrinogen binding protein of Streptococcus agalactiae) 
binds fibrinogen through a region which contains a number of 16 amino acid repeats (Schubert 
et al., 2002). A fibronectin binding lipoprotein of Borrelia burgdorferi, BBK32, is an 
MSCRAMM that has a C-terminal comprised of α-helices and an unordered N-terminal which 
binds fibronectin in the same way (Kim et al., 2004). The fibrinogen binding proteins of S. 
aureus are structured. The structure of the fibrinogen binding domain of FnbpA is yet to be 
elucidated. This domain shares homology with the fibrinogen binding domain of ClfA, which is 
structured (Ganesh et al., 2008). Eap binds fibrinogen and is structured (Geisbrecht et al., 2005, 
Hammel et al., 2007a). Coagulase is thought to bind fibrinogen through a domain comprised of 
repeats (Heilmann et al., 2002) however the details of this interaction are unclear. Efb-N shares 
homology with the fibrinogen binding domain of coagulase (Kaida et al., 1987). The 
mechanism of coagulase binding to fibrinogen has not been elucidated but based on this 
homology Efb-N and coagulase may bind fibrinogen in a similar manner. As absence of a native 
fold is a feature of fibronectin binding domains, it should be considered that Efb-N may bind 
fibronectin. Binding studies using immobilised fibronectin may reveal if this is the case. 
Are metal ions required for Efb-N folding or fibrinogen binding? 
Potential Ca2+ binding sites were identified within the repeat regions of N-terminal Efb (Wade 
et al., 1998a) and this was supported by an experiment that showed that Ca2+ enhanced the 
binding of Efb to Amicon filters (Wade et al., 1998b). This experiment, however, did not reach 
saturating conditions and so the binding identified in this experiment may be non-specific. In 
the same study, the binding of Efb to immobilised fibrinogen decreased upon increasing Ca2+ 
concentration. When Efb was immobilised, increased Ca2+ concentration resulted in increased 
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binding and so the role of Ca2+ in Efb-fibrinogen binding remains unclear. Binding of ClfA to 
immobilised fibrinogen decreased in increasing concentration of Ca2+ (O'Connell et al., 1998). 
Several potential Zn2+ binding sites have also been identified in Efb (Wade et al., 1998a) and it 
has been shown that binding of Efb to fibrinogen is enhanced by Ca2+ and Zn2+ (Palma et al., 
1998). A repeat of the NMR titration experiments with the addition of physiological levels of 
Ca2+ or Zn2+ may promote the binding of fibrinogen peptides to Efb. Alternatively, an NMR 
titration experiment whereby Ca2+ and Zn2+ are titrated into a sample of Efb could be 
informative. An experiment of this sort has previously been carried out in this lab but the results 
were inconclusive. Chemical shift perturbations were observed but may have been due to non-
specific effects. The addition of metal ions to the NMR samples may have changed the ionic 
strength and pH of the sample such that chemical shift perturbations occurred. Additionally, 
these experiments were carried out whereby due to the unfolded nature of N-terminal Efb, a 
limited number of N-terminal derived chemical shifts were observed. 
3.3.4. Summary 
The characteristics of the C-terminal region of Efb have been described (Hammel et al., 2007c, 
Lee et al., 2004b). The results of the complement assay carried out here are in agreement with 
previously published results which show that Efb inhibits both the classical and alternative 
pathways of complement activation. The results presented here provide additional information 
on the mode of action of Efb in complement inhibition and also show that Efb inhibits the lectin 
pathway. Most work focused on the N-terminal region of Efb (Efb-N). Analysis of the NMR 
data indicated that the N-terminal half of Efb within full length Efb is natively unstructured. 
Cloning of Efb-N was successful and subsequent analysis of this protein showed that isolated 
Efb-N is still unstructured. An attempt to obtain a more structured Efb-N sample by refolding 
was unsuccessful. An NMR titration experiment was not able to detect ligand binding-induced 
folding. Crystal trials with an Efb - Fragment D complex could not be set as preparation of pure 
fragment D could not be achieved. Natively unstructured domains are a characteristic of various 
fibronectin binding domains of S. aureus proteins however this is not the case with the 
fibrinogen binding proteins. More work is required to elucidate the mechanism of action of the 
N-terminal region of Efb. 
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4. Structural and functional analysis of Sbi IV 
4.1. Introduction 
The domain organisation of Sbi is shown in figure 4.1 
Figure 4.1 Structural organisation of Sbi, (from Burman et al., 2008)

Four N-terminal globular domains are shown. P represents a poly proline region and Y represents the

tyrosine-rich C-terminal domain. S is a signal sequence.

Sbi was hypothesised to be a cell wall-associated protein, with the highly conserved poly 
proline region expected to span the cell wall and the C-terminal domain expected to reside 
inside the bacterial cell (Zhang et al., 1998). The protein however lacks the LPXTG domain 
which is characteristic of cell wall-anchored proteins (Mazmanian et al., 2001) and Burman et al 
have provided further evidence that Sbi is not a  cell wall-associated protein, with the protein 
being found in the extracellular fractions of fractionated cells from various strains of S. aureus 
(Burman et al., 2008). 
Sbi I was characterised as an immunoglobulin binding domain with Sbi II having predicted 
immunoglobulin binding specificity (Zhang et al., 1998). Pull-down assays have since shown 
that Sbi I and Sbi II bind IgGs as predicted (Burman et al., 2008). Through its immunoglobulin 
binding domains Sbi sequesters IgG by the formation of insoluble complexes via IgG Fc 
fragment binding (Atkins et al., 2008). 
Pull-down experiments have shown that Sbi III and Sbi IV bind complement component C3. 
Surface plasmon resonance (SPR) analysis has shown that Sbi IV binds both the C3a and C3dg 
components of C3 (Burman et al., 2008). 
Complement assays have shown that Sbi IV specifically inhibits the alternative complement 
pathway whereas Sbi-E (which is composed of domains I to IV) and Sbi III-IV inhibit all three 
complement pathways. This observation suggests that Sbi III is required for interference with all 
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three complement activation pathways (Burman et al., 2008). It has also been shown that the 
mechanism of complement inhibition by Sbi III-IV and Sbi IV in this assay varies. Sbi IV alone 
binds to C3d in C3 such that C3 cannot be activated. Sbi III-IV, however, activates C3 to the 
extent that C3 is consumed and under assay conditions complement is inhibited. Upon 
activation of C3, activated C3b transacylates onto Sbi III-IV then gets degraded into an iC3b 
adduct of Sbi III-IV (Burman et al., 2008). 
The staphylococcal complement inhibitors Efb-C and Ehp bind complement component C3 
resulting in complement inhibition. The crystal structures of Efb-C and Ehp have been 
determined recently and both adopt a three-helix bundle conformation (Hammel et al., 2007c, 
Hammel et al., 2007b). This conformation is also seen in the C3 convertase binding S. aureus 
protein SCIN (Rooijakkers et al., 2007) and in the IgG binding domains of SpA (Sato et al., 
2004). 
In order to elucidate the molecular details of the Sbi complement modulatory characteristics, we 
decided to determine the structure of the C3d binding domain of Sbi, Sbi IV. NMR analysis of 
Sbi III has previously been carried out and revealed that this domain is natively unstructured 
(Upadhyay et al., 2008). This chapter describes the expression and purification of Sbi IV, 
functional analysis of this domain, and its NMR structure. 
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4.2. Results 
4.2.1. Purification of Sbi IV 
Sbi IV, comprised of amino acids 198 – 266 of Sbi, was previously cloned into the pET-based 
parallel vector pHIS-Parallel (Sheffield et al., 1999) to enable His tag purification (Burman et 
al., 2008). For the sequence of this construct refer to appendix 1. The plasmid was transformed 
into E. coli BL21(DE3) Arctic ExpressTM cells (Stratagene) and glycerol stocks were prepared 
as described in the Materials and Methods. 
Unlabelled His-Sbi IV was purified as described in the Materials and Methods. Figure 4.1 
shows the elution profile and figure 4.2 shows SDS PAGE analysis of fractions. 15N and 
15N/13C-labelled samples of Sbi IV were prepared for NMR analysis as described in the 
Materials and Methods. The chromatogram shown in figure 4.2 and the gel shown in figure 4.3 
are representative of those obtained for labelled samples. His-Sbi IV showed a relative mobility 
in SDS PAGE similar to its predicted molecular mass of 11.07 kDa. 
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Absorbance 
(mAU) 
Flow volume (ml) 
Figure 4.2 Elution profile of His-Sbi IV purification 
A 1.5 L culture was induced for 3 hours at 37 °C and 50 ml cleared lysate was produced as described in 
the Materials and Methods. His-Sbi IV was purified by loading 25 ml aliquots of cleared lysate on a 5 ml 
His trap FF column and eluting with an imidazole gradient of 0 – 500 mM (green line) using His buffer 
B. UV absorbance (blue line) is correlated with protein concentration. 
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Figure 4.3 SDS PAGE analysis of His-Sbi IV purification

His-Sbi IV was purified as described in the Materials and Methods. Lane 1 – uninduced; lane 2 –

induced; lane 3 – soluble fraction; lane 4 – flow through fraction X1; lane 5 – purified protein fraction

D5; lane 6 – purified protein fraction D6. His-Sbi IV is indicated with an arrow.

The His tag was removed from His-Sbi IV using TEV protease and the result, shown in figures 
4.4 and 4.5, shows that pure Sbi IV was successfully produced upon TEV protease cleavage and 
subsequent repurification. 
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Absorbance 
(mAU) 
Flow volume (ml) 
Figure 4.4 Ion-exchange chromatography of TEV protease-cleaved His-Sbi IV – elution profile 
Purified His-Sbi IV was buffer exchanged into TEV protease cleavage buffer and was subject to TEV 
protease cleavage. The resultant mixture was run on a 1 ml His Trap HP column and protein contained in 
the flow through, which contained cleaved Sbi IV, was diluted and further purified on a 1 ml MonoS 
column. Cleaved Sbi IV was eluted from the column using a sodium chloride gradient of 0 – 500 mM 
(green line) in 50 mM Tris pH 7.5. UV absorbance (blue line) is correlated with protein concentration. 
The elution profile of the MonoS purification is shown. 
Figure 4.5 SDS PAGE analysis of Sbi IV His tag removal 
His-Sbi IV was cleaved as described. Lane 1 – purified His-Sbi IV; lane 2 – His-Sbi IV in TEV protease 
buffer; lane 3 – His-Sbi IV post TEV protease; lane 4 – His-trap purification flow through; lane 5 – His-
trap purification peak; lane 6 – Pre MonoS column Sbi IV (reconcentrated); lane 7 – MonoS flow through 
fraction A4; lane 8 – pure Sbi IV fraction A14; lane 9 – pure Sbi IV fraction A15. 
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4.2.2. Sbi IV complement assay 
 
A complement assay was carried out to determine the effect that Sbi IV has on each of the three 
complement activation pathways. The assay was carried out using the ELISA-based Wielisa kit, 
as described in the Materials and Methods. The result, shown in figure 4.6, shows that Sbi IV 
has a limited effect on the classical and lectin pathways, with the effect being moreso after 
incubation at 37 °C than 4 °C. After incubation at 37 °C Sbi IV inhibits the alternative pathway 
leaving less than 10% residual activity. 
 
 
Figure 4.6 Sbi IV complement assay result 
His-Sbi IV at a final concentration of 1.2 mg ml-1 was incubated with human serum at either 4 °C (blue 
bars) or 37 °C (red bars) prior to addition to the assay wells. Percentage activity was calculated using 
absorbance values in the equation activity  =  [(sample – negative control)/positive control] x 100. Each 
assay well was set up in duplicate and error bars represent the upper and lower results.  
 
 
4.2.3. NMR analysis of Sbi IV 
 
NMR spectroscopy was carried out as described in the Materials and Methods. Initially an 
HSQC spectrum was recorded on 15N-labelled Sbi IV. Sequence-specific backbone and side-
chain resonance assignments were made using data sets obtained as described in the Materials 
and Methods (figure 4.7).  
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The protein contains 66 non-proline residues derived from the protein plus three vector-derived 
residues. There are 71 backbone peaks on this HSQC. All 66 non-proline Sbi IV residues and 
two of the three vector-derived resonances have been assigned leaving two extra unassigned 
peaks. The near 1:1 correspondence between the expected and observed number of peaks in the 
HSQC indicates that the protein adopts a single conformation in solution. The backbone peak 
dispersion is good with a good 1H resonance range of 7.15 – 9.21 ppm. This wide dispersion 
indicates that the protein has significant tertiary structure. 
Sbi IV Structure Determination 
A semi-automated procedure for iterative NOE assignment was used to determine the structure 
of Sbi IV. The final structures were generated using 1116 NOE-derived distance restraints 
(comprising 320 intraresidue, 621 sequential and medium range, and 175 long range NOEs 
where long range means between amino acids five or more apart in the sequence), 78 hydrogen 
bond restraints and 138 Φ and Ψ dihedral angle restraints (68 Φ and 70 Ψ) (Table 4.1). The 
ensemble of 20 simulated annealing structures selected from 50 calculations on the basis of 
lowest energy, and the average structure, are shown in figure 4.7. Over the regular secondary 
structure elements, the ensemble of structures has a backbone rmsd from the mean of 0.29 Å and 
an rmsd of 0.93 Å for all non-hydrogen atoms. A Ramachandran plot of the structures indicates 
that 100% of non-glycine and non-proline residues lie in the most favoured or additionally 
allowed regions (Table 4.1). 
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Number of NOE restraints 
Total 
Intraresidue 
Sequential/medium range 
Long range 
1116 
320 
621 
175 
Number of dihedral angle restraints 138 
Number of hydrogen bond restraints 78 
Rmsd for backbone atoms 0.29 Å 
Rmsd for non-hydrogen atoms 0.93 Å 
Average numbers of NOE violations >0.5 Å (per 
structure) 
1.5 
Average numbers of dihedral angle violations >0.5 
Å (per structure) 
0 
Ramachandran plot regions Average 
structure 
Ensemble 
Most favoured (%) 88.4 92.4 
Additional allowed (%) 11.6 7.6 
Generously allowed (%) 0.0 0.0 
Disallowed (%) 0.0 0.0 
Table 4.1 Structural statistics on the NMR-derived structures of Sbi IV 
The rmsds for backbone and non-hydrogen atoms are rmsds from the mean structure calculated over 
residues 201-222, 229-238, and 245-261. Ramachandran plot was calculated with PROCHECK-NMR 
(Laskowski et al., 1996). 
4.2.3.1. Sbi IV solution structure 
Figure 4.8 shows a ribbon representation of the solution structure of Sbi IV. The protein adopts 
a three-helix bundle conformation with approximate overall dimensions of 45 Å x 25 Å x 25 Å. 
Helix α1 (comprised of residues E201 – N222) is connected by a loop to helix α2 (comprised of 
residues E228 to N238), which is connected by a loop to helix α3 (comprised of residues L245 
to A261). Three N-terminal residues and five C-terminal residues are disordered. 
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Figure 4.8 Structure of Sbi IV (taken from Upadhyay et al., 2008) 
Ribbon representation of (A) the backbone (N, Cα and C’) trace of the twenty lowest energy structures 
coloured as a continuum from blue at the N-terminus to red at the C-terminus. (B) Ribbon diagram of the 
average structure coloured as in A. The α-helices and N- and C-termini are labelled.  
 
Hydrophilic residues are orientated towards the solvent and hydrophobic residues are found 
facing inward, forming the core of the three-helix bundle (figure 4.9). 
 
Figure 4.9 Sbi IV solution structure – positioning of hydrophobic and hydrophilic residues 
Ribbon representation of the solution structure of Sbi IV. (A) Residues which form part of the 
hydrophobic core of the protein are shown as sticks. (B) Side chains of hydrophilic solvent-exposed 
residues are shown as sticks. The N- and C-termini are indicated as are the α-helices. Figure prepared 
using MacPyMol (www.pymol.org). 
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Residues R131 and N138 of Efb-C were found to be essential for the Efb-C – C3d interaction 
(Hammel et al., 2007c). These residues align with residues R231 and N238 of Sbi IV. It has 
been shown that mutation of either or both of these residues to alanine abolishes binding of Sbi 
IV to C3d (Upadhyay et al., 2008). The position of these residues in helix α2 is shown in figure 
4.10. 
 
Figure 4.10 Residues R231 and N238 of Sbi IV 
Ribbon representation of the solution structure of Sbi IV. R231 and N238 side chains are shown as sticks. 
The N- and C-termini and the α-helices are indicated. Figure prepared using MacPyMol. 
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4.3. Discussion 
4.3.1. The effect of Sbi IV on the complement activation pathways 
Sbi IV inhibited the alternative pathway after incubation at 37 ºC. A more reduced inhibition 
was observed after incubation at 4 ºC. Inhibition of the classical and lectin pathways was greater 
at 37 ºC than at 4 ºC although in all cases was considerably less when compared to the 
alternative pathway after incubation at 37 ºC. These results at 37 °C concur with those obtained 
when this assay was carried out in this lab previously, showing residual activities of 65%, 55% 
and 0% for the classical pathway, lectin pathway and alternative pathway respectively (Burman 
et al., 2008). 
Staphylococcal complement inhibitor Efb-C and its homologue Ehp are though to inhibit the 
formation of C3b by inducing a conformational change in native C3, thereby inhibiting all three 
complement pathways. The specific inhibition of the alternative pathway by Sbi IV, however, 
indicates that its binding to C3 prevents formation of the alternative pathway convertase 
(C3bBb), whilst the classical and lectin pathway convertase (C2a4b) remains intact and active. 
Sbi III-IV inhibits complement activity by activating and consuming the complement 
component C3 (Burman et al., 2008). Sbi IV inhibits complement via a mechanism that does not 
involve C3 activation and consumption. Sbi IV inhibits complement activation through binding 
to and preventing activation of C3, or Sbi IV may bind another alternative pathway component, 
perhaps Factor B. 
Charge-charge interactions mediated by R131 and N138 of Efb-C and R75 and N82 of Ehp play 
a major role in the interaction of both Efb-C and Ehp with C3d (Haspel et al., 2008). Mutational 
studies on Sbi IV have indicated that R231 and N238 are crucial for the Sbi IV – C3d 
interaction. In the complement assay, inhibition of the alternative pathway by Sbi IV was 
greater at 37 °C than at 4 °C. This suggests that additional hydrophobic interactions with either 
C3 and/or additional alternative pathway components play a significant role in the specific 
inhibition of the alternative pathway convertase by Sbi IV. 
89

                                               
Figure 2 (Upadhyay et al)
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4.3.2. Sbi IV solution structure 
Sbi IV adopts a three-helix bundle conformation in solution. This conformation has been 
observed in various other staphylococcal immune system modulating proteins: Efb-C (Hammel 
et al., 2007c), Ehp (Hammel et al., 2007b), SCIN (Rooijakkers et al., 2007) and all SpA 
domains (Sato et al., 2004). Figure 4.11 shows a ribbon representation of each of these proteins 
along with schematic topology representations which illustrate the arrangement of the helices in 
each protein. 
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Figure 4.11 Comparison of the structures of staphylococcal immune modulation proteins (from Upadhyay 
et al., 2008) 
Sbi IV, Efb-C, Ehp, SCIN and SpA domain B (PDB codes 2jvh, 2gom, 2noj, 2qff and 1ss1 respectively) 
are shown in ribbon representation and with schematic topology representations. 
In each of the structures shown above, the three α-helices are connected by loops and are 
arranged in a similar manner. The α3 helices in SCIN and SpA are arranged slightly differently. 
Although these proteins all play a role in immune evasion, the mechanism of action of varies. 
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4.3.3. Summary 
The aim of this chapter was to investigate the effect of Sbi IV on each of the three complement 
activation pathways and to carry out a structural analysis of Sbi IV using NMR. The results of 
the complement assay concurred with those obtained previously (Burman et al., 2008). 
Subsequent to incubation of human serum with Sbi IV at 37 °C, specific alternative pathway 
inhibition occurred. The solution structure of Sbi IV has been solved by NMR. Sbi IV adopts a 
three-helix bundle conformation. This conformation is observed in a range of other S. aureus 
immune evasion proteins. 
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5. Characterisation of the Sbi IV – C3d interaction 
5.1. Introduction 
The staphylococcal immune evasion proteins Efb-C, Ehp and Sbi have been shown to facilitate 
S. aureus immune evasion through binding to and modulating the activity of the central 
complement component C3. C3 is a large multi-domain protein that becomes cleaved during the 
complement cascade. Cleavage of C3 results in exposure of a reactive thioester which is 
‘hidden’ in the intact C3 (Janssen et al., 2005). It is the thioester-containing C3d domain of C3 
through which Efb-C, Ehp and Sbi bind (Hammel et al., 2007c, Hammel et al., 2007b, Burman 
et al., 2008). 
The crystal structure of C3d has been determined to 2.0 Å resolution and is shown in figure 5.1 
(Nagar et al., 1998). 
Figure 5.1 C3d structure 
Ribbon representations of C3d are shown. The top view on the left shows the arrangement of the α-
helices. The right picture shows a side view of the α-α barrel. The concave and convex surfaces are 
indicated. Figure was prepared using MacPyMol. 
C3d is comprised of 12 α-helices arranged in an α-α barrel conformation. Consecutive helices 
alternate between the inner and outer barrel such that 6 helices comprise the core and are 
surrounded by 6 helices that are anti-parallel to the core. 
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Both Efb-C and Ehp bind C3 in such a manner that activation of C3 is inhibited. This prevents 
deposition of active C3b molecules onto the cell surface and hinders formation of the alternative 
pathway convertase C3bBb. The interaction of both Efb-C and Ehp with C3 has been well 
characterised through crystallographic study (Hammel et al., 2007c, Hammel et al., 2007b). 
Binding of Efb-C, Ehp and Sbi IV to C3d prevents binding of C3d to CR2 (Ricklin et al., 2008, 
Burman et al., 2008). This binding of bacterial surface-attached C3d to CR2 on B cells enhances 
B cell activation, making this interaction a crucial link between the innate and adaptive immune 
responses (Szakonyi et al., 2001). 
Sbi IV binding to C3 has been shown to also prevent activation of C3 in a similar fashion to 
Efb-C and Ehp. In the presence of Sbi III, activation of C3 via the alternative pathway occurs. 
This activation involves formation of a C3b - Sbi III-IV adduct (Burman et al., 2008). In order 
to investigate the molecular details of the interaction between Sbi and C3d, and to probe the 
details of the mechanism of activation of C3 by Sbi, NMR titration methods and X-ray 
crystallographic analysis were employed. 
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5.2. Results 
5.2.1. Protein purification 
Sbi IV was purified as described in the Materials and Methods and the result is shown in figures 
4.1 and 4.2. 
C3d was purified for use in the NMR titration experiment described in section 5.2.2 and for the 
crystallisation trials described in section 5.2.3. 
C3d, comprised of amino acids 996-1303 of C3, was previously cloned into the pET15b vector 
to enable purification by ion-exchange chromatography (Nagar et al., 1998). The N-terminal His 
tag coding sequence was deleted from this vector such that C3d was expressed without the His 
tag. For the sequence of this C3d construct refer to appendix 1. The plasmid was transformed 
into E. coli BL21(DE3) cells (Stratagene) and glycerol stocks were prepared as described in the 
Materials and Methods. C3d was purified and the results, shown in figures 5.2 and 5.3, show 
that C3d was successfully purified using the method described. 
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Flow volume (ml) 
Figure 5.2 C3d purification elution profile 
A 1 L culture was induced over night at 18 °C and 50 ml cleared lysate was produced as described in the 
Materials and Methods. C3d was purified by loading 25 ml aliquots of cleared lysate on a 5 ml HiTrap 
column and eluting with a sodium chloride gradient of 0 – 500 mM (green line) using HEPES buffer B. 
UV absorbance (blue line) is correlated with protein concentration. 
Figure 5.3 SDS PAGE analysis of C3d purification

C3d was purified as described. Lane 1 – uninduced; lane 2 – induced; lane 3 – soluble; lane 4 – insoluble;

lane 5 – flow through fraction X5; lane 6 – lane 11 – purified protein fractions E6 – E11. C3d showed a

relative mobility in SDS PAGE similar to its predicted molecular mass of 34.7 kDa.

95

5.2.2. Sbi IV – C3d NMR titration 
C3d has previously been identified as a binding partner for Sbi IV. An NMR titration 
experiment was carried out to identify residues of Sbi IV that are important in the Sbi IV – C3d 
interaction. The conditions for each HSQC acquisition are shown in table 5.1. 
Sample 1 
Spectrum number Concentration of C3d 
(mM) 
Molar ratio 
(Sbi IV:C3d) 
1 0 1 : 0 
3 0.06 1 : 0.1 
5 0.17 1 : 0.28 
7 0.26 1 : 0.429 
9 0.326 1 : 0.543 
11 0.381 1 : 0.635 
Sample 2 
2 1.2 1 : 2.0 
4 1.17 1 : 1.95 
6 1.04 1 : 1.73 
8 0.9 1 : 1.50 
10 0.8 1 : 1.33 
12 0.78 1 : 1.30 
Table 5.1 Sbi IV – C3d NMR titration experiment – conditions of each acquisition 
The concentration of Sbi IV was 0.6 mM in each case. The concentration of C3d and the molar ratio of 
the two proteins at each stage are shown. 
Spectra 2, 4, 6, 8 and 9 were of poor quality. These spectra contained a small number of poorly-
dispersed peaks. As such, no NMR data were recorded for samples 10, 11 or 12. Spectra 1, 3, 5 
and 7 were good. HSQC spectrum 1 was comparable to the original HSQC (figure 4.6) such that 
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 all resonances could be assigned in the new HSQC except K224 and V211. The peak from 
K224 was present only in HSQC 7 and the peak from V211 could not be identified in spectrum 
1. An overlay of spectra 1 and 7 is shown in figure 5.4. 
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Figure 5.4 Sbi IV – C3d NMR titration experiment HSQC overlay 
Blue peaks are derived from a 1H-15N spectrum of uniformly 15N-enriched Sbi IV recorded at 16 ºC and 
600 MHz (spectrum number 1 from table 5.1). The sample contained 5 mM MES, 100 mM sodium 
chloride, 1 mM EDTA,1 mM benzamidine and 10% D2O, pH 5.5. Red peaks are from an HSQC spectrum 
on the same sample with an addition of C3d at a final concentration of 0.26 mM to give an Sbi IV : C3d 
molar ratio of 1 : 0.429 (spectrum number 7 from table 5.1). Negative peaks derived from spectrum 1 and 
spectrum 7 are coloured green and cyan, respectively. 
 
Figure 5.4 shows that the chemical shifts of all peaks are perturbed to some extent (shown by 
changes in 1H (the NH proton) and 15N chemical shifts for each peak) upon C3d binding. The 
extent of perturbation varies between peaks. A general loss of intensity of peaks is seen as the 
concentration of C3d increases, with some peaks losing more intensity than others. Some peaks 
broaden beyond detection. H207 intensified. Some peaks split. Examples of the variation in 
chemical shift perturbation and peak intensity loss is shown in figure 5.5. Examples of peak 
splitting and an example of broadening beyond detection are also shown. 
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Figure 5.5 Sbi IV – C3d NMR titration experiment –panels taken from figure 5.4 
Panels are taken from the HSQC spectra shown in figure 5.4. The Sbi IV:C3d molar ratio is 1:0 (blue 
peaks) and 1:0.429 (red peaks). Variation between chemical shift perturbation and loss of peak intensity 
is shown. The V256 and A203 peaks undergo splitting. The D208 peak broadened beyond detection and 
so no red peak can be seen for this residue. 
In order to clearly see the extent of chemical shift perturbation, chemical shift perturbations 
were plotted in a bar chart. Figure 5.6 shows the combined NH proton and 15N chemical shift 
change in ppm - Δδ(NH/15N) - which is calculated as follows: 
2 
2 (Δδ[15N])(Δδ[NH]) + 25Δδ(NH /15N) = 2 
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Peaks which broadened beyond detection were present in HSQCs 1, 3 and 5 but absent from 
HSQC 7 except D208 which was present in HSQCs 1 and 3 but was absent from HSQCs 5 and 
7. The top ten perturbed chemical shifts are observed for residues N238, R231, R210, V244, 
E209, E201, V205, Q258, V198 and L248. These residues are spread throughout the Sbi IV 
structure (figure 5.7). Residues with the highest chemical shift perturbations, R231 and N238, 
are found in the α2 helix. Five of these residues are found within the N-terminal half of the α1 
helix and the N-terminus. Three occur along the α3 helix. This suggests that more than one 
binding site for C3d is present in Sbi IV. 
 
Figure 5.7 Sbi IV – C3d chemical shift perturbation mapping; Sbi IV 
The solution structure of Sbi IV is shown in ribbon representation (blue). Positions of residues that 
exhibit a chemical shift perturbation of  >0.04 ppm (red), 0.035 – 0.04 ppm (orange), and 0.03 – 0.035 
ppm (yellow) are identified. The N- and C-termini and the α1, α2 and α3 helices are marked.  
 
In order to clearly see the extent of peak intensity loss, these data were plotted in a bar chart. In 
the Analysis program used to analyse these data, peak intensity is represented by a measurement 
of peak height. The overall loss of height for each peak was calculated using the equation peak 
height decrease = [(initial peak height – final peak height)/initial peak height] x 100. 
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5.2.3. X-ray crystallographic analysis of the Sbi IV- and Sbi III-IV – 
C3d protein complexes 
5.2.3.1. Crystal trials 
Previous attempts to crystallise the Sbi IV – C3d complex, using a Sbi IV construct inserted in 
pHIS-Parallel containing a 25 residue N-terminal tag, were unsuccessful. Because the presence 
of 25 disordered residues on the Sbi IV construct may hinder crystal formation, the histidine 
tag-containing part of the linker was removed using TEV protease cleavage. This, however, 
resulted in low recovery of Sbi IV such that the Sbi IV – C3d complex could not be produced. 
5.2.3.2. Re-cloning of Sbi IV and Sbi III-IV 
Cloning of Sbi IV and Sbi III-IV into pQE30 using the restriction endonucleases Bam HI and 
Hind III would facilitate expression of the proteins with a ten residue non-cleavable N-terminal 
His tag. In this construct the His tag is considerably smaller than the tag derived from the pHIS-
Parallel (for details of this construct refer to appendix 1). Cloning of the genes into pET28a 
using the restriction endonucleases Nco I and Hind III would facilitate expression of the 
proteins without a tag. Expression of these constructs from pQE30 or pET28a would negate the 
need for His tag removal which previously resulted in loss of protein. 
Details of the cloning are contained in the Materials and Methods. Initially, a DNA annealing 
temperature screen was carried out to determine the optimal annealing temperature for PCR. 
The most intense bands, corresponding to the highest amount of PCR product, were seen when 
an annealing temperature of 59.6 °C was used and so subsequent amplification was carried out 
using this temperature. Agarose gel analysis of the amplified DNA is shown in figure 5.9. 
Figure 5.9 Agarose gel analysis of Sbi IV and Sbi III-IV DNA fragments 
PCRs were carried out using an annealing temperature of 59.6 °C and then were cleaned up using 
standard buffers in a PCR purification kit. DNA was eluted in 50 µl water and 3 µl of each sample was 
added to 0.5 µl 6 x DNA sample buffer and was visualised on an agarose gel. M1 – NEB PCR ladder; M2 
Fermentas 1kb ladder; lane 1 – positive control; lane 2 – Sbi IV (Bam HI); lane 3 – Sbi IV (Nco I); lane 4 
– Sbi III-IV (Bam HI); lane 5 – Sbi III-IV (Nco I). 
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The Sbi IV and Sbi III-IV PCR products were then digested in preparation for insertion into the 
pQE30 and pET28a vectors. Agarose gel analysis of the digested fragments is shown in figure 
5.10. 
Figure 5.10 Agarose gel analysis of pET28a and pQE30 restriction digestion 
pET28a (lane 1) was restricted with Nco I and Hind III (lane 2). pQE30 (lane 3) was subject to sequential 
restriction digest, firstly with Bam HI (lane 4) then Hind III (lane 5). A sample of the pHIS Parallel_Sbi 
III-IV plasmid, which was used as a DNA template for PCR, is also shown (lane 6). 
Each of the Sbi IV and Sbi III-IV fragments were subjected to ligation with the pQE30 and 
pSV281 vectors and 10 µl ligation mixture was then used to transform the sub-cloning 
efficiency cells E. coli XL1-Blue as per the manufacturer’s instructions. No colonies were 
obtained on the pSV281 agar plates. Four of the resultant colonies from each pQE30 agar plate 
were screened for the desired insert as described in the Materials and Methods. The result is 
shown in figure 5.11. 
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Figure 5.11 PCR screen for positive clones of Sbi IV and Sbi III-IV in pQE30

A PCR screen was carried out to identify positive clones. A - four Sbi III-IV clones were screened –

clones 2, 3 and 4 are positive; B - four Sbi IV clones were screened – all four are positive; B5 - PCR

positive control.

Plasmids containing the correct inserts were isolated and samples of isolated plasmids were 
sequenced. The sequencing results showed that the correct inserts were present in the vector. 
Plasmids were then used to transform the expression strain BL21(DE3) and glycerol stocks 
were prepared as described in the Materials and Methods. 
5.2.3.3. Expression and purification 
Expression and purification of Sbi IV and Sbi III-IV from the pQE30 vector was tested and the 
results are shown in figure 5.12, 5.13 and 5.14. Sbi IV derived from pQE30 has a predicted 
molecular mass of 9.23 kDa. Sbi III-IV derived from pQE30 has a predicted molecular mass of 
14.82 kDa. 
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Flow volume (ml) 
Figure 5.12 Elution profile of pQE30_Sbi III-IV 
A 200 ml culture was induced for 1 hour at 37 °C and 12 ml cleared lysate was produced as described in 
the Materials and Methods. Sbi III-IV was purified by loading the 12 ml cleared lysate on a 1 ml His trap 
FF column and eluting with an imidazole gradient of 0 – 500 mM (green line) using His buffer B. UV 
absorbance (blue line) is correlated with protein concentration. 
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Figure 5.13 Elution profile of pQE30_Sbi IV 
A 200 ml culture was induced for 1 hour at 37 °C and 12 ml cleared lysate was produced as described in 
the Materials and Methods. Sbi IV was purified by loading the 12 ml cleared lysate on a 1 ml His trap FF 
column and eluting with an imidazole gradient of 0 – 500 mM (green line) using His buffer B. UV 
absorbance (blue line) is correlated with protein concentration. 
Figure 5.14 SDS PAGE analysis of Sbi III-IV and Sbi IV expression and purification 
Lanes 1 to 7 - Sbi III-IV; lane 1 – uninduced; lane 2 – induced; lane 3 – soluble; lane 4 – insoluble; lane 5 
- flow through fraction B14; lane 6 – purified fraction C2; lane 7 – purified fraction C3. Lanes 8 to 14 – 
Sbi IV; lane 8 – uninduced; lane 9 – induced; lane 10 – soluble; lane 11 – insoluble; lane 12 - flow 
through fraction C13; lane 13 – purified fraction D1; lane 14 – purified fraction D2. Arrows indicate 
positions of migrating Sbi III-IV and Sbi IV. Sbi III-IV and Sbi IV showed relative mobility in SDS 
PAGE close their predicted molecular masses of 14.8 kDa and 9.2 kDa respectively. 
106

5.2.3.4. Preparation of protein complexes 
Complexes of each of Sbi IV – C3d (figure 5.15 and 5.16) and Sbi III-IV – C3d (figures 5.17 
and 5.18) were prepared as described in the Materials and Methods. 
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Figure 5.15 Elution profiles of Sbi IV – C3d complex preparation 
Purified Sbi IV was run over a 1 ml His trap HP column (A). Purified C3d was run over the column and 
the protein complex was eluted with an imidazole gradient of 0 – 500 mM (green line) using His buffer B 
(B). UV absorbance (blue line) is correlated with protein concentration. 
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Figure 5.16 SDS PAGE analysis of the Sbi IV – C3d elution profile

Lanes 1 to 3 - fractions A1 to A3 (figure 5.15A); lanes 4 to 9 – fractions A5 to A10 (figure 5.15B)
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Figure 5.17 Elution profiles of Sbi III-IV – C3d complex preparation 
Purified Sbi III-IV was run over a 1 ml His trap HP column (A). Purified C3d was run over the column 
and the protein complex was eluted with an imidazole gradient of 0 – 500 mM (green line) using His 
buffer B (B). UV absorbance (blue line) is correlated with protein concentration. 
 
 
!"
#"
Absorbance 
(mAU) 
Flow volume (ml) 
Absorbance 
(mAU) 
Flow volume (ml) 
Figure 5.18 SDS PAGE analysis of the Sbi III-IV – C3d elution profile 
Lane 1 – Sbi III-IV pre loading; lane 2 – C3d pre-loading; lanes 3,4 and 5 – factions A1, A2 and A3 
(figure 5.17A); lanes 6 to 11 – fractions A6 – A11 (figure 5.17B). Sbi III-IV is marked with an arrow. 
5.2.3.5. Crystallisation trials 
A ProPlex screen and a tacsimate screen were set up for each of the Sbi IV – C3d and Sbi III-IV 
– C3d complexes. The Sbi IV – C3d complex produced small needle-like crystals in various 
conditions of the ProPlex screen within 7 days. Crystals grew in ProPlex-96 condition 1.29: 100 
mM Tris pH 8.0, 20% w/v PEG 4000; condition 1.32: 200 mM sodium chloride, 100 mM Tris 
pH 8.0, 20% w/v PEG 4000; and condition 2.36: 100 mM sodium HEPES pH 7.0, 1 M sodium 
citrate. Optimisations of these conditions through seeding yielded larger crystals with 
dimensions that were suitable for X-ray analysis. 
5.2.3.6. The crystal structure of the Sbi IV – C3d complex 
Crystals of the complex of Sbi IV – C3d diffracted to 1.7 Å resolution. Data were collected at 
the Diamond Light Source as described in the Materials and Methods. Data were processed 
using the HKL2000 package (Otwinowski and Minor, 1997). Data collection statistics are 
shown in table 5.2. 
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Cell dimensions 53.4 Å x 81.0 Å x 87.7 Å, α = β = γ = 90˚ 
Space group P212121 
Asymmetric unit 1 complex 
Wavelength 0.9702 Å 
Resolution 1.7 Å 
Temperature 100 K 
Measured reflections 1369401 
Unique reflections (1.70 – 1.76Å) 41186 (3710) 
I/σI (1.70 – 1.76Å) 30.4 (3.3) 
Completeness (1.70 – 1.76Å) 96.0% (87.6%) 
Table 5.2 Data collection statistics 
The structure of the Sbi IV – C3d complex was determined using molecular replacement using 
the crystal structure of C3d (PDB databank accession code 1C3D). The crystal data revealed 
that there are two possible orientations of Sbi IV in relation to the C3d molecule, related by 
crystallographic symmetry. The two models were refined separately and will be referred to from 
now on as model 1 and model 2. The refinement statistics for each model are shown in table 
5.3. Ramachandran plots for each model are shown in figure 5.19. 
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Model 1 Model 2 
Resolution 45 – 1.7 Å 45 – 1.7 Å 
R 0.1688 0.1722 
Rfree 0.2047 0.2049 
Atoms (no.) 3280 3227 
Residues (no.) 357 356 
Water molecules (no.) 357 336 
Rmsd bonds 0.011 Å 0.011 Å 
Rmsd angles 1.208 ° 1.231 ° 
Average B-factors (Sbi IV/C3d) 27.10 Å2/21.86 Å2 27.20 Å2/21.83 Å2 
Table 5.3 Data refinement statistics 
Data refinement statistics are shown for each model. B factors were calculated using moleman2 (part of 
the Uppsala Software Factory; http://xray.bmc.uu.se/usf). 
B-factors – model 1 
The B-factors from Sbi IV ranged from 15.08 to 57.37 with an average of 27.10. The B-factors 
from C3d ranged from 11.15 to 60.18 with an average of 21.87. In each chain, B-factors were 
highest towards the termini. 
B-factors – model 2 
The B-factors from Sbi IV ranged from 15.25 to 55.62 with an average of 27.20. The B-factors 
from C3d ranged from 10.18 to 58.14 with an average of 21.83. In each chain, B-factors were 
highest towards the termini. 
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5.2.3.7. Sbi IV – C3d structure model 1 
Model 1 is shown in ribbon representation in figure 5.20. 
Figure 5.20 Sbi IV – C3d model 1 
Ribbon representations of Sbi IV – C3d model 1 side view (A) and top view (B). C3d is coloured green 
and Sbi IV in red. The concave and convex sides of C3d are indicated. The N- and C-termini of each 
molecule are indicated and the α-helices of Sbi IV are specified. Figure was prepared using MacPyMol. 
In this model Sbi IV displays the same three-helix bundle fold as was seen in the solution 
structure described in section 4.2.3.1 (Upadhyay et al., 2008). A structural alignment using 
LSQman (part of the Uppsala Software Factory; http://xray.bmc.uu.se/usf) was performed 
(figure 5.21). A corresponding superposition of the Sbi IV molecule observed in the crystal 
structure and the NMR solution structure is presented in figure 5.22. The rmsd of the 54 
residues that were within 3.5 Å of one another in the superimposed structures was 1.838 Å. The 
notable difference between the two structures is the orientation of the α3 helix. In the crystal 
structure, this helix is positioned closer to the α1 and α2 helices, making the three-helix bundle 
more compact. This is reflected in the sequence representation of the structural alignment 
(figure 5.21), showing a 14-residue gap in the alignment of the C-terminal residues. The 
structural alignment further reveals several smaller structural discrepancies, including residues 
R210 and V211 located within the α1 helix, N222 and E223 (α2 - α3 loop), and residues E246 
and H247 of the N-terminal part of the α3 helix. 
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Sequence 1 ---VSIEKAIVRHDERV-KSANDAISKLNE-KDSIENRRLAQREVNKAPMDVK-EHLQKQ

 .=ALI |=ID |||||||||||| . |||||||||| . |||||||||||||||||||||| . ||||

 Sequence 2 GAMVSIEKAIVRHDE-RVKSANDAISKL-NEKDSIENRRLAQREVNKAPMDVKEH-LQKQ

 Sequence 1 LDA-------------LVAEKDAEK

 .=ALI |=ID | .                      

 Sequence 2 L-DALVAQKDAEKKVA--------
-
Figure 5.21 Sbi IV structural alignment 
Sequence alignment representation of the structural alignment between Sbi IV in complex with C3d 
(sequence 1) and the Sbi IV solution structure (2JVE.pdb) (sequence 2). 
Figure 5.22 Sbi IV crystal structure superimposed onto the Sbi IV observed in the solution structure 
Sbi IV of the crystal structure was rotated onto the solution structure and this rotated structure (shown in 
yellow) is shown superimposed onto the crystal structure (shown in red). The N- and C-termini are 
indicated as are the α-helices. Figure was prepared using MacPyMol. 
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In this crystal structure C3d adopts the α-α barrel conformation seen in the C3d crystal structure 
(Nagar et al., 1998). Structural alignment of the 292 residues that were within 3.5 Å of one 
another in the superimposed structures revealed an rmsd value of 0.668 Å. 
In model 1, Sbi IV binds C3d mainly through its α2 helix side, interacting with the concave side 
of C3d. Table 5.4 shows the main contacts. 
Sbi IV residue 
number 
Sbi IV helix C3d contacting residue(s) 
R206 α1 E1160 
R210 α1 E1160, E1165 
I227 α1 - α2 loop D1029, W1024, L1039, R1042 
E228 α2 K1284 
R230 α2 R1042 
R231 α2 H1026, D1029, E1030, N1091, L1092 
Q234 α2 V1090, N1091, L1092, I1093 
R235 α2 V1090, N1091,D1156, I1157 
N238 α2 V1090, I1093, A1094, I1095, S1097 
K239 α2 - α3 loop D1156, I1157 
M242 α2 - α3 loop D1096, Q1098 
K245 α3 I1095, S1097 
Q249 α3 A1094 
V256 α3 A1094 
D260 α3 Q1043 
K263 C terminus L1039 
Table 5.4 Sbi IV – C3d model 1, contacting residues

Main contacting residues of Sbi IV and the residues they contact in C3d are shown.

Comparison of the Sbi IV – C3d complex with the Efb-C – C3d and Ehp – C3d structures 
In model 1, Sbi IV binds to C3d in much the same way as both Efb-C (Hammel et al., 2007c) 
and Ehp (Hammel et al., 2007b). Figure 5.23 shows that Sbi IV, Efb-C and Ehp bind at the 
periphery of the acidic pocket on the concave side of C3d. 
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Figure 5.23 Sbi IV, Efb-C and Ehp in complex with C3d

Ribbon representations of the complexes of (A) Sbi IV – C3d, (B) Efb-C – C3d and (C) Ehp – C3d.

Figure was prepared using MacPyMol.

Sbi IV and Efb-C have a similar shape complementarity with C3d, with buried surface areas of 
1572.3 Å2 and 1967 Å2 respectively. 
The α2 helix interaction interfaces in Efb-C, Ehp and Sbi IV also show comparable charge 
complementarity with the concave side of C3d (figure 5.24). The α2 helix side of the three 
complement modulators is largely positively charged whereas the concave side of C3d is 
predominantly negatively charged. 
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Figure 5.24 Surface potentials of α2 helices of Efb, Ehp and Sbi IV, and the concave side of C3d.

Surface potentials are shown. The positions of the aligned asparagine and arginine residues are indicated.

Figure was prepared with GRASP (Nicholls et al., 1991).

Hammel et al showed that most of the contacting residues in their crystal structure were from 
the α2 helix of Efb-C, as is the case with Sbi IV. The main contacting residues in Efb-C – C3d 
from the Efb-C α2 helix are H130, R131, K135 and N138. Efb-C residues R131 and N138 align 
with R231 and N238 of Sbi IV and these residues can be seen making comparable contacts with 
C3d (figures 5.25 and 5.26). 
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Figure 5.25 Comparison of the residues at the contact interface with C3d in (A) Efb-C R131, (B) Ehp R75 
and (C) Sbi IV R231 
Side chains of contacting residues are shown as sticks. In each case, residues from the C3d α1 and α3 
helices are making contacts. Helices are labelled. Figure was prepared with MacPyMol. 
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Figure 5.26 Comparison of the residues at the contact interface with C3d in (A) Efb-C N138, (B) Ehp N82 
and (C) Sbi IV N238.  
Main chain/side chains of contacting residues are shown as sticks. In each case, residues from the C3d α4 
- α5 loop are making contacts. Helices are labelled. Figure was prepared with MacPyMol. 
 
Residues H130 and K135 of Efb-C do not align with Sbi IV. The equivalent positions in Sbi IV 
are R230 and R235, both of which make contacts with C3d. R235 of Sbi IV aligns with R79 of 
Ehp. Figure 5.27 shows these residues making contacts. 
 
 
Figure 5.27 Comparison of the residues at the contact interface with C3d in Sbi IV R135 (A) and Ehp 
R79 (B). 
Contacting residues are shown as sticks. Helices are labelled. Figure was prepared with MacPyMol. 
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In the Efb-C – C3d interaction, side chains from lysine residues within the Efb-C α1 helix were 
shown to have a role in stabilising the Efb-C – C3d interaction. These residues, K106, K110 and 
K148 do not align with residues of Sbi IV. 
5.2.3.8. Sbi IV – C3d model 2 
Model 2 is shown in ribbon representation in figure 5.28. 
Figure 5.28 Sbi IV – C3d model 2 
Ribbon representations of Sbi IV – C3d model 2 side view (A) and top view (B). C3d is coloured green 
and Sbi IV in blue. The concave and convex sides of C3d are indicated. The N- and C-termini of each 
molecule are indicated and the α-helices of Sbi IV are specified. Figure was prepared using MacPyMol. 
In model 2 Sbi IV binds to the convex face of C3d predominantly via its α1 and α3 helices and 
the α2 - α3 loop to the convex side of C3d. Table 5.5 lists the contacting residues and the 
binding interface is shown in figure 5.29. 
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Sbi IV 
residue 
number 
Sbi IV helix C3d contacting residue(s) 
E201 α1 T1006, S1008 
I204 α1 S1008, G1009, Q1013 
V205 α1 G1009 
H207 α1 H1126 
D208 α1 G1009, A1010, Q1013 
V211 α1 Y1069, I1125 
K212 α1 F1069 
N215 α1 F1069, K1071, R1072 
D216 α1 K1071 
S219 α1 K1071 
D243 α3 R1134, Y1266 
V244 α3 I1125, H1126 
H247 α3 R1072, P1123, V1124, I1125 
L248 α2 - α3 loop I1125 
Q251 α2 - α3 loop R1072 
Table 5.5 Sbi IV – C3d model 2, contacting residues

Main contacting residues of Sbi IV and the residues they contact in C3d are shown.
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Figure 5.29 Sbi IV – C3d binding interface   
Sbi IV and C3d are shown in ribbon representation and are coloured red and green respectively. Main 
contacting residues of Sbi IV α1 (A and B) and α3 helices (C) are shown. The α-helices of Sbi IV are 
labelled. Contacting residues of each protein are shown as sticks and are labelled with the residue 
number. Figure was prepared using MacPyMol. 
 
The shape complementarity between Sbi IV and C3d in this model is comparable to model 1, 
with buried surface areas 1336.6 Å2 and 1572.3 Å2 respectively. The α1-α3 helix side of Sbi IV 
and the convex face of C3d are both very hydrophobic, whereas the α1-α3 sides of Efb-C and 
Ehp are more charged (figure 5.30). 
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Figure 5.30 Surface potential of α1-α3 helices of Efb, Ehp and Sbi IV, and the convex side of C3d. 
Surface potentials are shown. Figure was prepared using GRASP (Nicholls et al., 1991). 
Effect of the C1010 → A1010 mutation 
The construct of C3d used in this study contains a cysteine – alanine substitution at position 
1010. This cysteine forms part of the highly reactive thioester in native C3. This cysteine has 
been changed to an alanine in order to prevent aggregation of C3d during the purification 
process. In the Sbi IV – C3d binding mode seen in model 2, Sbi IV contacts C3d at this 
important thioester region. We found that the replacement of A1010 with the original C1010 in 
this model did not cause any steric hindrance that might affect the binding of Sbi IV to native 
C3. 
5.2.3.9. Comparison between model 1 and model 2 
As described above, the structure of Sbi IV in complex with C3d revealed two models for this 
complex. In model 1, Sbi IV binds through its α2 helix, to the concave side of the C3d 
molecule. In model 2, Sbi IV binds through its α1 and α3 helices, to the convex, thioester-
125

containing side of the C3d molecule. Both models were refined with good refinement statistics 
–  Roverall and Rfree values, respectively, were 0.1688 and 0.2047 for model 1, and 0.1722 and 
0.2049 for model 2. Evidence was sought to determine if either of these modes of binding were 
brought about due to the nature of the positioning of molecules in the crystal lattice. 
The Protein interfaces, surfaces and assemblies service (PISA) at the European Bioinformatics 
Institute (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html) was accessed (Krissinel and 
Henrick, 2007). The result is shown in table 5.6. 
Sbi IV – C3d model Interface score P-value Sbi IV P-value C3d 
Model 1 0.000 0.896 0.680 
Model 2 0.000 0.572 0.417 
Table 5.6 PISA analysis 
Interface scores of 0.000 indicate that the interaction interface of each model may not be significant. P 
values of > 0.5 for both models indicates that both interfaces could be artefacts of crystal packing. 
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5.3. Discussion 
5.3.1. Sbi IV – C3d NMR titrations 
An NMR titration experiment was carried out to track changes in the 1H-15N HSQC spectrum of 
Sbi IV upon addition of C3d in order to identify Sbi IV residues involved in binding. All peaks 
shifted to some degree and this chemical shift perturbation was calculated and is plotted in 
figure 5.6. The most perturbed residues upon C3d binding are spread throughout the Sbi IV 
molecule. Despite low sequence identity of Sbi IV with Efb-C (19% over a 43 residue stretch), 
R131 and N138 of Efb-C align with R231 and N238 of Sbi IV (Upadhyay et al., 2008). 
Mutation analysis showed that if either or both of these residues was mutated to alanine, C3d 
binding was abolished (Upadhyay et al., 2008). Perturbation of the backbone chemical shifts of 
these two residues upon C3d addition supports their importance in the Sbi IV – C3d interaction. 
Considerable chemical shift perturbation throughout the three helices of Sbi IV may indicate 
that binding of C3d is occurring at or near these sites. This would suggest that there is more 
than one binding site for C3d on Sbi IV. It should be noted, however, that chemical shifts are 
very sensitive and perturbations do not necessarily indicate that residues are directly involved in 
binding. Chemical shifts are sensitive to the extent that perturbation can occur at sites remote 
from the binding site. 
Chemical shift mapping results are most significant ‘when a contiguous surface patch of 
shifting resonances is obtained’ (Zuiderweg, 2002). In this case, there is no cluster of large 
chemical shift perturbations that would be indicative of a specific binding site. 
Subsequent to the NMR titration, X-ray crystallographic analysis of the Sbi IV – C3d 
interaction was carried out. 
5.3.2. X-ray crystallographic analysis of Sbi IV – C3d 
The crystal structure revealed two binding modes for this complex and analyses were carried 
out to clarify if both of these binding modes could be physiologically relevant and do not occur 
simply due to the positioning of the molecules in the crystal lattice. The buried surface areas for 
each model are similar - 1572.3 Å2 for model 1 and 1336.6 Å2 for model 2. The charge 
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complementarity between the interacting surface in each model is good as shown in figures 5.26 
and 5.32. The α2 helix side of Sbi IV is predominantly negatively charged and the convex side 
of C3d is predominantly positive. Both the α1-3 side of Sbi IV and the convex side of C3d are 
largely hydrophobic. The complement inhibition assay results shown in figure 4.5 indicated that 
hydrophobic interactions may play an important role in Sbi IV – C3d binding. 
Small-angle X-ray scattering analysis of the Sbi IV – C3d complex has produced data which 
suggests that two conformations of the complex may occur (van den Elsen, unpublished data). 
The PISA result is inconclusive. 
Comparing the NMR titration results with the crystal structure 
The crystal structure reveals that R231 and N238 of Sbi IV are directly involved in binding to 
C3d. R231 extends into a pocket of C3d. N238 makes side chain interactions with a loop of 
C3d. These are the most perturbed resonances in the NMR titration. R210, V244, E201 and 
L248 of Sbi IV also make contacts with C3d and shown considerable chemical shift 
perturbation. There are, however, a number of interactions between Sbi IV and C3d in the 
crystal structure that are not reflected in the NMR titration. 
The structural alignment between the Sbi IV solution structure and the Sbi IV crystal structure 
(figures 5.21 and 5.22) shows that the positioning of the C-terminal half of the α3 helix differs 
considerably. If the binding of C3d to Sbi IV that occurred during the NMR titration experiment 
brought about the conformational change observed in Sbi IV seen in the crystal structure, then 
one would expect to observe considerable chemical shift perturbation for the residues in this 
part of Sbi IV. The chemical shift perturbations in this region are not particularly notable which 
suggests that the more compact positioning of the Sbi IV α3 helix observed in the crystal 
structure occurs as a result of crystal packing rather than C3d binding alone. 
The structural alignment between the Sbi IV solution structure and the Sbi IV crystal structure 
shows that residues R210 and V211 of the Sbi IV α1 helix are mis-aligned. V211 could not be 
tracked in the NMR titration however R210 showed one of the largest chemical shift 
perturbations. Of the 10 residues for which the chemical shift perturbation was >0.03 ppm, 4 are 
found within the α1 helix. 
The biological significance of each Sbi IV – C3d binding mode 
It is proposed that the binding seen in model 1 induces a conformational change in C3 such that 
C3 cannot be activated. C3b deposition is thereby inhibited and the C3bBb convertase cannot 
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form. This mode of action has been observed for Efb-C and Ehp. This, however, does not 
account for the specific inhibition of the alternative pathway by Sbi IV. In a physiological 
setting, where Sbi domain III is also present, complement inhibition of the three complement 
pathways results from consumption of C3 via the alternative pathway. 
The binding mode seen in model 1 also accounts for Sbi IV inhibition of C3d – CR2 binding. 
Sbi IV binds at the periphery of the acidic pocket on the concave side of C3d. Recent binding 
studies using site-directed mutagenesis show that the CR2 and Sbi IV binding sites on C3d 
overlap (Professor David Isenman, unpublished results). In this mode, Sbi IV could play a role 
in inhibiting a crucial link between the adaptive and innate immune responses. 
The binding seen in model 2 is only possible in an activated C3 molecule, as the face of C3d to 
which Sbi IV binds is not exposed in the intact C3 molecule. It is proposed that binding of Sbi 
IV to C3d in this mode occurs after activation of C3 by Sbi III-IV. This would prevent 
deposition of an activated C3b molecule on to a cell surface. This may also be the binding mode 
employed by the Sbi III-IV – C3 covalent adduct. This covalent adduct is thought to stabilise 
the alternative pathway convertase leading to the futile consumption of C3 observed with Sbi 
III-IV. 
Taken together, these binding modes can facilitate the proposal of a model for Sbi III-IV 
activation of C3. The proposed sequence of events is: initial binding of Sbi III-IV to C3 occurs. 
The Sbi IV – C3d interaction is that seen in model 1 of the Sbi IV – C3d crystal structure. Sbi 
III-IV activates C3. A rearrangement occurs such that Sbi IV binds C3d as seen in model 2. 
This binding stabilises the Sbi III-IV – C3b covalent adduct. 
In this model, binding of Sbi III-IV to C3d via the α2 helix of Sbi IV (model 1) is required 
before the alternative binding mode (model 2) can occur. Long range electrostatic interactions 
involving Sbi IV residues R231 and N238 may bring the proteins into proximity such that the 
binding mode observed in model 2 can occur. This may explain why mutation of R231, N238 or 
both residues abolishes binding of Sbi IV to C3d (Upadhyay et al., 2008). 
A two-site binding mode for Sbi IV – C3d contradicts isothermal titration calorimetry (ITC) 
analysis of the complex which shows that Sbi IV binds C3d at a molar ratio of 1:1 (Upadhyay et 
al., 2008). A further independent measure of the stoichiometry of the interaction is required. 
ITC analysis of Ehp revealed a two-site binding mode for the Ehp – C3d interaction (Hammel et 
al., 2007b). Subsequent crystallographic analysis of the complex was carried out using a 
construct of Ehp which contained a mutation to abolish the second binding site and so the 
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details of this interaction are unclear. Ehp alternative pathway inhibition is more potent than 
that of Efb-C and this increased potency of Ehp has been attributed to a second binding site 
(Hammel et al., 2007b). Protein modelling programs can now be used to determine if this model 
is possible. 
The exact mechanism of action of Sbi III remains to be elucidated however it is clear that Sbi III 
plays a key role in the activation of C3 by Sbi III-IV. Small-angle X-ray scattering data indicate 
that each of the N-terminal domains I to IV of Sbi are globular (Burman et al., 2008). NMR 
analysis has revealed that domain III of Sbi has no significant tertiary structure and that this is 
the case in the presence of domain IV (Upadhyay et al., 2008). Sbi III may be intrinsically 
unstructured or in the complete Sbi molecule this domain may be structured. NMR analysis of a 
construct of Sbi domains II, III and IV may reveal if Sbi III is structured in the presence of 
domains II and IV. Flexibility between these domains would, however, reduce the quality of 
any NMR spectra produced. 
Sbi III may undergo binding-induced folding. The crystal structure of Sbi III-IV – C3d could 
reveal if this was the case. Attempts to crystallise this complex have thus far been unsuccessful. 
An NMR titration experiment like the one carried out for Sbi IV – C3d could identify binding-
induced folding. A titration experiment of this kind has been carried out in this lab. A labelled 
construct of Sbi III-IV was tracked by HSQC as C3d was titrated into the sample. The results of 
this experiment were unclear. 
Crystal trials were carried out in an attempt to grow crystals of a complex of Sbi III-IV – C3d 
but these were unsuccessful. The ProPlex-96 screen identified some conditions in which a small 
amount of precipitation was seen. The tacsimate screen also produced some precipitation. Work 
to optimise these conditions may lead to the growth of crystals. Optimisation should initially 
focus on screening around the conditions which produce some precipitation. Slight changes in 
pH and concentration of salt, precipitant, and protein can affect crystal growth and screening of 
these parameters may identify conditions in which crystals of this complex grow. 
Further analysis of the Sbi IV – C3d interaction 
Haspel et al 2008 point out that the static nature of proteins in a crystal means that subtle key 
interactions can be missed and so carried out a detailed analysis of the interaction between Efb-
C and C3d using techniques which analyse the thermodynamic and kinetic aspects of the 
interaction (Haspel et al., 2008). Further analysis of the Sbi IV – C3d interaction using such 
techniques would complement the crystal structure data. 
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5.3.3. Summary 
The aim of this chapter was to characterise the interaction of Sbi IV with C3d. The result of the 
NMR titration experiment suggests that more than one binding site for C3d may exist in Sbi IV. 
The nature of chemical shift perturbation analysis, however, is such that results can be difficult 
to interpret. The crystal structure data on the Sbi IV – C3d complex has revealed two possible 
binding-modes . Analysis has been carried out to assess whether both binding modes are viable 
and physiologically relevant. Analysis of each binding interface suggests that both binding 
modes are possible. The physiological relevance of each binding mode has been discussed and a 
model for Sbi III-IV binding to C3 has been proposed. Further work is required, however, to 
further characterise the mechanism of action of Sbi III-IV. 
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6. IsaB 
6.1. Introduction 
IsaB was first identified as an immunodominant antigen which is expressed in vivo during 
MRSA sepsis; antibody response to IsaB was considerably higher for individuals with MRSA 
sepsis compared to that of colonised and healthy individuals (Lorenz et al., 2000). A genomic 
analysis of IsaB showed that the gene is absent from two hypervirulent strains of S. aureus 
(Cassat et al., 2005), and IsaB expression is down-regulated in response to S. aureus neutrophil 
phagocytosis (Voyich et al., 2005). IsaB expression was upregulated in S. aureus cells growing 
in a biofilm in comparison to those growing planktonically (Resch et al., 2005) and IsaB 
expression was upregulated in a switch from aerobic to anaerobic growth of S. aureus (Fuchs et 
al., 2007). It has been suggested that IsaB may be correlated with immune evasion, however the 
exact function of the protein remains to be elucidated. Structural and functional analysis of IsaB 
will be carried out. 
6.2. Results 
6.2.1. IsaB homology search 
A Blast search was carried out on the full length IsaB sequence to identify proteins with 
homology to IsaB. The result, shown in table 6.1, shows that various subspecies of S. aureus, as 
well as 5 other Staphylococcal species, contain an open reading frame within their genome 
which codes for a protein that shares considerable sequence homology to IsaB. 
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Organism(s) Length Identity (%) E-value 
17 subspecies of S. aureus 175 100 2 e-95 
3 subspecies of S. aureus 175 82 5 e-81 
S. epidermis strain M23864:W1 173 55 1 e-49 
S. haemolyticus strain JCSC1435 176 47 5 e-40 
S. hominis SK119 173 46 1 e-37 
S. capitis SK14 173 48 3 e-37 
S. hominis SK119 174 44 3 e-33 
Table 6.1 IsaB BLAST search 
A BLAST search was carried out using the BLAST feature of the UniProt website 
(http://services.uniprot.org/blast, accessed 17/09/09). The top 25 hits are displayed. 
6.2.2. IsaB purification 
IsaB was previously cloned in this lab into the pHIS-parallel and pGST-parallel vectors to 
enable His- and GST-tag purification. Various expression strains were transformed and it was 
found that the best expression was from E. coli BL21(DE3) Star cells (Philippe, 2005). For the 
sequence of this construct refer to appendix 1. Glycerol stocks of BL21(DE3) Star cells 
transformed with His-IsaB and GST-IsaB were prepared as described in the Materials and 
Methods. 
His-IsaB was purified as described in the Materials and Methods. Figure 6.1 shows the elution 
profile and figure 6.2 shows a gel of fractions. The elution profile and the gel of fractions are 
representative of those obtained for 15N-labelled samples of His-IsaB. His-IaB and showed a 
relative mobility in SDS PAGE similar to its predicted molecular mass of 19.01 kDa. 
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Absorbance 
(mAU) 
Flow volume (ml) 
Figure 6.1 Elution profile of His-IsaB purification 
A 100 ml culture was induced for 3 hours at 37 °C and 10 ml cleared lysate was produced as described in 
the Materials and Methods. His-IsaB was purified by loading the 10 ml cleared lysate on a 1 ml His trap 
FF column and eluting with an imidazole gradient of 0 – 500 mM (green line) using His buffer B. UV 
absorbance (blue line) is correlated with protein concentration. 
Figure 6.2 SDS PAGE analysis of His-IsaB purification

His-IsaB was purified as described. Lane 1 – uninduced; lane 2 – induced; lane 3 – soluble; lane 4 –

insoluble; lane 5 – flow through fraction X6; lanes 6 to 10 – purified protein fractions F7 to F11.

The His tag was cleaved from 15N-labeled samples of His-IsaB as described in the Materials and 
Methods and the result, shown in figures 6.3 and 6.4, shows that uncleaved IsaB was 
successfully produced using the methods described. 
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Absorbance 
(mAU) 
Flow volume (ml) 
Figure 6.3 Elution profile of His-IsaB His tag cleavage 
Purified 15N-labelled His-IsaB was subjected to TEV protease cleavage as described in the Materials and 
Methods. The TEV protease-treated sample was run over a 1 ml His trap column. IsaB without the His 
tag was contained in the flow through fraction and His tag and any uncleaved His-IsaB was eluted using 
an imidazole gradient of 0 – 500 mM (green line) using His buffer B. UV absorbance (blue line) is 
correlated with protein concentration. 
Figure 6.4 SDS analysis of His-IsaB His tag cleavage 
Fractions of His-IsaB purification and His tag cleavage are shown. Lane 1 – uninduced; lane 2 – induced; 
lane 3 – purified His-IsaB (1st purification); lane 4 – purified His-IsaB (2nd purification); lane 5 – His-
IsaB in TEV protease cleavage buffer; lane 6 – flow through from His-IsaB concentration; lane 7 – TEV 
protease-treated His-IsaB pre His trap loading; lane 8 – His trap elution fraction C5; lane 9 – flow through 
fraction X3 – pure cleaved IsaB. 
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GST-IsaB was purified as described in the Materials and Methods and showed a relative 
mobility in SDS PAGE similar to its predicted molecular mass of ~24 kDa. The elution profile 
is shown in figure 6.5. The samples shown in lane 1 of figure 6.10 are representative of the 
purified GST-IsaB fractions obtained. 
Absorbance 
(mAU) 
Flow volume (ml) 
Figure 6.5 Elution profile of GST-IsaB purification 
A 750 ml culture was induced at 37 °C for 3 hours and 20 ml cleared lysate was produced as described in 
the Materials and Methods. GST-IsaB was purified by loading 20 ml cleared lysate on a 5 ml GSTtrap 
column and eluting with an imidazole gradient of 0 – 500 mM (green line) using GST buffer B. UV 
absorbance (blue line) is correlated with protein concentration. 
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6.2.3. NMR analysis of IsaB 
A 1H-15N HSQC NMR spectrum of 15N-IsaB was recorded and is shown in figure 6.7. 
Figure 6.7 1H-15N HSQC spectrum of IsaB 
1H-15N HSQC spectrum of uniformly 15N-enriched IsaB recorded at 37 ºC and 600 MHz. The sample 
contained 50 mM potassium phosphate, 200 mM sodium chloride and 5 mM EDTA pH 5.5. The 
concentration of IsaB in the sample as determined by UV spectroscopy was ~0.625 mM (~10 mg ml-1). 
The HSQC spectrum contains ~170 well-dispersed backbone peaks. The good peak dispersion 
indicates that the protein is folded. The IsaB construct contains 146 non-proline residues. The 
discrepancy between the expected (146) and observed (~170) number of peaks suggests that the 
protein may be adopting more than one conformation in solution. 
6.2.4. Functional analysis of IsaB 
6.2.4.1. Identification of binding partners for IsaB in serum 
Purified His-IsaB was coupled to a 1 ml NHS-activated HiTrap column (GE Healthcare) as 
described in the Materials and Methods. To identify proteins in human serum which might bind 
IsaB a pull-down experiment was performed and the result is shown in figure 6.8. 
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Mass 
(kDa) M 1 2 
116.0 
66.2 
45.0 
35.0 
25.0 
18.4 
14.4 
S1 
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S4 
G1 
S5 
S6 
Figure 6.8 SDS analysis of IsaB – human serum pull-down experiment 
His-IsaB was coupled to a 1 ml HiTrap NHS activated column and a human serum pull-down experiment 
was carried out as described in the Materials and Methods. Bound proteins were eluted with 5 ml 1 M 
sodium chloride pH 7.0 (lane 1) and 1 M glycine pH 4.0 (lane 2). 5 ml eluates were concentrated to 500 
µl and 10 µl samples were added to 2 µl 2 x SDS sample buffer. Bands labelled S1 to S6 in lane 2 and G1 
in lane 3 were excised and sent for MALDI-TOF analysis. 
It was thought that S1 and S4 may correspond to human IgM heavy and light chains, 
respectively. S1 PMF gave a match to human heavy-chain IgM. Sample S4 gave poor raw data. 
It was thought that S3 and G1 correspond to human IgG heavy and light chains, respectively. 
The PMF of S3 did not match any proteins in the Swissprot database. G1 gave poor raw data. 
The S2 PMF gave a good match to human serum albumin. The S5 PMF gave a match to human 
keratin. A closer inspection of the data for S5 revealed that the fragments produced upon 
digestion of the excised band were derived from all regions of the 67 kDa human keratin which 
is found in differentiating epidermis. The excised band migrated at <14.4 kDa. It was suspected 
that the human keratin protein contaminated the sample. 
To verify which human serum components bound to IsaB and to find out if IsaB binds serum 
proteins of other animals, the serum pull-down was repeated with serum from each of human, 
calf and horse. The result is shown in figure 6.9. 
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Figure 6.9 SDS analysis of IsaB – human, calf and horse serum pull-down experiment 
The pull-down experiments were carried out as for the human serum pull-down experiment. Each sample 
was run on two lanes to ensure that a maximal amount of protein was available for MALDI-TOF 
analysis. Sample 1 – human serum, salt elution; sample 2 – human serum, glycine elution; sample 3 – calf 
serum, salt elution; sample 4 – calf serum, glycine elution; sample 5 – horse serum, salt elution; sample 6 
– horse serum, glycine elution. Highlighted bands were excised and sent for MALDI-TOF analysis. 
None of the PMFs of any of the samples sent for MALDI-TOF analysis matched any proteins in 
the Swissprot database. It was thought that protein contained within the bands which may be 
IgG and IgM heavy and light chains may display a trypsin digest profile which does not match 
any protein in the SwissProt database due to the variable nature of immunoglobulins. 
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6.2.4.2. Verification of IsaB immunoglobulin binding 
The antigenic nature of IgG and IgM is such that the binding of IsaB to IgG and IgM shown in 
the pull-down experiments may have no biological significance. A binding experiment was 
carried out to identify whether IsaB has preference for binding to either the Fc or Fab regions of 
IgG. The result is shown in figure 6.10. The absence of any immunoglobulin bands in lanes 11 
and 14 indicate that the immunoglobulin fragments did not bind immobilised IsaB. 
Mass 
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Figure 6.10 SDS analysis of GST-IsaB binding experiment 
A binding experiment was carried out using glutathione sepharose beads as described in the Materials and 
Methods. Initially, each of Fc and Fab were incubated with a sample of beads to check for Fc or Fab binding 
to the beads (lanes 6 – 9). Lane 6 – beads post-Fc incubation; lane 7 – unbound Fc; lane 8 - beads post-Fab 
incubation; lane 9 – unbound Fab. GST-IsaB was bound to the beads. IgG Fc or Fab was incubated with the 
beads which were then washed and bound proteins eluted with GST buffer B. Lane 1 – purified GST-
IsaB; lane 2 – GST-IsaB in PBST; lane 3 – GST-IsaB pre-loading (Fc experiment); lane 4 – GST-IsaB 
pre-loading (Fab experiment); lane 5 – unbound GST-IsaB post-loading; lane 10 - unbound Fc post-
incubation; lane 11 – unbound Fab post-incubation; lane 12 –  Fc experiment elution; lane 13 – Fc 
experiment beads post-elution; lane 14 – Fab experiment elution; lane 15 – Fab experiment beads post-
elution. 
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6.3. Discussion 
IsaB was first identified when it elicited an immune response in patients with MRSA sepsis 
whereas colonised and healthy individuals this was to a lesser extent (Lorenz et al., 2000). The 
presence of the IsaB gene in particular S. aureus strains led to the suggestion that it could be 
correlated with immune evasion (Cassat et al., 2005). Work was carried out to elucidate the 
structure and function of this protein. 
The result of the NMR analysis suggests that IsaB is folded in solution. Optimisation of the 
NMR sample conditions may lead to the production of more informative NMR data. 
The pull-down with human serum identified that IsaB may be binding IgG and IgM in serum. 
One band which showed relative mobility on SDS PAGE close to that of heavy-chain IgM was 
confirmed as heavy-chain IgM by MALDI-TOF analysis. Bands thought to be IgG, however, 
did not match. The experiment was repeated with human, calf and horse serum and the profiles 
of the eluates were similar across all three. Bands of IgG and IgM could be seen but mass 
spectrometry analysis was unable to identify them. This may be due to the presence of variable 
regions in the immunoglobulins. The heavy-chain IgM band got a hit in the first MALDI-TOF 
analysis however equivalent bands in the second round of MALDI-TOF analysis did not. 
Subsequent binding experiments did not clarify that IsaB binds IgG. Clarification of the IsaB 
IgM binding is yet to be tested. 
Immunoglobulins are highly promiscuous so the binding observed in the pull-down may not be 
physiologically significant. Also, Lorenz et al identified IsaB as an immunodominant protein 
whereby 7 of 15 healthy donors showed a weak antibody response to IsaB – antibodies against 
IsaB may well be present in the human serum used in these experiments. It is possible that the 
pull-down experiment isolates these anti-IsaB antibodies. 
After commencing this work, IsaB was characterised as a cell surface-associated nucleic acid 
binding protein (Mackey-Lawrence et al., 2009). Extracellular DNA has been associated with 
biofilm formation, and IsaB expression was upregulated in S. aureus cells within a biofilm 
(Resch et al., 2005). This led the authors to also examine the contribution of IsaB to biofilm 
formation using an IsaB negative mutant. Biofilm formation was not affected by the absence of 
the IsaB gene (Mackey-Lawrence et al., 2009). 
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It has not been possible to clearly identify the function of IsaB. IsaB has recently been 
characterised as a nucleic acid binding protein however the consequence of this is unclear and 
further functional analysis of the protein in required. Further structural analysis may aid in 
elucidation of IsaB function. 
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7. General discussion 
S. aureus is a common commensal of the skin and anterior nares. Upon invasion, the bacterium 
is able to cause disease ranging from superficial skin infection through to more serious invasive 
disease such as endocarditis. The ability of S. aureus to colonise and establish infection in a 
wide variety of tissues is due to the vast number of proteins which it produces to aid its 
attachment, invasion and immune evasion. Characterisation of the structures and functions of 
these proteins is required to deepen our understanding of infection and immunity. More 
specifically, proteins which are required for establishment and persistence of infection are 
targets for antibacterial therapy. The emergence of MRSA has highlighted the need for 
continued development of such therapy. An understanding of the structure and function of such 
proteins provides a basis for the development of antibacterial therapy. 
ClfA, for example, has been recognised as a crucial virulence factor in septic arthritis 
and immunization with anti-ClfA antibody reduces severity of infection (Josefsson et al., 2001). 
Characterisation of ClfA bound to a synthetic peptide which mimics the ClfA binding site in 
fibrinogen has provided the basis for development of novel therapy for S. aureus disease 
(Ganesh et al., 2008). 
Efb binds both fibrinogen (Boden and Flock, 1994) and the central complement 
component C3 (Lee et al., 2004a). Efb is an important S. aureus protein and immunisation with 
anti-Efb antibodies reduces severity of S. aureus infection (Shannon et al., 2006). The Efb-C 
complement modulating properties are well described (Hammel et al., 2007c). The N-terminal 
region of Efb is less well characterised and so structural and functional analysis of the N-
terminal region of Efb was carried out. The results presented in this thesis suggest that the N-
terminal region of Efb, Efb-N, is natively unfolded. Native unfolding is a feature of the 
fibronectin binding domains of S. aureus proteins. FnbpA binds fibronectin through its N-
terminal repeat regions. These regions are natively unfolded and undergo binding-induced 
folding (Bingham et al., 2008). Binding induced folding of Efb-N upon fibrinogen binding 
could not be observed but it may be possible. Further work is required to elucidate this. The 
fibrinogen binding proteins of S. aureus characterised thus far have shown that fibrinogen 
binding is mediated via folded domains. Efb-N binds to a region of fibrinogen different from 
these other proteins and therefore it would not be surprising to learn that Efb-N may use a 
different mechanism for fibrinogen binding. The unique action of Efb-N in the inhibition, as 
opposed to activation, of platelets suggests that Efb has a role in specific stages of infection or 
in different infection types. Inhibition of platelet activation by Efb leads to impaired wound 
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healing (Shannon et al., 2005). This is in contrast to platelet activation by other fibrinogen 
binding proteins such as ClfA which leads to formation of a bacterial thrombus (O'Brien et al., 
2002a). It has been shown that recombinant Efb can bind both C3b and fibrinogen 
simultaneously (Lee et al., 2004b) but the significance of this is unclear. 
Within the immune evasion proteins of S. aureus are proteins that modulate the complement 
system. Aberrant complement activity is a feature of various inflammatory diseases such as 
rheumatoid arthritis. Drugs which mimic the complement modulating proteins of S. aureus 
could potentially be used as therapy for such diseases. Elucidation of the structure and function 
of such proteins is required as a basis for the development of such drugs. CHIPS, for example, 
is a potent inhibitor of neutrophil activation by C5a and therefore may be able to provide anti-
inflammatory therapy (Rooijakkers et al., 2009). The C3 binding proteins Efb-C and Sbi IV 
inhibit complement activation through binding to and preventing activation of C3. A 
complement assay was carried out to investigate the effect of each of Efb and Sbi IV on the 
three pathways of complement activation. The results are indicative of differences between the 
interactions of each of Efb and Sbi IV with C3. 
The solution structure of Sbi IV has been determined by NMR spectroscopy. Sbi IV adopts a 
three-helix bundle conformation similar to that seen for some other S. aureus immune evasion 
proteins. The fold is shared by Efb-C (Hammel et al., 2007c) and Ehp (Hammel et al., 2007b), 
both of which bind to C3 such that C3 cannot be activated. Crystal data have revealed that Sbi 
IV binds C3d in a similar manner to that of Efb-C and Ehp. This binding is located to the 
periphery of the acidic pocket on the concave side of C3d. This inhibits the interaction of CR2 
on B cells with C3d, thereby interfering with a crucial link between the innate and adaptive 
immune systems. The NMR titration data suggested that a second binding site in Sbi IV for C3d 
was present and the crystal data has supported this. In this second binding mode, Sbi IV binds 
the convex side of C3d. Analysis of this structure has revealed that both binding modes may be 
physiologically relevant as opposed to being brought about due to the arrangement of molecules 
in the crystal lattice. A dual binding mode, however, is contradictory to ITC data which 
suggested a stoichiometry of 1:1 between Sbi IV and C3d. Although further analysis is required, 
the dual binding mode is physiologically viable whereby both binding modes are relevant to 
Sbi’s role in immune evasion. Sbi III has been seen to be essential for C3 activation but the 
mechanism of action is still unclear. NMR data indicates that Sbi III is natively unfolded. In the 
absence of sufficient NMR or crystal data on the Sbi III-IV – C3d complex, protein modelling 
may be able to elucidate how these proteins are interacting. 
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IsaB is expressed during MRSA sepsis (Lorenz et al., 2000). Little else was known about this 
protein. Preliminary structural analysis of IsaB has been carried out and the results suggest that 
the protein is folded in solution. This makes IsaB suitable for further NMR analysis. The results 
of the functional analysis to date are inconclusive and more work is required to positively 
identify the presence of IsaB binding partners in serum. IsaB has recently been characterised as 
a nucleic acid binding protein (Mackey-Lawrence et al., 2009). Further work is required to 
investigate the significance of this and how nucleic acid binding by IsaB may relate to IsaB 
expression in particular S. aureus strains and under different growth conditions. 
Taken together, the results presented in this thesis have strengthened the field of knowledge on 
the broad range of proteins produced by S. aureus. Efb and Sbi both inhibit complement 
however their modes of action in this regard are quite distinct. Both Efb and Sbi bind other 
ligands as well as C3 which enhances their contribution to attachment and immune evasion. 
Both proteins ultimately promote survival of S. aureus within the host. The role of IsaB remains 
unclear but it is apparent that IsaB may contribute to S. aureus survival in a way which is 
distinct from Efb and Sbi. 
The results presented in this thesis enhance understanding of infection and immunity and more 
specifically help to elucidate the mode of action of the clinically important bacterium S. aureus. 
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9. Appendices 
Appendix 1: Protein sequences 
Affinity tags and other vector-derived residues are underlined. Cleavage sites are indicated by /. 
Sbi IV in pHis-parallel 
MSYYHHHHHH DYDIPTTENL YFQ/GAMVSIE KAIVRHDERV KSANDAISKL 

NEKDSIENRR LAQREVNKAP MDVKEHLQKQ LDALVAQKDA EKKVA

Sbi IV in pQE30 
MRGSHHHHHH MVSIEKAIVR HDERVKSAND AISKLNEKDS IENRRLAQRE 

VNKAPMDVKE HLQKQLDALV AQKDAEKKVA

Sbi III-IV in pQE30 
MRGSHHHHHH MERQNIENAD KAIKDFQDNK APHDKSAAYE ANSKLPKDLR 

DKNNRFVEKV SIEKAIVRHD ERVKSANDAI SKLNEKDSIE NRRLAQREVN 

KAPMDVKEHL QKQLDALVAQ KDAEKKVA

C3d in pET15b 
MLDAERLKHL IVTPSGAGEQ NMIGMTPTVI AVHYLDETEQ WEKFGLEKRQ 

GALELIKKGY TQQLAFRQPS SAFAAFVKRA PSTWLTAYVV KVFSLAVNLI 

AIDSQVLCGA VKWLILEKQK PDGVFQEDAP VIHQEMIGGL RNNNEKDMAL 

TAFVLISLQE AKDICEEQVN SLPGSITKAG DFLEANYMNL QRSYTVAIAG 

YALAQMGRLK GPLLNKFLTT AKDKNRWEDP GKQLYNVEAT SYALLALLQL 

KDFDFVPPVV RWLNEQRYYG GGYGSTQATF MVFQALAQYQ KDAPDHQELN 

LDVSLQLPSR 

Efb in pET15b 
MGSSHHHHHH SSGLVPR/GSH MASEGYGPRE KKPVSINHNI VEYNDGTFKY 
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QSRPKFNSTP KYIKFKHDYN ILEFNDGTFE YGARPQFNKP AAKTDATIKK 

EQKLIQAQNL VREFEKTHTV SAHRKAQKAV NLVSFEYKVK KMVLQERIDN VLKQGLVR

Efb-N in pSV281 
MGSSHHHHHH ENLYFQ/GMAS EGYGPREKKP VSINHNIVEY NDGTFKYQSR

PKFNSTPKYI KFKHDYNILE FNDGTFEYGA RPQFNKPAAK TDA

Efb-N in pBG101 
MGSSHHHHHH GSS. . GST (221 residues). . LEVLFQ/GP 
MASEGYGPRE KKPVSINHNI VEYNDGTFKY QSRPKFNSTP 
KYIKFKHDYN ILEFNDGTFE YGARPQFNKP AAKTDA 
IsaB in pHIS-Parallel 
MSYYHHHHHH DYDIPTTENL YFQ/GAMAITP YYTYNGYIGN NANFILDKNF 

INAIKYDNVK FNGIKLAKTN TIKKVEKYDQ TFKGVSAKGN EASQLQFVVK 

NNISLKDIQK AYGKDLKKEN GKTKEADSGI FYYQNAKKTL GIWFVVDHNR 

VVEVTVGHTP YKTSK 

IsaB in pGST-Parallel 
GST (221 residues). . IDTTENLYFQ/ GAMAITPYYT YNGYIGNNAN FILDKNFINA 
IKYDNVKFNG IKLAKTNTIK KVEKYDQTFK GVSAKGNEAS QLQFVVKNNI 
SLKDIQKAYG KDLKKENGKT KEADSGIFYY QNAKKTLGIW FVVDHNRVVE 
VTVGHTPYKT SK 
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Appendix 2: ProPlex-96 screen 
 
The following table lists details of the Molecular Dimensions ProPlex-96 screen.  
 
 
moleculardimensions.com
 
!"
ProPlex     Box 1     MD1-38"
Tube # Salt Buffer pH Precipitant 
#$#" %&'(" )$#"*"+,-." /$)" 012"343"567"!1)"**6"
#$0" )$#"*"89:8-;<"98(=9=(" )$#"*"*6>" ?$)" #12"343"567"@))"
#$!" )$#"*":-=A-;<"8A:&,-B(" )$#"*"%9"C656>" D$1" 0)2"343"567"@))"
#$@" %&'(" )$#"*"+,-." /$)" 012"343"567"@))"
#$1" %&'(" )$#"*"*6>" ?$1" #12"343"567"11)"**6"
#$?" )$0"*".&B-;<"8A:&,-B(" )$#"*"%94E"FA&.FA9=(" ?$1" 012"G43"567"#)))"
#$D" )$#"*"9<<&'-;<".;:H9=(" )$#"*"+,-." D$1" 0)2"G43"567"#1))"
#$/" )$0"*"9<<&'-;<".;:H9=(" )$#"*".&B-;<"98(=9=(" 1$1" #)2"G43"567"0)))"**6"
#$I" )$0"*".&B-;<"8A:&,-B(" )$#"*"*6>" ?$)" 0)2"G43"567"0)))"**6"
#$#)" )$#"*"F&=9..-;<"8A:&,-B(" )$#"*"+,-." /$)" #12"G43"567"0)))"**6"
#$##" %&'(" )$#"*"%9"C656>" D$1" 012"G43"567"0)))"**6"
#$#0" )$0"*".&B-;<"98(=9=(" )$#"*".&B-;<"8-=,9=(" 1$1" 12"G43"567"@)))"
#$#!" )$0"*":-=A-;<".;:H9=(" )$#"*"+,-." D$1" 12"G43"567"@)))"
#$#@" )$#"*"89:8-;<"98(=9=(" )$#"*".&B-;<"98(=9=(" @$1" #)2"G43"567"@)))"
#$#1" )$0"*".&B-;<"98(=9=(" )$#"*".&B-;<"8-=,9=(" 1$1" #)2"G43"567"@)))"
#$#?" )$0"*".&B-;<"8A:&,-B(" )$#"*"*6>" ?$1" #)2"G43"567"@)))"
#$#D" )$#"*"<9J'(.-;<"8A:&,-B(" )$#"*"%9"C656>" D$1" #)2"G43"567"@)))"
#$#/" %&'(" )$#"*"%9"C656>" D$)" #)2"G43"567"@)))4#)2"343"0KF,&F9'&:"
#$#I" )$0"*"9<<&'-;<"98(=9=(" )$#"*".&B-;<"98(=9=(" @$)" #12"G43"567"@)))"
#$0)" )$#"*"<9J'(.-;<"8A:&,-B(" )$#"*".&B-;<"8-=,9=(" 1$)" #12"G43"567"@)))"
#$0#" %&'(" )$#"*".&B-;<"898&BL:9=(" ?$)" #12"G43"567"@)))"
#$00" )$#1"*"9<<&'-;<".;:H9=(" )$#"*"*6>" ?$)" #12"G43"567"@)))"
#$0!" %&'(" )$#"*"%9"C656>" D$)" #12"G43"567"@)))"
#$0@" )$#"*"<9J'(.-;<"8A:&,-B(" )$#"*"%9"C656>" D$)" #12"G43"567"@)))"
#$01" )$#1"*"9<<&'-;<".;:H9=(" )$#"*"+,-." /$)" #12"G43"567"@)))"
#$0?" %&'(" )$#"*".&B-;<"8-=,9=(" @$1" 0)2"G43"567"@)))"
#$0D" )$0"*"9<<&'-;<"98(=9=(" )$#"*".&B-;<"98(=9=(" 1$)" 0)2"G43"567"@)))"
#$0/" )$0"*":-=A-;<".;:H9=(" )$#"*"*6>" ?$)" 0)2"G43"567"@)))"
#$0I" %&'(" )$#"*"+,-." /$)" 0)2"G43"567"@)))"
#$!)" )$#1"*"9<<&'-;<".;:H9=(" )$#"*"%9"C656>" D$)" 0)2"G43"567"@)))"
#$!#" %&'(" )$#"*".&B-;<"8-=,9=(" 1$?" 0)2"G43"567"@)))40)2"343"0KF,&F9'&:"
#$!0" )$0"*".&B-;<"8A:&,-B(" )$#"*"+,-." /$)" 0)2"G43"567"@)))"
#$!!" %&'(" )$#"*".&B-;<"898&BL:9=(" 1$1" 012"G43"567"@)))"
#$!@" )$#1"*"9<<&'-;<".;:H9=(" )$#"*"*6>" 1$1" 012"G43"567"@)))"
#$!1" %&'(" )$#"*".&B-;<"898&BL:9=(" ?$1" 012"G43"567"@)))"
#$!?" )$0"*"F&=9..-;<"-&B-B(" )$#"*"*6>" ?$1" 012"G43"567"@)))"
#$!D" )$0"*".&B-;<"8A:&,-B(" )$#"*"%9"C656>" D$1" 012"G43"567"@)))"
#$!/" %&'(" )$#"*"*6>" ?$1" #)2"G43"567"1)))"**64#02"343"#KF,&F9'&:"
#$!I" )$#"*"F&=9..-;<"8A:&,-B(" )$#"*"%9"C656>" D$)" #12"G43"567"1)))"**6"
#$@)" )$0"*"9<<&'-;<".;:H9=(" )$#"*"+,-." D$1" 0)2"G43"567"1)))"**6"
#$@#" )$#"*"<9J'(.-;<"8A:&,-B(" )$#"*"*6>" ?$)" /2"G43"567"?)))"
#$@0" )$#1"*".&B-;<"8A:&,-B(" )$#"*"+,-." /$)" /2"G43"567"?)))"
#$@!" %&'(" )$#"*".&B-;<"8-=,9=(" 1$1" #12"G43"567"?)))"
#$@@" )$#"*"<9J'(.-;<"98(=9=(" )$#"*".&B-;<"898&BL:9=(" ?$1" #12"G43"567"?)))"
#$@1" %&'(" )$#"*"*6>" ?$1" #12"G43"567"?)))412"G43"*5M"
#$@?" )$#"*"F&=9..-;<"8A:&,-B(" )$#"*"%9"C656>" D$1" #12"G43"567"?)))"
#$@D" %&'(" )$#"*"+,-." /$1" #12"G43"567"?)))"
#$@/" %&'(" )$#"*"+,-." /$1" 0)2"G43"567"?)))"
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!"
ProPlex       Box 2     MD1-38"
Tube # Salt Buffer pH Precipitant 
#$%" &$%"'"()*+,-./(")0,1)1," &$%"'"-23./(")0,1)1," !$4" 56"789":;<"5&&&"
#$#" =2+," &$%"'"-23./("0.1>)1," 4$&" 56"789":;<"5&&&"
#$?" &$#"'"-23./("0@A2>.3," &$%"'"-23./("0)023BA)1," C$&" 56"789":;<"5&&&"
#$!" =2+," &$%"'"=)"D;:;E" F$&" 56"789":;<"5&&&"
#$4" =2+," &$%"'"G>.-" 5$&" 56"789":;<"5&&&"
#$C" &$%"'"0)A0./(")0,1)1," &$%"'"-23./("0)023BA)1," 4$4" %#6"789":;<"5&&&"
#$F" =2+, &$%"'"-23./("H@2-H@)1," C$4" %#6"789":;<"5&&&"
#$5" &$%"'"()*+,-./(")0,1)1," &$%"'"'I:E" F$4" %#6"789":;<"5&&&"
#$J" &$#"'"-23./("0@A2>.3," &$%"'"=)"D;:;E" F$4" %#6"789":;<"5&&&"
#$%&" &$#"'")((2+./("-/AK)1," &$%"'"G>.-" 5$4" %#6"789":;<"5&&&"
#$%%" =2+," &$%"'"-23./("0.1>)1," 4$&" #&6"789":;<"5&&&"
#$%#" &$#"'")((2+./("-/AK)1," &$%"'"';E" C$4" #&6"789":;<"5&&&"
#$%?" =2+," &$%"'"=)"D;:;E" F$&" #&6"789":;<"5&&&"
#$%!" &$#"'"A.1@./("0@A2>.3," &$%"'"G>.-" 5$&" #&6"789":;<"5&&&"
#$%4" &$%"'"()*+,-./(")0,1)1," &$%"'"';E" C$4" %&6"789":;<"%&&&&"
#$%C" =2+," &$%"'"=)"D;:;E" F$&" %56"789":;<"%#&&&"
#$%F" &$%"'"-23./("0@A2>.3," &$%"'"G>.-" 5$&" 56"789":;<"#&&&&"
#$%5" =2+," &$%"'"=)"D;:;E" F$&" %46"789":;<"#&&&&"
#$%J" =2+," &$%"'"';E" C$4" &$4"'")((2+./("-/AK)1,"
#$#&" =2+," &$%"'"-23./(")0,1)1," 4$&" %"'")((2+./("-/AK)1,"
#$#%" =2+," &$%"'"';E" C$4" %"'")((2+./("-/AK)1,"
#$##" =2+," &$%"'"G>.-" 5$&" %"'")((2+./("-/AK)1,"
#$#?" =2+," &$%"'"-23./(")0,1)1," 4$&" %$4"'"")((2+./("-/AK)1,"
#$#!" =2+," &$%"'"=)"D;:;E" F$&" %$4"'")((2+./("-/AK)1,"
#$#4" =2+," &$%"'"G>.-" 5$&" %$4"'")((2+./("-/AK)1,"
#$#C" =2+," &$%"'"-23./(")0,1)1," 4$&" #"'")((2+./("-/AK)1,"
#$#F" =2+," &$%"'"=)"D;:;E" F$&" #"'")((2+./("-/AK)1,"
#$#5" =2+," &$%"'"G>.-" 5$&" #"'")((2+./("-/AK)1,"
#$#J" %"'"H21)--./("0@A2>.3," &$%"'"=)"D;:;E" F$&" %"'")((2+./("-/AK)1,"
#$?&" =2+," &$%"'"-23./(")0,1)1," 4$&" #"'"-23./("K2>()1,"
#$?%" =2+," &$%"'"G>.-" F$4" ?"'"-23./("L2>()1,"
#$?#" =2+," =2+," F$4" &$5"'"=)8M"@B3>2*,+"H@2-H@)1,"
#$??" =2+," =2+," F$&" %$?"'"=)8M"@B3>2*,+"H@2-H@)1,"
#$?!" =2+," =2+," C$4" %$C"'"=)8M"@B3>2*,+"H@2-H@)1,"
#$?4" =2+," &$%"'"=)"D;:;E" F$4" %"'"-23./(")0,1)1,"
#$?C" =2+," &$%"'"=)"D;:;E" F$&" %"'"-23./("0.1>)1,"
#$?F" =2+," &$%"'"-23./("0.1>)1," C$&" #"'"-23./("0@A2>.3,"
#$?5" =2+," &$%"'"';E" C$4" %"'"A.1@./("-/AK)1,"
#$?J" =2+," &$%"'"G>.-" 5$&" %$C"'"A.1@./("-/AK)1,"
#$!&" =2+," =2+," C$&" %$!"'"-23./("()A2+)1,"
#$!%" =2+," &$%"'"G>.-" 5$&" %$#"'"=)8M"1)>1>)1,"
#$!#" =2+," &$%"'"';E" C$4" %$C"'"()*+,-./("-/AK)1,"
#$!?" =2+," &$%"'"-23./(")0,1)1," 4$&" #6"789":;<"!&&&8%46"989"':N"
#$!!" 4&"('"0)A0./(")0,1)1," &$%"'"-23./("0)023BA)1," C$&" #46"989"':N"
#$!4" =2+," &$%"'".(.3)O2A," F$&" 4&6"989"':N"
#$!C" 4&"('"()*+,-./("0@A2>.3," &$%"'"';E" C$4" 46"789":;<"!&&&8%&6"989"#PH>2H)+2A"
#$!F" &$#"'")((2+./(")0,1)1," &$%"'"=)"D;:;E" F$4" #46"989"#PH>2H)+2A"
#$!5" &$%"'"-23./("0@A2>.3," &$%"'"G>.-" 5$&" 46"989"':N8%46"989",1@)+2A"
 
Abbreviations: 
Na HEPESQ"=PR#P@B3>2SB,1@BATPH.H,>)O.+,P=UP#P,1@)+,-/AK2+.0")0.3"E23./("E)A1V"MESQ"#PR=P(2>H@2A.+2T,1@)+,-/AK2+.0")0.3V"MMEQ"'2+2(,1@BA,1@,>V"
PEGQ":2AB,1@BA,+,"*AB02AV TrisQ #PW(.+2P#PR@B3>2SB(,1@BATH>2H)+,P%V?P3.2AV"MOPS; 3-(N-Morpholino)-propanesulfonic acid"
"
')+/K)01/>,>X-"-)K,1B"3)1)-@,,1-")>,")9).A)YA,"2+">,Z/,-1$"
Appendix 3: Tacsimate screen 
Details of the Hampton Research tacsimate solutions. 
Each solution contains 1.8305 M malonic acid, 250 mM ammonium citrate tribasic, 120 mM 
succinic acid, 300 mM DL-malic acid, 100 mM sodium acetate trihydrate, 500 mM sodium 
formate, 160 mM ammonium tartrate dibasic and sodium hydroxide for pH adjusting. 
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Appendix 4: Additives screen 
Composition of the additives screen 
Well 
number 
Additive (1% [v/v]) 
1 1M ammonium sulphate 
2 1M calcium chloride 
3 1M magnesium chloride 
4 1M caesium chloride 
5 Ethylene glycol 
6 Dioxane 
7 m-phenylenediamine (MPD) 
8 2-propanol 
9 Ethanol 
10 1M potassium iodide 
11 1M lithium sulphate 
12 No additive 
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Appendix 5: Efb NMR assignments 
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Appendix 6: Sbi IV NMR assignments 
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